附錄 V — 參考文獻
本手冊引用之國際指引與共識文件完整列表。文中以 [來源代碼] 標註。
V.1 ISHLT 系列（20 份）
| 代碼 | 全名 | 年份 |
|---|---|---|
| [ISHLT-CS-2021] | ISHLT Consensus Document for the Selection of Lung Transplant Candidates | 2021 |
| [ISHLT-CTD-2021] | ISHLT Consensus on Lung Transplantation in Patients with Connective Tissue Disease | 2021 |
| [ISHLT-Anes-2021] | International Consensus Recommendations for Anesthetic and Intensive Care Management of Lung Transplantation (EACTAIC/SCA/ISHLT/ESOT/ESTS/AST) | 2021 |
| [ISHLT-Swall-2021] | Swallowing and Laryngeal Complications in Lung and Heart Transplantation | 2021 |
| [ISHLT-DP-2020] | ISHLT Consensus: Donor Heart and Lung Procurement | 2020 |
| [ISHLT-CLAD-2019] | ISHLT Consensus: Chronic Lung Allograft Dysfunction — Definition, Diagnostic Criteria, and Approaches to Treatment | 2019 |
| [ISHLT-Airway-2018] | ISHLT Consensus: Airway Complications after Lung Transplantation | 2018 |
| [ISHLT-PGD] | ISHLT Working Group on PGD: Definition and Grading — 2016 Update | 2017 |
| [ISHLT-AMR-2016] | ISHLT Consensus: Antibody-Mediated Rejection of the Lung | 2016 |
| [ISHLT-ECLS-Pre] | ISHLT Consensus: Perioperative Use of ECLS — Preoperative Considerations | 2025 |
| [ISHLT-ECLS-Intra] | ISHLT Consensus: Perioperative Use of ECLS — Intraoperative Considerations | 2024 |
| [ISHLT-ECLS-Post] | ISHLT Consensus: Perioperative Use of ECLS — Postoperative Considerations | 2025 |
| [ISHLT-ECLS-Persp] | ISHLT Perspective: Perioperative Use of ECLS | 2025 |
| [ISHLT-PAH-2025] | ISHLT Consensus: Risk Stratification in Pulmonary Arterial Hypertension | 2025 |
| [ISHLT-Vacc-2025] | ISHLT Statement on Vaccines in Transplant Recipients | 2025 |
| [ISHLT-Ped-2025] | ISHLT Consensus: Referral and Selection of Pediatric Lung Transplant Candidates | 2025 |
| [ISHLT-CTE-2025] | ISHLT Consensus: Endpoints in Lung Transplant Clinical Trials | 2025 |
| [ISHLT-STS-2026] | ISHLT Consensus: Short Telomere Syndrome and Lung Transplantation | 2026 |
| [ISHLT-Skin-2024] | ISHLT: Initial Skin Cancer Screening for Solid Organ Transplant Recipients | 2024 |
| [ISHLT-MCS-Inf] | ISHLT Consensus: MCS Infection Definitions | 2024 |
V.2 其他國際組織（23 份）
| 代碼 | 全名 | 年份 |
|---|---|---|
| [AST-IS-2025] | AST Ch6: Lung Immunosuppression | 2025 |
| [AST-Inf-2024] | AST: Post-Transplant Infectious Diseases | 2024 |
| [AATS-DLP-2024] | AATS Expert Consensus: Current Standards in Donor Lung Procurement and Preservation | 2024 |
| [AATS-MCS-2023] | AATS Expert Consensus: Mechanical Circulatory Support in Lung Transplantation (Hartwig et al., J Thorac Cardiovasc Surg 2023;165:301–326) | 2023 |
V.3 OpenEvidence 驗證之 primary literature（逐題標記）
| 代碼 | 全名 |
|---|---|
| [OE-Moser-2018] | Moser B, et al. Lung Transplantation for Idiopathic PAH on Intraoperative and Postoperatively Prolonged ECMO. Eur J Cardiothorac Surg 2018;53(1):178-185. doi:10.1093/ejcts/ezx212 |
| [OE-Hoetzenecker-2018] | Hoetzenecker K, et al. Intraoperative ECMO and the Possibility of Postoperative Prolongation Improve Survival in Bilateral Lung Transplantation. J Thorac Cardiovasc Surg 2018;155(5):2193-2206.e3. doi:10.1016/j.jtcvs.2017.10.144 |
| [OE-DellAmore-2020] | Dell’Amore A, et al. Extracorporeal Life Support During and After Bilateral Sequential Lung Transplantation in Patients with PAH. Artif Organs 2020;44(6):628-637. doi:10.1111/aor.13628 |
| [OE-Kawashima-2025] | Kawashima M, et al. Extended Use of Central Veno-Arterial ECMO in Lung Transplantation for Pulmonary Arterial Hypertension. Eur J Cardiothorac Surg 2025;67(8):ezaf256. doi:10.1093/ejcts/ezaf256 |
| [OE-Rosenzweig-2019] | Rosenzweig EB, et al. Extracorporeal Life Support Bridge for Pulmonary Hypertension: A High-Volume Single-Center Experience. J Heart Lung Transplant 2019;38(12):1275-1285. doi:10.1016/j.healun.2019.09.004 |
| [OE-Oh-2021] | Oh DK, et al. Effects of the Duration of Bridge to Lung Transplantation with ECMO. PLoS ONE 2021;16(7):e0253520. doi:10.1371/journal.pone.0253520 |
| [OE-Chicotka-2018] | Chicotka S, Pedroso FE, et al. Increasing Opportunity for Lung Transplant in ILD with PH — VA vs VV ECMO BTT. Ann Thorac Surg 2018. doi:10.1016/j.athoracsur.2018.04.068 |
| [OE-Wisniewski-2025] | Wisniewski AM, Suzuki Y, et al. Cannulation Configuration and Effects on Bridging to Lung Transplantation (ELSO Registry, n=1,066). Ann Thorac Surg 2025. doi:10.1016/j.athoracsur.2024.12.011 |
| [OE-Bernhardt-2023] | Bernhardt AM, et al. ISHLT/HFSA Consensus on Acute MCS: Post-LTx and PH Considerations. J Heart Lung Transplant 2023. |
| [OE-Xia-2022] | Xia Y, Ragalie W, et al. VA vs VV ECMO as Bridge to Lung Transplantation (UCLA, n=58). Ann Thorac Surg 2022. doi:10.1016/j.athoracsur.2021.11.016 |
| [OE-Usman-2024] | Usman AA, et al. Venopulmonary (VP) ECMO with Protek-Duo for RV Support in Lung Transplant Bridging. ASAIO J 2024. doi:10.1097/mat.0000000000002179 |
| [OE-Ghadimi-2022] | Ghadimi K, et al. INSPIRE-FLO Trial: Inhaled Epoprostenol vs Inhaled Nitric Oxide for Transplantation. JAMA Surg 2022;157(1):e215856. doi:10.1001/jamasurg.2021.5856 |
| [OE-Ardehali-2001] | Ardehali A, et al. Inhaled Nitric Oxide for Pulmonary Hypertension after Heart-Lung and Lung Transplantation. Transplantation 2001;72(1):112-115. doi:10.1097/00007890-200107150-00022 |
| [OE-Khan-2009] | Khan TA, et al. Inhaled Nitric Oxide vs Inhaled Prostacyclin in Heart/Lung Transplantation (Crossover RCT). J Thorac Cardiovasc Surg 2009;138(6):1417-1424. doi:10.1016/j.jtcvs.2009.04.063 |
| [OE-Abman-2015] | Abman SH, et al. Pediatric Pulmonary Hypertension: Guidelines from AHA/ATS. Circulation 2015;132(21):2037-2099. doi:10.1161/CIR.0000000000000329 |
| [OE-Rajagopal-2023] | Rajagopal S, et al. AHA Scientific Statement: PH in Noncardiac Surgery. Circulation 2023;147(17):1317-1343. doi:10.1161/CIR.0000000000001136 |
| [OE-Scaravilli-2023] | Scaravilli V, Guzzardella A, Madotto F, et al. Hemodynamic Failure and Graft Dysfunction After Lung Transplantation. Clin Transplant 2023;37(12):e15122. doi:10.1111/ctr.15122 |
| [OE-Landoni-2017] | Landoni G, Lomivorotov VV, Alvaro G, et al. Levosimendan for Hemodynamic Support After Cardiac Surgery (LEVO-CTS). N Engl J Med 2017;376(21):2021-2031. doi:10.1056/NEJMoa1616325 |
| [OE-Hu-2021] | Hu Y, Wei Z, Zhang C, et al. Effect of Levosimendan on RV Function: Systematic Review and Meta-Analysis. Sci Rep 2021;11:24097. doi:10.1038/s41598-021-03317-5 |
| [OE-GuzmanBofarull-2025] | Guzman-Bofarull J, et al. Pre-Heart Transplant Levosimendan, Post-Transplant Vasoplegia and PGD. Clin Transplant 2025;39(10):e70327. doi:10.1111/ctr.70327 |
| [OE-Katz-1996] | Katz WE, et al. Immediate Effects of LTx on Right Ventricular Morphology and Function in PH. J Am Coll Cardiol 1996;27(2):384-391 |
| [OE-Mendeloff-2002] | Mendeloff EN, et al. Lung Transplantation for Pulmonary Vascular Disease (n=100). Ann Thorac Surg 2002;73(1):209-217 |
| [OE-Gorter-2017] | Gorter TM, et al. Right Ventricular Recovery After Bilateral LTx for PAH (cMRI). Interact Cardiovasc Thorac Surg 2017;24(6):890-897 |
| [OE-Sarashina-2017] | Sarashina T, et al. Temporal RV Reverse Remodeling at 3 and 12 Months After LTx for PH. Circ J 2017;81(3):383-390 |
| [OE-Saggar-2008] | Saggar R, et al. Pulmonary Hypertension Associated with Chronic Allograft Dysfunction (BOS) After LTx. Am J Transplant 2008;8(9):1921-1930 |
| [OE-Maritati-2022] | Maritati F, et al. Kidney Transplantation in Systemic Sclerosis. Front Immunol 2022;13:878736. doi:10.3389/fimmu.2022.878736 |
| [OE-Perelas-2020] | Perelas A, et al. Systemic Sclerosis-Associated Interstitial Lung Disease. Lancet Respir Med 2020;8(3):304-320. doi:10.1016/S2213-2600(19)30480-1 |
| [OE-Pradere-2018] | Pradère P, et al. Lung Transplantation for Scleroderma Lung Disease: Multicenter Experience (n=90). J Heart Lung Transplant 2018;37(7):903-911. doi:10.1016/j.healun.2018.03.003 |
| [OE-Dellgren-2024] | Dellgren G, et al. Tacrolimus vs Cyclosporine in Lung Transplantation (ScanCLAD RCT). Lancet Respir Med 2024;12(1):34-44. doi:10.1016/S2213-2600(23)00293-X |
| [OE-Raghu-2024] | Raghu G, et al. Treatment of Systemic Sclerosis-Associated ILD (ATS Guideline). Am J Respir Crit Care Med 2024;209(2):137-152. doi:10.1164/rccm.202306-1113ST |
| [OE-Kitterman-2012] | Kitterman N, Poms A, Miller DP, et al. Bloodstream Infections in Patients with Pulmonary Arterial Hypertension Treated with IV Prostanoids (REVEAL Registry). Mayo Clin Proc 2012;87(9):825-834. doi:10.1016/j.mayocp.2012.05.014 |
| [OE-Rich-2012] | Rich JD, Glassner C, Wade M, et al. The Effect of Diluent pH on BSI Rates in Patients Receiving IV Treprostinil. Chest 2012;141(1):36-42. doi:10.1378/chest.11-0245 |
| [OE-Ivy-2009] | Ivy DD, Calderbank M, Wagner BD, et al. Child-Specific Prostanoid Infection Rates (Pediatric PH). Infect Control Hosp Epidemiol 2009;30(9):823-829. doi:10.1086/605320 |
| [OE-Doran-2008] | Doran AK, Ivy DD, Barst RJ, et al. Guidelines for the Prevention of Central Venous Catheter-Related Bloodstream Infections with Prostanoid Therapy for PAH. Int J Clin Pract Suppl 2008;(160):5-9. doi:10.1111/j.1742-1241.2008.01811.x |
| [OE-Dickinson-2009] | Dickinson MG, Kornfield I, Bresnahan W. Treprostinil-Associated Bloodstream Infections Reduced with Closed-Hub System. J Heart Lung Transplant 2009;28(3):273-279. doi:10.1016/j.healun.2008.11.913 |
| [OE-Hopper-2025] | Hopper RK, Hansmann G, Hollander SA, et al. Clinical Management and Transplant Considerations in Pediatric Pulmonary Hypertension Due to Left Heart Disease: AHA Scientific Statement. Circ Heart Fail 2025;18(1):e000086. doi:10.1161/HHF.0000000000000086 |
| [OE-Lahm-2010] | Lahm T, McCaslin CA, Wozniak TC, et al. Medical and Surgical Treatment of Acute Right Ventricular Failure. J Am Coll Cardiol 2010;56(18):1435-1446. doi:10.1016/j.jacc.2010.05.046 |
| [OE-Cuiper-1996] | Cuiper LL, Price PV, Christman BW. Systemic and Pulmonary Hypertension After Abrupt Cessation of Prostacyclin: Role of Thromboxane A2. J Appl Physiol 1996;80(1):191-197. doi:10.1152/jappl.1996.80.1.191 |
V.4 v2.0 Ch01 驗證新增（2026-04-20）— 38 筆完整 OpenEvidence 證據
完整 38 筆引用 metadata 見
qa/oe_papers_library/Ch01_recipient_selection/Ch01_citations.json。此處僅列直接會用於手冊引用之關鍵論文。
| 代碼 | 全名 |
|---|---|
| [OE-Weill-2015] | Weill D, et al. A consensus document for the selection of lung transplant candidates: 2014 update (ISHLT Pulmonary Transplantation Council). J Heart Lung Transplant 2015;34(1):1-15. doi:10.1016/j.healun.2014.06.014 |
| [OE-Christie-2024-NEJM] | Christie JD, Van Raemdonck D, Fisher AJ. Lung Transplantation (Review). N Engl J Med 2024;391(19):1822-1836. doi:10.1056/NEJMra2401039 |
| [OE-Vock-2017] | Vock DM, et al. Survival Benefit of Lung Transplantation in the Modern Era. Ann Am Thorac Soc 2017;14(2):172-181. doi:10.1513/AnnalsATS.201606-507OC |
| [OE-Hamada-2007] | Hamada K, et al. Significance of PA Pressure and DLCO as Prognosticator in IPF. Chest 2007;131(3):650-656. doi:10.1378/chest.06-1466 |
| [OE-Maher-2024-JAMA] | Maher TM. Interstitial Lung Disease: A Review (GAP III 39.2%/76.8%). JAMA 2024;331(19):1655-1665. doi:10.1001/jama.2024.3669 |
| [OE-Snyder-2019] | Snyder L, et al. Predictors of Death/LTx in IPF: IPF-PRO Registry. Respir Res 2019;20(1):105. doi:10.1186/s12931-019-1043-9 |
| [OE-Guenther-2025] | Guenther A, et al. European IPF Registry — IPF+PH prognosis (HR 2.03). J Clin Med 2025;14(20):7352. doi:10.3390/jcm14207352 |
| [OE-Wensel-2002] | Wensel R, et al. Assessment of Survival in PAH: Importance of CPET. Circulation 2002;106(3):319-324. doi:10.1161/01.cir.0000022687.18568.2a |
| [OE-Weatherald-2018-Circ] | Weatherald J, et al. Prognostic Value of Follow-Up Hemodynamic Variables in PAH (French Registry n=981; SVI HR 1.28). Circulation 2018;137(7):693-704. doi:10.1161/CIRCULATIONAHA.117.029254 |
| [OE-Boucly-2017] | Boucly A, et al. Risk Assessment in PAH (French Registry n=603). Eur Respir J 2017;50(2):1700889. doi:10.1183/13993003.00889-2017 |
| [OE-Sinning-2018-RV-Index] | Sinning C, et al. RV Index for Risk Stratification in PAH (RAP × PVR/SvO₂ > 91). Respiration 2018;96(3):249-258. doi:10.1159/000489231 |
| [OE-Chung-2014-Chest] | Chung L, et al. REVEAL SSc-PAH Survival. Chest 2014;146(6):1494-1504. doi:10.1378/chest.13-3014 |
| [OE-Distler-2024-Rheum] | Distler O, et al. COMPERA CTD-PAH (SSc-PAH 3-yr 59%). Rheumatology 2024;63(4):1139-1146. doi:10.1093/rheumatology/kead360 |
| [OE-Degano-2010] | Degano B, Guillaume M, Savale L, et al. HIV-PAH Survival (73/60/47%; CD4 >212). AIDS 2010;24(1):67-75. doi:10.1097/QAD.0b013e328331c65e |
| [OE-Ramos-2019-CFF] | Ramos KJ, et al. CFF Consensus: LTx Referral in CF (PASP >50). J Cyst Fibros 2019;18(3):321-333. doi:10.1016/j.jcf.2019.03.002 |
| [OE-Kurihara-2022-JAMA] | Kurihara C, et al. Northwestern COVID-ARDS LTx Series. JAMA 2022. |
| [OE-Goh-2017] | Goh NS, et al. Short-term Pulmonary Function Trends Predict Mortality in SSc-ILD (composite endpoint). Arthritis Rheumatol 2017. doi:10.1002/art.40105 |
| [OE-Halpern-2020] | Halpern AL, et al. L3 SMI Sarcopenia in LTx — NOT associated with outcomes. Ann Thorac Surg 2020;109(1):233-240 |
| [OE-Hachem-2018-HALT] | Hachem RR, et al. HALT Study: DSA in Lung Transplantation. J Heart Lung Transplant 2018 |
| [OE-LePavec-2016] | Le Pavec J, et al. De Novo DSA after LTx (Month-1 DSA ≥3000 → mortality HR 2.71). J Heart Lung Transplant 2016 |
| [OE-Stein-2011-Meta] | Stein EM, et al. Prevention of Fractures after SOT: Meta-analysis (OR 0.50). J Clin Endocrinol Metab 2011;96(11):3457-3465. doi:10.1210/jc.2011-1448 |
| [OE-Maurer-1998] | Maurer JR, Frost AE, Estenne M, et al. International guidelines for the selection of lung transplant candidates. Transplantation 1998;66(7):951-956. doi:10.1097/00007890-199810150-00033 🔒 手動 |
| [OE-Brahmbhatt-2022] | Brahmbhatt JM, Hee Wai T, Goss CH, et al. Lung allocation score and other available models lack predictive accuracy for post-lung transplant survival. J Heart Lung Transplant 2022;41(8):1063-1074. doi:10.1016/j.healun.2022.05.008 |
| [OE-Wang-2022-FrontPharmacol] | Wang Y, Guo Z, Ma R, et al. Prognostic predictive characteristics in patients with fibrosing interstitial lung disease: a retrospective cohort study. Front Pharmacol 2022;13:924754. doi:10.3389/fphar.2022.924754 |
| [OE-Kim-2025-Lung] | Kim HJ, Weber JM, Neely ML, et al. Predictors of Long-Term Survival in Patients With Idiopathic Pulmonary Fibrosis: Data From the IPF-PRO Registry. Lung 2025;203(1):40. doi:10.1007/s00408-025-00797-4 |
| [OE-Humbert-2022-ESC-ERS] | Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2023;61(1):2200879. doi:10.1183/13993003.00879-2022 |
| [OE-Diesler-2026] | Diesler R, et al. HYPID cohort — severe PH in IPF (PVR >5 WU). Eur Respir J 2026. doi:10.1183/13993003.02233-2025 🔒 手動 |
| [OE-Olsson-2023] | Olsson KM, et al. Pulmonary Hypertension Associated with Lung Disease. Lancet Respir Med 2023;11(9):820-835. doi:10.1016/s2213-2600(23)00259-x |
| [OE-McLaughlin-2013] | McLaughlin VV, et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D73-D81. doi:10.1016/j.jacc.2013.10.034 |
| [OE-Khirfan-2020] | Khirfan G, et al. Mixed Venous Oxygen Saturation is a Better Prognosticator than Cardiac Index in Pulmonary Arterial Hypertension. Chest 2020;158(6):2546-2555. doi:10.1016/j.chest.2020.06.053 |
| [OE-Hjalmarsson-2025] | Hjalmarsson C, et al. Risk Assessment Models — SPAHR Analysis. J Heart Lung Transplant 2025;44(11):1787-1797. doi:10.1016/j.healun.2024.10.029 |
| [OE-Kylhammar-2018] | Kylhammar D, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J 2018;39(47):4175-4181. doi:10.1093/eurheartj/ehx257 |
| [OE-Ramjug-2017] | Ramjug S, et al. Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison. Chest 2017;152(1):92-102. doi:10.1016/j.chest.2017.02.010 |
| [OE-Nunes-2003] | Nunes H, Humbert M, Sitbon O, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167(10):1433-1439. doi:10.1164/rccm.200204-330OC |
| [OE-Kapnadak-2020-CFF] | Kapnadak SG, et al. CFF Consensus Guidelines for the Care of Individuals with Advanced Cystic Fibrosis Lung Disease. J Cyst Fibros 2020;19(3):344-354. doi:10.1016/j.jcf.2020.02.015 |
| [OE-Bermudez-2024] | Bermudez C, et al. Lung transplantation for COVID-2019 respiratory failure in the United States: Outcomes 1-year posttransplant and the impact of preoperative ECMO support. J Thorac Cardiovasc Surg 2023. doi:10.1016/j.jtcvs.2023.04.016 |
| [OE-Sobanski-2025-EUSTAR] | Sobanski V, Hoffmann-Vold AM, et al. SSc-ILD progression: EUSTAR cohort analysis. Rheumatology 2025. |
| [OE-Hsu-2019-Psoas] | Hsu J, et al. Psoas muscle size predicts outcomes after lung transplantation. Ann Thorac Surg 2019;107(4):1082-1088. |
| [ATS-IPF-2022] | ATS/ERS/JRS/ALAT: Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis — Clinical Practice Guideline |
| [GOLD-2025] | GOLD 2025 Report: Global Strategy for Diagnosis, Management, and Prevention of COPD |
| [ESC-PH-2022] | ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension |
| [ELSO-VV] | ELSO: Management of Adult Patients Supported with VV ECMO |
| [ELSO-Resp] | ELSO: Adult Respiratory Failure Guidelines |
| [ELSO-AC] | ELSO: Anticoagulation Guidelines |
| [CMV-4th-2025] | 4th International Consensus Guidelines on Management of CMV in Solid Organ Transplantation |
| [SCCM-PADIS-2025] | SCCM PADIS Focused Update: Pain, Anxiety, Agitation/Sedation, Delirium, Immobility, Sleep Disruption in Adult ICU |
| [CHEST-Lib-2017] | ATS/CHEST: Liberation from Mechanical Ventilation in Critically Ill Adults |
| [KDIGO-CKD-2024] | KDIGO 2024 Clinical Practice Guideline: Evaluation and Management of CKD |
| [KDIGO-KTx] | KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients |
| [Banff-Lung-2022] | Banff 2022 Lung Report |
| [Banff-Kidney-2022] | Banff 2022 Kidney Meeting Report |
| [EMA-SOT-IS] | EMA Guideline on Clinical Investigation of Immunosuppressants for Solid Organ Transplantation |
| [ESOT-Prehab-2023] | ESOT Consensus Statement on Prehabilitation for SOT Candidates |
| [ESOT-MP-2024] | ESOT Consensus on Machine Perfusion in Cardiothoracic Transplant |
| [BTS-DCD-2023] | BTS UK Guidelines on Transplantation from Deceased Donors after Circulatory Death |
| [ASPEN-Nutr-2024] | ASPEN: Nutrition Support Management of Organ Transplant Recipients in the Acute Post-transplant Phase |
| [WHO-GP-2010] | WHO Guiding Principles on Human Cell, Tissue and Organ Transplantation |
| [WHO-WHA77-2024] | WHA77.4: Increasing Availability, Ethical Access and Oversight of Transplantation |
V.5 v2.1 Ch02 OE 證據（2026-04-20）— 32 筆新增
| 代碼 | 全名 |
|---|---|
| [OE-Pehlivan-2018-IMT] | Pehlivan E, Mutluay F, Balcı A, et al. The effect of inspiratory muscle training on exercise capacity, dyspnea and respiratory functions in lung transplantation candidates: a randomized controlled trial. Clin Rehabil 2018;32(10):1328-1339. doi:10.1177/0269215518777560 |
| [OE-Ge-2018-PreopIMT] | Ge X, Wang W, Hou L, et al. Effect of preoperative inspiratory muscle training on postoperative pulmonary complications after cardiothoracic and upper abdominal surgery: a systematic review and meta-analysis. J Thorac Cardiovasc Surg 2018;156(3):1290-1300.e5. doi:10.1016/j.jtcvs.2018.02.105 |
| [OE-Lisboa-1997-IMT] | Lisboa C, Villafranca C, Leiva A, et al. Inspiratory muscle training with target pressures in patients with chronic airflow limitation: effect on dyspnea and 6-minute walk distance. Eur Respir J 1997;10(3):537-542. |
| [OE-Ammous-2023-Cochrane-IMT] | Ammous O, Feki W, Lotfi T, et al. Inspiratory muscle training, with or without concomitant pulmonary rehabilitation, for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2023;1:CD013778. doi:10.1002/14651858.CD013778.pub2 |
| [OE-Figueiredo-2020-IMT] | Figueiredo RIN, Azambuja AM, Cureau FV, Sarmento-Leite ER. Inspiratory muscle training in COPD: a meta-analysis. Respir Care 2020;65(8):1189-1201. doi:10.4187/respcare.07098 |
| [OE-Saglam-2015-PAH-IMT] | Saglam M, Arikan H, Vardar-Yagli N, et al. Inspiratory muscle training in pulmonary arterial hypertension. J Cardiopulm Rehabil Prev 2015;35(3):198-206. doi:10.1097/HCR.0000000000000117 |
| [OE-Upala-2016-ObesityMeta] | Upala S, Panichsillapakit T, Wijarnpreecha K, et al. Underweight and obesity increase the risk of mortality after lung transplantation: a systematic review and meta-analysis. Transpl Int 2016;29(3):285-296. doi:10.1111/tri.12721 |
| [OE-Lederer-2011-LTOG] | Lederer DJ, Kawut SM, Wickersham N, et al. Obesity and primary graft dysfunction after lung transplantation: the Lung Transplant Outcomes Group Obesity Study. Am J Respir Crit Care Med 2011;184(9):1055-1061. doi:10.1164/rccm.201104-0728OC |
| [OE-Anderson-2023-UNOS] | Anderson MR, Ozsoy A, Kim A, et al. BMI and cause of death after lung transplantation: evidence from the UNOS registry. Ann Am Thorac Soc 2023;20(6):825-833. doi:10.1513/AnnalsATS.202207-613OC |
| [OE-Clausen-2018-Duke] | Clausen ES, Frankel C, Palmer SM, et al. Pretransplant weight loss and clinical outcomes after lung transplantation. J Heart Lung Transplant 2018;37(12):1443-1447. doi:10.1016/j.healun.2018.07.015 |
| [OE-Chandrashekaran-2015] | Chandrashekaran S, Keller CA, Kremers WK, et al. Weight loss prior to lung transplantation is associated with improved survival. J Heart Lung Transplant 2015;34(5):651-657. doi:10.1016/j.healun.2014.11.018 |
| [OE-Jomphe-2018-Montreal] | Jomphe V, Mailhot G, Damphousse V, et al. The impact of waiting list BMI changes on the short-term outcomes of lung transplantation. Transplantation 2018;102(2):318-325. doi:10.1097/TP.0000000000001919 |
| [OE-Orandi-2020-Bariatric] | Orandi BJ, Purvis JW, Cannon RM, et al. Bariatric surgery in end-stage organ disease patients as a bridge to transplantation: a systematic review. Am J Surg 2020;220(3):566-579. doi:10.1016/j.amjsurg.2020.04.041 |
| [OE-Latorre-2025-Bariatric] | Latorre-Rodríguez AR, et al. Lung transplantation outcomes after prior bariatric surgery: a propensity-matched analysis. Obes Surg 2025;35(7):2436-2444. doi:10.1007/s11695-025-07932-3 |
| [OE-Huang-2025-GLP1-Tx] | Huang YN, et al. Effect of pre-transplant GLP-1 receptor agonist and SGLT2 inhibitor combination on post-transplant mortality: a target trial emulation. Adv Sci 2025. doi:10.1002/advs.202518813 |
| [OE-ADA-2026-Ch9] | American Diabetes Association Professional Practice Committee. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2026. Diabetes Care 2026;49(Suppl 1):S183-S215. doi:10.2337/dc26-S009 |
| [OE-Park-2018-ProteinRCT] | Park Y, Choi JE, Hwang HS. Protein supplementation increases muscle mass in frail elderly: a 12-week randomized trial comparing 1.5 g/kg/day vs standard intake. Am J Clin Nutr 2018;108(5):1026-1033. doi:10.1093/ajcn/nqy214 |
| [OE-Kirwan-2022-ProteinMeta] | Kirwan RP, Mazidi M, Rodríguez García C, et al. The effect of dietary protein supplementation on muscle mass and strength in older adults: a systematic review and meta-analysis. Am J Clin Nutr 2022;115(3):897-913. doi:10.1093/ajcn/nqab355 |
| [OE-Chamogeorgakis-2013] | Chamogeorgakis T, Mountis M, Gonzalez-Stawinski GV, et al. The impact of pre-transplant nutritional status on post-transplant outcomes after lung transplantation. J Heart Lung Transplant 2013;32(7):693-700. doi:10.1016/j.healun.2013.04.005 |
| [OE-KDIGO-CKD-2024] | Stevens PE, Ahmed SB, Carrero JJ, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018 |
| [OE-Annema-2023-ESOT-Prehab] | Annema C, De Smet S, Castle EM, et al. European Society for Organ Transplantation (ESOT) Consensus Statement on prehabilitation for solid organ transplantation candidates. Transpl Int 2023;36:11564. doi:10.3389/ti.2023.11564 |
| [OE-Manothummetha-2022-COVID] | Manothummetha K, Chuleerarux N, Sanguankeo A, et al. Immunogenicity and risk factors associated with poor humoral immune response of SARS-CoV-2 vaccines in solid organ transplant recipients: a systematic review and meta-analysis. JAMA Netw Open 2022;5(4):e226822. doi:10.1001/jamanetworkopen.2022.6822 |
| [OE-Mombelli-2024-STOPFLU] | Mombelli M, Neofytos D, Huynh-Do U, et al. Immunogenicity of high-dose versus MF59-adjuvanted versus standard influenza vaccine in solid organ transplant recipients: the STOP-FLU trial. Clin Infect Dis 2024. doi:10.1093/cid/ciad477 |
| [OE-Chen-2023-COVID-SOT] | Chen X, Luo D, Mei B, et al. Immunogenicity of COVID-19 vaccines in solid organ transplant recipients: a systematic review and meta-analysis. Clin Microbiol Infect 2023;29(4):441-456. doi:10.1016/j.cmi.2022.12.004 |
| [OE-Hirzel-2021-RZV-Lung] | Hirzel C, Chruscinski A, Ferreira VH, et al. Safety and immunogenicity of the adjuvanted recombinant zoster vaccine in lung transplant recipients. Am J Transplant 2021. doi:10.1111/ajt.16534 |
| [OE-Stark-2002-HBV] | Stark K, Günther M, Schönfeld C, et al. Immunisations in solid-organ transplant recipients. Lancet 2002;359(9310):957-965. doi:10.1016/S0140-6736(02)08028-5 |
| [OE-Danziger-2019-ASTIDCOP] | Danziger-Isakov L, Kumar D; AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019;33(9):e13563. doi:10.1111/ctr.13563 |
| [OE-Walti-2023-STCS] | Walti LN, Mugglin C, Sidler D, et al. Vaccine-preventable infections among solid organ transplant recipients in Switzerland. JAMA Netw Open 2023;6(4):e2310687. doi:10.1001/jamanetworkopen.2023.10687 |
| [OE-Tello-2018-TAPSEsPAP] | Tello K, Wan J, Dalmer A, et al. Validation of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio for the assessment of right ventricular-arterial coupling in severe pulmonary hypertension. Int J Cardiol 2018;266:229-235. doi:10.1016/j.ijcard.2018.01.053 |
| [OE-Hahn-2023-JACC-RV] | Hahn RT, Lerakis S, Delgado V, et al. Multimodality imaging of right heart function: JACC Scientific Statement. J Am Coll Cardiol 2023;81(19):1954-1973. doi:10.1016/j.jacc.2023.03.392 |
| [OE-Vicenzi-2022-PLoS] | Vicenzi M, Caravita S, Rota I, et al. The added value of right ventricular function normalized for afterload to improve risk stratification of patients with pulmonary arterial hypertension. PLoS One 2022;17(5):e0265059. doi:10.1371/journal.pone.0265059 |
| [OE-Gargani-2023-JACC] | Gargani L, Pugliese NR, De Biase N, et al. Exercise stress echocardiography in pulmonary hypertension: insights into mechanisms and outcomes. J Am Coll Cardiol 2023;82(21):1973-1985. doi:10.1016/j.jacc.2023.09.807 |
V.6 v2.1 Ch03 OE 證據（2026-04-20）— 42 筆新增
| 代碼 | 全名 |
|---|---|
| [OE-Martinu-2020-BAL] | Martinu T, Koutsokera A, Benden C, et al. International Society for Heart and Lung Transplantation consensus statement: A standardized method for the quantification of bronchoalveolar lavage procedures. J Heart Lung Transplant 2020;39(11):1171-1190. doi:10.1016/j.healun.2020.07.006 |
| [OE-Avlonitis-2003] | Avlonitis VS, Krause A, Luzzi L, et al. Bacterial colonization of the donor lower airways is a predictor of poor outcome in lung transplantation. Eur J Cardiothorac Surg 2003;24(4):601-607. doi:10.1016/s1010-7940(03)00454-8 |
| [OE-Ahmad-2018-PPB] | Ahmad O, Shafii AE, Mannino DM, et al. Donor-derived bacterial infections in lung transplant recipients: a retrospective review. Transpl Infect Dis 2018;20(6):e12986. doi:10.1111/tid.12986 |
| [OE-Abdulqawi-2024-MDR] | Abdulqawi R, et al. Donor bacterial contamination and outcomes after lung transplantation. J Infect 2024;88(2):139-148. doi:10.1016/j.jinf.2023.12.013 |
| [OE-Fisher-2004-Selection] | Fisher AJ, Donnelly SC, Hirani N, et al. Objective assessment of criteria for selection of donor lungs suitable for transplantation. Thorax 2004;59(5):434-437. doi:10.1136/thx.2003.007542 |
| [OE-Chaney-2014] | Chaney J, Suzuki Y, Cantu E, van Berkel V. Lung donor selection criteria. J Thorac Dis 2014;6(8):1032-1038. doi:10.3978/j.issn.2072-1439.2014.03.24 |
| [OE-Kalil-2016-IDSA] | Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;63(5):e61-e111. doi:10.1093/cid/ciw353 |
| [OE-Dhar-2013-MPvsHC] | Dhar R, Cotton C, Coleman J, et al. Comparison of high- and low-dose corticosteroid regimens for organ donor management. J Crit Care 2013;28(1):111.e1-e7. doi:10.1016/j.jcrc.2012.04.015 |
| [OE-Dupuis-2014-SAFB2] | Dupuis S, Amiel JA, Desgroseilliers M, et al. Corticosteroids in the management of brain-dead potential organ donors: a systematic review. Br J Anaesth 2014;113(3):346-359. doi:10.1093/bja/aeu154 |
| [OE-DAragon-2017-Meta] | D’Aragon F, Belley-Cote E, Agarwal A, et al. Effect of corticosteroid administration on neurologically deceased organ donors and transplant recipients: a systematic review and meta-analysis. BMJ Open 2017;7(6):e014436. doi:10.1136/bmjopen-2016-014436 |
| [OE-Follette-1998] | Follette DM, Rudich SM, Babcock WD. Improved oxygenation and increased lung donor recovery with high-dose steroid administration after brain death. J Heart Lung Transplant 1998;17(4):423-429. |
| [OE-Pinsard-2014-CORTICOME] | Pinsard M, Ragot S, Mertes PM, et al. Interest of low-dose hydrocortisone therapy during brain-dead organ donor resuscitation: the CORTICOME study. Crit Care 2014;18(4):R158. doi:10.1186/cc13997 |
| [OE-Kotsch-2008] | Kotsch K, Ulrich F, Reutzel-Selke A, et al. Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial. Ann Surg 2008;248(6):1042-1050. doi:10.1097/SLA.0b013e318190e70c |
| [OE-Seshadri-2023-AAST] | Seshadri A, Cuschieri J, Kaups KL, et al. Management of organ donation in the surgical intensive care unit: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document. Trauma Surg Acute Care Open 2023;8(1):e001107. doi:10.1136/tsaco-2023-001107 |
| [OE-Dhar-2023-TRAPHT] | Dhar R, Stahlschmidt E, Marklin GF. Intravenous Levothyroxine for Unstable Brain-Dead Heart Donors. N Engl J Med 2023;389(22):2029-2038. doi:10.1056/NEJMoa2305969 |
| [OE-Macdonald-2012-Meta] | Macdonald PS, Aneman A, Bhonagiri D, et al. A systematic review and meta-analysis of clinical trials of thyroid hormone administration to brain dead potential organ donors. Crit Care Med 2012;40(5):1635-1644. doi:10.1097/CCM.0b013e3182416ee7 |
| [OE-Novitzky-2014] | Novitzky D, Mi Z, Sun Q, Collins J, Cooper DK. Thyroid Hormone Therapy in 63,593 Brain-Dead Organ Donors: A Retrospective Analysis. Transplantation 2014;98(10):1119-1127. doi:10.1097/TP.0000000000000187 |
| [OE-Dhar-2019-T3SHOT] | Dhar R, Stahlschmidt E, Yan Y, Marklin G. A randomized controlled trial comparing treatments for vasopressor-dependent brain-dead organ donors. Clin Transplant 2019;33(3):e13486. doi:10.1111/ctr.13486 |
| [OE-Cavalcante-2025-Meta] | Cavalcante LFF, et al. Impact of Thyroid Hormones on Brain-Dead Organ Donors and Transplant Outcomes: A Systematic Review and Meta-Analysis. Transplant Proc 2025;57(5):698-705. doi:10.1016/j.transproceed.2025.03.028 |
| [OE-VanBakel-2022] | Van Bakel AB, Hino SAF, Welker D, et al. Hemodynamic Effects of High-Dose Levothyroxine and Methylprednisolone in Brain-Dead Potential Organ Donors. Transplantation 2022;106(8):1677-1689. doi:10.1097/TP.0000000000004072 |
| [OE-Mulvihill-2020-Center] | Mulvihill MS, Yerokun BA, Davis RP, et al. The association of donor age and survival is independent of ischemic time following deceased donor lung transplantation. J Heart Lung Transplant 2020;39(4):353-362. doi:10.1016/j.healun.2019.12.010 |
| [OE-Halpern-2025-AOOS] | Halpern SE, et al. Allocation Out of Sequence in Lung Transplantation. JAMA Surg 2025;160(9):955-963. doi:10.1001/jamasurg.2025.2142 |
| [OE-Valapour-2025-OPTN] | Valapour M, Lehr CJ, Wey A, et al. OPTN/SRTR 2023 Annual Data Report: Lung. Am J Transplant 2025;25(2S1):S422-S489. doi:10.1016/j.ajt.2025.01.025 |
| [OE-Heiden-2023-LUNDON] | Heiden BT, et al. The Lung Donor (LUNDON) acceptability score: A prediction tool for identifying acceptable lung donors. Am J Transplant 2023;23(4):540-548. doi:10.1016/j.ajt.2022.12.014 |
| [OE-Okahara-2021] | Okahara S, Levvey B, McDonald M, D’Costa R, et al. Reasons for lung donor decline. Ann Thorac Surg 2021;112(2):443-449. doi:10.1016/j.athoracsur.2020.08.042 |
| [OE-VanRaemdonck-2019-DCD] | Van Raemdonck D, Keshavjee S, Levvey B, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part IV: Recipient-related risk factors and markers. J Heart Lung Transplant 2019;38(12):1235-1245. doi:10.1016/j.healun.2019.09.007 |
| [OE-Levvey-2019-DCDReg] | Levvey B, Keshavjee S, Cypel M, et al. Influence of lung donor agonal and warm ischemic times on early mortality: Analyses from the ISHLT DCD Registry. J Heart Lung Transplant 2019;38(1):26-34. doi:10.1016/j.healun.2018.08.006 |
| [OE-Qaqish-2021-Toronto] | Qaqish R, Watanabe Y, Hoetzenecker K, et al. Impact of donor warm ischemia in lung transplantation from donors after circulatory death. J Thorac Cardiovasc Surg 2021;161(4):1546-1555.e1. doi:10.1016/j.jtcvs.2020.04.181 |
| [OE-Levvey-2008-Australian] | Levvey BJ, Westall GP, Kotsimbos T, et al. Excellent clinical outcomes from a national donation-after-determination-of-cardiac-death lung transplant collaboration. Transplantation 2008;86(12):1702-1706. doi:10.1097/TP.0b013e3181901f24 |
| [OE-Williams-2025-UK-NRP] | Williams LJL, et al. Impact of abdominal normothermic regional perfusion on DCD lung transplantation outcomes: UK registry analysis. J Heart Lung Transplant 2025;44(8):1307-1318. doi:10.1016/j.healun.2025.03.019 |
| [OE-Mora-2022-Spanish] | Mora V, et al. Lung transplantation using donation after circulatory death with abdominal normothermic regional perfusion: Spanish multicenter experience. Am J Transplant 2022;22(7):1852-1860. doi:10.1111/ajt.17057 |
| [OE-Zhou-2023-USTANRP] | Zhou AL, et al. Early US outcomes of thoracoabdominal normothermic regional perfusion for DCD lung transplantation. J Heart Lung Transplant 2023;42(6):693-696. doi:10.1016/j.healun.2023.03.001 |
| [OE-Warnecke-2018-INSPIRE] | Warnecke G, Van Raemdonck D, Smith MA, et al. Normothermic ex-vivo preservation with the OCS Lung device for donor lungs from donors declined by other centers: an international, multicentre, randomised, non-inferiority trial (INSPIRE). Lancet Respir Med 2018;6(5):357-367. doi:10.1016/S2213-2600(18)30136-X |
| [OE-Loor-2019-EXPAND] | Loor G, Warnecke G, Villavicencio MA, et al. Portable normothermic ex-vivo lung perfusion, ventilation, and functional assessment with the Organ Care System on donor lungs used for transplantation (EXPAND): a single-arm, pivotal trial. Lancet Respir Med 2019;7(11):975-984. doi:10.1016/S2213-2600(19)30200-0 |
| [OE-Loor-2025-EXPAND5yr] | Loor G, et al. Five-year outcomes of extended-criteria donor lungs preserved with the Organ Care System Lung: the EXPAND trial long-term analysis. eClinicalMedicine 2025;85:103334. doi:10.1016/j.eclinm.2025.103334 |
| [OE-Keshavjee-2025-Toronto1000] | Keshavjee S, et al. One thousand consecutive lung transplants with ex-vivo lung perfusion: the Toronto experience. J Thorac Cardiovasc Surg 2025. doi:10.1016/j.jtcvs.2025.08.036 |
| [OE-Peel-2026-CostUtility] | Peel JK, et al. Cost-utility analysis of ex vivo lung perfusion in lung transplantation. J Heart Lung Transplant 2026. doi:10.1016/j.healun.2026.01.032 |
| [OE-Ali-2023-NEJMEvidence] | Ali A, Wang A, Ribeiro RVP, et al. Static Lung Storage at 10°C Maintains Mitochondrial Health and Preserves Donor Organ Function: First-in-Human Clinical Trial. NEJM Evidence 2023;2(6):EVIDoa2300008. doi:10.1056/EVIDoa2300008 |
| [OE-Hoetzenecker-2025-AnnSurg] | Hoetzenecker K, et al. Controlled hypothermic storage at 10°C for extended lung preservation in lung transplantation: a multicenter study. Ann Surg 2025;281(4):664-670. doi:10.1097/SLA.0000000000006632 |
| [OE-Ali-2021-SciTransMed] | Ali A, Wang A, Ribeiro RVP, et al. Static lung storage at 10°C preserves mitochondrial health and enables prolonged preservation. Sci Transl Med 2021;13(611):eabf7601. doi:10.1126/scitranslmed.abf7601 |
| [OE-Abramov-2026-USSC] | Abramov A, et al. Clinical outcomes of lung transplantation using controlled hypothermic storage at 10°C: a single-center cohort study. J Thorac Cardiovasc Surg 2026;171(2):532-539.e2. doi:10.1016/j.jtcvs.2025.09.024 |
| [OE-Cenik-2024-Review] | Cenik I, Van Slambrouck J, Provoost AL, et al. Controlled hypothermic storage for lung preservation: leaving the ice behind. Transplant International 2024;37:12601. doi:10.3389/ti.2024.12601 |
V.7 v2.1 Ch04 OE 證據（2026-04-21）— 37 筆新增
| 代碼 | 全名 |
|---|---|
| [OE-Munshi-2013-Donor] | Munshi L, Keshavjee S, Cypel M. Donor Management and Lung Preservation for Lung Transplantation. The Lancet. Respiratory Medicine 2013. doi:10.1016/s2213-2600(12)70064-4 |
| [OE-Yeung-2017-Extended12h] | Yeung JC, Krueger T, Yasufuku K, et al. Outcomes After Transplantation of Lungs Preserved for More Than 12 H: A Retrospective Study. The Lancet. Respiratory Medicine 2017. doi:10.1016/s2213-2600(16)30323-x |
| [OE-FDA-2025-Heparin1] | Food and Drug Administration. Heparin Sodium. |
| [OE-Honarmand-2021-Antemortem] | Honarmand K, Alshamsi F, Foroutan F, et al. Antemortem Heparin in Organ Donation After Circulatory Death Determination: A Systematic Review of the Literature. Transplantation 2021. doi:10.1097/tp.0000000000003793 |
| [OE-Kramer-2022-Premortem] | Kramer AH, Holliday K, Keenan S, et al. Premortem Anticoagulation Timing and Dose in Donation After Circulatory Death: Multicentre Study of Associations With Graft Function. Canadian Journal of Surgery. Journal Canadien De Chirurgie 2022. doi:10.1503/cjs.023120 |
| [OE-VanDeWauwer-2014-Retrograde] | Van De Wauwer C, Neyrinck AP, Rega FR, Verbeken E, Van Raemdonck DE. Retrograde Flush Is More Protective Than Heparin in the Uncontrolled Donation After Circulatory Death Lung Donor. The Journal of Surgical Research 2014. doi:10.1016/j.jss.2013.11.1100 |
| [OE-Chan-2025-Bloodless] | Chan EG, Deitz RL, Ryan JP, et al. Bloodless Lung Transplantation: Comparison Between 2 Central Venoarterial Extracorporeal Membrane Oxygenation Anticoagulation Strategies and Their Impact on Lung Transplant Outcomes. The Journal of Thoracic and Cardiovascular Surgery 2025. doi:10.1016/j.jtcvs.2024.09.055 |
| [OE-Inokawa-2005-NHBD] | Inokawa H, Date H, Okazaki M, et al. Effects of Postmortem Heparinization in Canine Lung Transplantation With Non-Heart-Beating Donors. The Journal of Thoracic and Cardiovascular Surgery 2005. doi:10.1016/j.jtcvs.2004.05.009 |
| [OE-Aoe-1994-PGE1] | Aoe M, Trachiotis GD, Okabayashi K, et al. Administration of Prostaglandin E1 After Lung Transplantation Improves Early Graft Function. The Annals of Thoracic Surgery 1994. doi:10.1016/0003-4975(94)90723-4 |
| [OE-Lin-1994-UW-PGE1] | Lin PJ, Hsieh MJ, Cheng KS, Kuo TT, Chang CH. University of Wisconsin Solution Extends Lung Preservation After Prostaglandin E1 Infusion. Chest 1994. doi:10.1378/chest.105.1.255 |
| [OE-Mayer-1992-18h] | Mayer E, Puskas JD, Cardoso PF, et al. Reliable Eighteen-Hour Lung Preservation at 4 Degrees and 10 Degrees C by Pulmonary Artery Flush After High-Dose Prostaglandin E1 Administration. The Journal of Thoracic and Cardiovascular Surgery 1992. |
| [OE-Naka-1996-cAMP] | Naka Y, Roy DK, Liao H, et al. cAMP-mediated Vascular Protection in an Orthotopic Rat Lung Transplant Model. Insights Into the Mechanism of Action of Prostaglandin E1 to Improve Lung Preservation. Circulation Research 1996. doi:10.1161/01.res.79.4.773 |
| [OE-dePerrot-2001-PGE1] | de Perrot M, Fischer S, Liu M, et al. Prostaglandin E1 Protects Lung Transplants From Ischemia-Reperfusion Injury: A Shift From Pro- To Anti-Inflammatory Cytokines. Transplantation 2001. doi:10.1097/00007890-200111150-00006 |
| [OE-Sasaki-1999-PGE1vasoK] | Sasaki S, Yasuda K, McCully JD, LoCicero J. Does PGE1 Attenuate Potassium-Induced Vasoconstriction in Initial Pulmonary Artery Flush on Lung Preservation?. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 1999. doi:10.1016/s1053-2498(98)00003-5 |
| [OE-ChaconAlberty-2023-PGDreview] | Chacon-Alberty L, Fernandez R, Jindra P, et al. Primary Graft Dysfunction in Lung Transplantation: A Review of Mechanisms and Future Applications. Transplantation 2023. doi:10.1097/tp.0000000000004503 |
| [OE-Alderete-2024-PGDfactors] | Alderete IS, Medina CK, Pontula A, et al. Donor and Recipient Factors Associated With Primary Graft Dysfunction Following Lung Transplantation: A Donor Management Goal Registry Analysis. The Journal of Thoracic and Cardiovascular Surgery 2024. doi:10.1016/j.jtcvs.2024.10.045 |
| [OE-Keshavjee-1992-Dextran] | Keshavjee SH, Yamazaki F, Yokomise H, et al. The Role of Dextran 40 and Potassium in Extended Hypothermic Lung Preservation for Transplantation. The Journal of Thoracic and Cardiovascular Surgery 1992. |
| [OE-Thabut-2001-Preservation] | Thabut G, Vinatier I, Brugière O, et al. Influence of Preservation Solution on Early Graft Failure in Clinical Lung Transplantation. American Journal of Respiratory and Critical Care Medicine 2001. doi:10.1164/ajrccm.164.7.2012135 |
| [OE-Berzenji-2025-IRI] | Berzenji L, Hendriks JMH, Verleden SE, et al. Lung Ischemia-Reperfusion Injury in Lung Transplant Surgery: Where Do We Stand?. Antioxidants 2025. doi:10.3390/antiox14111295 |
| [OE-Wang-2019-Necroptosis] | Wang X, O’Brien ME, Yu J, et al. Prolonged Cold Ischemia Induces Necroptotic Cell Death in Ischemia-Reperfusion Injury and Contributes to Primary Graft Dysfunction After Lung Transplantation. American Journal of Respiratory Cell and Molecular Biology 2019. doi:10.1165/rcmb.2018-0207oc |
| [OE-Pan-2025-PGDmeta] | Pan J, Zhang J, Lu X. Incidence of Primary Graft Dysfunction and Its Associated Risk Factors After Lung Transplantation: A Systematic Review and Meta-Analysis. Surgery Today 2025. doi:10.1007/s00595-025-03129-4 |
| [OE-Wittwer-2005-Route] | Wittwer T, Franke UF, Fehrenbach A, et al. Experimental Lung Transplantation: Impact of Preservation Solution and Route of Delivery. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2005. doi:10.1016/j.healun.2004.07.004 |
| [OE-Xuan-2024-DrivingP] | Xuan C, Gu J, Chen J, Xu H. Driving Pressure Association With Mortality in Post-Lung Transplant Patients: A Prospective Observational Study. The Journal of International Medical Research 2024. doi:10.1177/03000605241259442 |
| [OE-Tague-2021-DonorVent] | Tague LK, Bedair B, Witt C, et al. Lung Protective Ventilation Based on Donor Size Is Associated With a Lower Risk of Severe Primary Graft Dysfunction After Lung Transplantation. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2021. doi:10.1016/j.healun.2021.06.016 |
| [OE-Marczin-2021-AnesICU] | Marczin N, de Waal EEC, Hopkins PMA, et al. International Consensus Recommendations for Anesthetic and Intensive Care Management of Lung Transplantation. An EACTAIC, SCA, ISHLT, ESOT, ESTS, and AST Approved Document. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2021. doi:10.1016/j.healun.2021.07.012 |
| [OE-Mascia-2010-ProtVent] | Mascia L, Pasero D, Slutsky AS, et al. Effect of a Lung Protective Strategy for Organ Donors on Eligibility and Availability of Lungs for Transplantation: A Randomized Controlled Trial. The Journal of the American Medical Association 2010. doi:10.1001/jama.2010.1796 |
| [OE-Mal-2020-French] | Mal H, Santin G, Cantrelle C, et al. Effect of Lung-Protective Ventilation in Organ Donors on Lung Procurement and Recipient Survival. American Journal of Respiratory and Critical Care Medicine 2020. doi:10.1164/rccm.201910-2067oc |
| [OE-Swanson-2021-DMG] | Swanson EA, Patel MS, Hutchens MP, et al. Critical Care and Ventilatory Management of Deceased Organ Donors Impact Lung Use and Recipient Graft Survival. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2021. doi:10.1111/ajt.16719 |
| [OE-Ware-2025-OpenLungRCT] | Ware LB, Koyama T, Shaver CM, et al. A Randomized Trial of Open Lung Protective Ventilation Compared to Conventional Mechanical Ventilation in Deceased Organ Donors. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2025. doi:10.1016/j.healun.2025.03.027 |
| [OE-Date-1992-10C] | Date H, Lima O, Matsumura A, et al. In a Canine Model, Lung Preservation at 10 Degrees C Is Superior to That at 4 Degrees C. A Comparison of Two Preservation Temperatures on Lung Function and on Adenosine Triphosphate Level Measured by Phosphorus 31-Nuclear Magnetic Resonance. The Journal of Thoracic and Cardiovascular Surgery 1992. |
| [OE-Shaver-2025-Lancet] | Shaver CM, Reese PP, Griesemer A, Zuckermann A, Bacchetta M. Scientific Advances in the Assessment, Modification, and Generation of Transplantable Organs for Patients With End-Stage Organ Diseases. Lancet 2025. doi:10.1016/s0140-6736(25)00239-9 |
| [OE-AbdelnourBerchtold-2022-10C] | Abdelnour-Berchtold E, Ali A, Baciu C, et al. Evaluation of 10°C as the Optimal Storage Temperature for Aspiration-Injured Donor Lungs in a Large Animal Transplant Model. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2022. doi:10.1016/j.healun.2022.08.025 |
| [OE-Grimm-2015-UNOS-CIT] | Grimm JC, Valero V, Kilic A, et al. Association Between Prolonged Graft Ischemia and Primary Graft Failure or Survival Following Lung Transplantation. JAMA Surgery 2015. doi:10.1001/jamasurg.2015.12 |
| [OE-Halpern-2021-8hCIT] | Halpern SE, Au S, Kesseli SJ, et al. Lung Transplantation Using Allografts With More Than 8 Hours of Ischemic Time: A Single-Institution Experience. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2021. doi:10.1016/j.healun.2021.05.008 |
| [OE-Casillan-2024-CIT] | Casillan AJ, Zhou AL, Ruck JM, et al. The Effect of Allograft Ischemic Time on Outcomes Following Bilateral, Single, and Reoperative Lung Transplantation. The Journal of Thoracic and Cardiovascular Surgery 2024. doi:10.1016/j.jtcvs.2023.05.027 |
| [OE-Wadowski-2023-Volume] | Wadowski BJ, Wang S, Angel LF, et al. Prolonged Ischemia Increases Complications Among High- And Low-Volume Centers in Lung Transplantation. The Annals of Thoracic Surgery 2023. doi:10.1016/j.athoracsur.2022.10.018 |
| [OE-Hayes-2017-CenterVol] | Hayes D, Hartwig MG, Tobias JD, Tumin D. Lung Transplant Center Volume Ameliorates Adverse Influence of Prolonged Ischemic Time on Mortality. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2017. doi:10.1111/ajt.13916 |
V.8 v2.1 Ch05 OE 證據（2026-04-21）— 66 筆新增
| 代碼 | 全名 |
|---|---|
| [OE-Vajter-2024-VienaECMO] | Vajter J, Holubova G, Novysedlak R, et al. Anaesthesiologic Considerations for Intraoperative ECMO Anticoagulation During Lung Transplantation: A Single-Centre, Retrospective, Observational Study. Transplant International 2024. doi:10.3389/ti.2024.12752 |
| [OE-Lv-2021-LowAnticoag] | Lv X, Deng M, Wang L, et al. Low vs Standardized Dose Anticoagulation Regimens for Extracorporeal Membrane Oxygenation: A Meta-Analysis. PloS One 2021. doi:10.1371/journal.pone.0249854 |
| [OE-Gratz-2020-LMWH] | Gratz J, Pausch A, Schaden E, et al. Low Molecular Weight Heparin Versus Unfractioned Heparin for Anticoagulation During Perioperative Extracorporeal Membrane Oxygenation: A Single Center Experience in 102 Lung Transplant Patients. Artificial Organs 2020. doi:10.1111/aor.13642 |
| [OE-Bernhardt-2023-ISHLTMCS] | Bernhardt AM, Copeland H, Deswal A, Gluck J, Givertz MM. The International Society for Heart and Lung Transplantation/Heart Failure Society of America Guideline on Acute Mechanical Circulatory Support. J Cardiac Failure 2023. doi:10.1016/j.cardfail.2022.11.003 |
| [OE-AATS-2023-MCS-LTx] | Hartwig M, van Berkel V, et al. The American Association for Thoracic Surgery (AATS) 2022 Expert Consensus Document: The Use of Mechanical Circulatory Support in Lung Transplantation. J Thorac Cardiovasc Surg 2023. doi:10.1016/j.jtcvs.2022.06.024 |
| [OE-Vajter-2026-Viscoelastic] | Vajter J, Garaj M, Holubova G, et al. Viscoelastic Testing to Guide Anticoagulation During Extracorporeal Membrane Oxygenation in Lung Transplantation. ASAIO Journal 2026. doi:10.1097/mat.0000000000002653 |
| [OE-Guglin-2019-VAECMO] | Guglin M, Zucker MJ, Bazan VM, et al. Venoarterial ECMO for Adults: JACC Scientific Expert Panel. JACC 2019. doi:10.1016/j.jacc.2018.11.038 |
| [OE-Langmuur-2025-Anterolateral] | Langmuur SJJ, Seghers L, Hoek RAS, et al. Anterolateral vs. Clamshell Thoracotomy for Bilateral Lung Transplantation. Clin Transplantation 2025. doi:10.1111/ctr.70406 |
| [OE-Venuta-2003-Bilateral] | Venuta F, Rendina EA, De Giacomo T, et al. Bilateral Sequential Lung Transplantation Without Sternal Division. Eur J Cardiothorac Surg 2003. doi:10.1016/s1010-7940(03)00107-6 |
| [OE-Elde-2017-Incision] | Elde S, Huddleston S, Jackson S, et al. Tailored Approach to Surgical Exposure Reduces Surgical Site Complications After Bilateral Lung Transplantation. Surgical Infections 2017. doi:10.1089/sur.2017.144 |
| [OE-ParkJM-2023-SternumSparing] | Park JM, Son J, Kim DH, Son BS. A Comparative Study of a Sternum-Sparing Procedure and Clamshell Incision in Bilateral Lung Transplantation. Yonsei Medical Journal 2023. doi:10.3349/ymj.2023.0104 |
| [OE-Marczin-2016-MiniInvasive] | Marczin N, Popov AF, Zych B, et al. Outcomes of Minimally Invasive Lung Transplantation in a Single Centre: The Routine Approach for the Future or Do We Still Need Clamshell Incision?. Interact Cardiovasc Thorac Surg 2016. doi:10.1093/icvts/ivw004 |
| [OE-ParkJH-2026-VATS] | Park JH, Park S, Bae SY, et al. Safety and Feasibility of Bilateral Lung Transplantation With Video-Assisted Thoracic Surgery. Surgical Endoscopy 2026. doi:10.1007/s00464-026-12689-6 |
| [OE-Taghavi-1999-Anterolateral] | Taghavi S, Bîrsan T, Seitelberger R, et al. Initial Experience With Two Sequential Anterolateral Thoracotomies for Bilateral Lung Transplantation. Ann Thorac Surg 1999. doi:10.1016/s0003-4975(99)00228-3 |
| [OE-Shah-2017-ECMO-PAH] | Shah PR, Boisen ML, Winger DG, et al. Extracorporeal Support During Bilateral Sequential Lung Transplantation in Patients With Pulmonary Hypertension: Risk Factors and Outcomes. J Cardiothorac Vasc Anesth 2017. doi:10.1053/j.jvca.2016.08.021 |
| [OE-Kubisa-2022-RV] | Kubisa B, Kubisa A, Piotrowska M, et al. Right Heart Echocardiography Parameters and Other Predictors to Evaluate Mechanical Cardiac Support Necessity During Lung Transplantation. Transplantation Proceedings 2022. doi:10.1016/j.transproceed.2022.08.022 |
| [OE-Kawashima-2025-Extended] | Kawashima M, Ijiri N, Konoeda C, et al. Extended Use of Central Veno-Arterial Extracorporeal Membrane Oxygenation in Lung Transplantation for Patients With Pulmonary Arterial Hypertension. Eur J Cardiothorac Surg 2025. doi:10.1093/ejcts/ezaf256 |
| [OE-Moser-2018-Vienna] | Moser B, Jaksch P, Taghavi S, et al. Lung Transplantation for Idiopathic Pulmonary Arterial Hypertension on Intraoperative and Postoperatively Prolonged Extracorporeal Membrane Oxygenation Provides Optimally Controlled Reperfusion and Excellent Outcome. Eur J Cardiothorac Surg 2018. doi:10.1093/ejcts/ezx212 |
| [OE-Christensen-2012-Hemorrhage] | Christensen MC, Dziewior F, Kempel A, von Heymann C. Increased Chest Tube Drainage Is Independently Associated With Adverse Outcome After Cardiac Surgery. J Cardiothorac Vasc Anesth 2012. doi:10.1053/j.jvca.2011.09.021 |
| [OE-Colson-2016-ActiveBleed] | Colson PH, Gaudard P, Fellahi JL, et al. Active Bleeding After Cardiac Surgery: A Prospective Observational Multicenter Study. PloS One 2016. doi:10.1371/journal.pone.0162396 |
| [OE-Bercovitz-2018-PedsBleed] | Bercovitz RS, Shewmake AC, Newman DK, et al. Validation of a Definition of Excessive Postoperative Bleeding in Infants Undergoing Cardiac Surgery With Cardiopulmonary Bypass. J Thorac Cardiovasc Surg 2018. doi:10.1016/j.jtcvs.2017.12.038 |
| [OE-Shou-2023-EarlyReop] | Shou BL, Aravind P, Ong CS, et al. Early Reexploration for Bleeding Is Associated With Improved Outcome in Cardiac Surgery. Ann Thorac Surg 2023. doi:10.1016/j.athoracsur.2022.07.037 |
| [OE-Gonzalez-2009-Reop] | González D, Paradela M, Parente I, et al. Reoperation in the Postoperative Period of Lung Transplantation. Transplantation Proceedings 2009. doi:10.1016/j.transproceed.2009.06.014 |
| [OE-Adelmann-2019-Bleed] | Adelmann D, Koch S, Menger J, et al. Risk Factors for Early Bleeding Complications After Lung Transplantation - A Retrospective Cohort Study. Transplant International 2019. doi:10.1111/tri.13491 |
| [OE-Dellgren-2024-ScanCLAD] | Dellgren G, Lund TK, Raivio P, et al. Effect of Once-Per-Day Tacrolimus Versus Twice-Per-Day Ciclosporin on 3-Year Incidence of Chronic Lung Allograft Dysfunction After Lung Transplantation in Scandinavia (ScanCLAD): A Multicentre Randomised Controlled Trial. Lancet Respir Med 2024. doi:10.1016/s2213-2600(23)00293-x |
| [OE-Penninga-2013-Cochrane] | Penninga L, Møller CH, Penninga EI, et al. Antibody Induction Therapy for Lung Transplant Recipients. Cochrane Database Syst Rev 2013. doi:10.1002/14651858.cd008927.pub2 |
| [OE-Aharinejad-2004-Prediction] | Aharinejad S, Taghavi S, Klepetko W, Abraham D. Prediction of Lung-Transplant Rejection by Hepatocyte Growth Factor. Lancet 2004. doi:10.1016/s0140-6736(04)16148-5 |
| [OE-Diamond-2013-LTOG] | Diamond JM, Lee JC, Kawut SM, et al. Clinical Risk Factors for Primary Graft Dysfunction After Lung Transplantation. Am J Respir Crit Care Med 2013. doi:10.1164/rccm.201210-1865oc |
| [OE-Loor-2022-ECLS] | Loor G, Huddleston S, Hartwig M, et al. Effect of Mode of Intraoperative Support on Primary Graft Dysfunction After Lung Transplant. J Thorac Cardiovasc Surg 2022. doi:10.1016/j.jtcvs.2021.10.076 |
| [OE-ChaconAlberty-2023-Albumin] | Chacon-Alberty L, Ye S, Elsenousi A, et al. Effect of Intraoperative Support Mode on Circulating Inflammatory Biomarkers After Lung Transplantation Surgery. Artificial Organs 2023. doi:10.1111/aor.14474 |
| [OE-Whitlock-2015-SIRS] | Whitlock RP, Devereaux PJ, Teoh KH, et al. Methylprednisolone in Patients Undergoing Cardiopulmonary Bypass (SIRS): A Randomised, Double-Blind, Placebo-Controlled Trial. Lancet 2015. doi:10.1016/s0140-6736(15)00273-1 |
| [OE-Pastores-2018-Guidelines] | Pastores SM, Annane D, Rochwerg B. Guidelines for the Diagnosis and Management of Critical Illness-Related Corticosteroid Insufficiency (CIRCI) in Critically Ill Patients (Part II): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med 2018. doi:10.1007/s00134-017-4951-5 |
| [OE-Bourbon-2004-MPCPB] | Bourbon A, Vionnet M, Leprince P, et al. The Effect of Methylprednisolone Treatment on the Cardiopulmonary Bypass-Induced Systemic Inflammatory Response. Eur J Cardiothorac Surg 2004. doi:10.1016/j.ejcts.2004.07.044 |
| [OE-DellaRocca-2008-InhPGE1] | Della Rocca G, Coccia C, Pompei L, et al. Inhaled Aerosolized Prostaglandin E1, Pulmonary Hemodynamics, and Oxygenation During Lung Transplantation. Minerva Anestesiologica 2008. |
| [OE-Ghadimi-2022-Epoprostenol] | Ghadimi K, Cappiello J, Cooter-Wright M, et al. Inhaled Pulmonary Vasodilator Therapy in Adult Lung Transplant: A Randomized Clinical Trial. JAMA Surgery 2022. doi:10.1001/jamasurg.2021.5856 |
| [OE-Moreno-2009-iNO] | Moreno I, Vicente R, Mir A, et al. Effects of Inhaled Nitric Oxide on Primary Graft Dysfunction in Lung Transplantation. Transplantation Proceedings 2009. doi:10.1016/j.transproceed.2009.05.019 |
| [OE-Gorman-2022-ARDS] | Gorman EA, O’Kane CM, McAuley DF. Acute Respiratory Distress Syndrome in Adults: Diagnosis, Outcomes, Long-Term Sequelae, and Management. Lancet 2022. doi:10.1016/s0140-6736(22)01439-8 |
| [OE-Beer-2014-MechVent] | Beer A, Reed RM, Bölükbas S, et al. Mechanical Ventilation After Lung Transplantation. An International Survey of Practices and Preferences. Ann Am Thorac Soc 2014. doi:10.1513/annalsats.201312-419oc |
| [OE-Verbeek-2017-OpenLung] | Verbeek GL, Myles PS, Westall GP, et al. Intra-Operative Protective Mechanical Ventilation in Lung Transplantation: A Randomised, Controlled Trial. Anaesthesia 2017. doi:10.1111/anae.13964 |
| [OE-Durila-2021-ROTEM-RCT] | Durila M, Vajter J, Garaj M, et al. Rotational Thromboelastometry Reduces Blood Loss and Blood Product Usage After Lung Transplantation. J Heart Lung Transplant 2021. doi:10.1016/j.healun.2021.03.020 |
| [OE-Smith-2017-ROTEM-LTx] | Smith I, Pearse BL, Faulke DJ, et al. Targeted Bleeding Management Reduces the Requirements for Blood Component Therapy in Lung Transplant Recipients. J Cardiothorac Vasc Anesth 2017. doi:10.1053/j.jvca.2016.06.027 |
| [OE-Vajter-2023-Albumin] | Vajter J, Vachtenheim J, Prikrylova Z, et al. Effect of Targeted Coagulopathy Management and 5% Albumin as Volume Replacement Therapy During Lung Transplantation on Allograft Function: A Secondary Analysis of a Randomized Clinical Trial. BMC Pulmonary Medicine 2023. doi:10.1186/s12890-023-02372-0 |
| [OE-Seay-2020-HighFFP] | Seay T, Guinn N, Maisonave Y, et al. The Association of Increased FFP:RBC Transfusion Ratio to Primary Graft Dysfunction in Bleeding Lung Transplantation Patients. J Cardiothorac Vasc Anesth 2020. doi:10.1053/j.jvca.2020.05.043 |
| [OE-Brunskill-2025-Cochrane] | Brunskill SJ, Disegna A, Wong H, et al. Blood Transfusion Strategies for Major Bleeding in Trauma. Cochrane Database Syst Rev 2025. doi:10.1002/14651858.cd012635.pub2 |
| [OE-Holcomb-2015-PROPPR] | Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients With Severe Trauma: The PROPPR Randomized Clinical Trial. JAMA 2015. doi:10.1001/jama.2015.12 |
| [OE-Li-2019-TEGmeta] | Li C, Zhao Q, Yang K, Jiang L, Yu J. Thromboelastography or Rotational Thromboelastometry for Bleeding Management in Adults Undergoing Cardiac Surgery: A Systematic Review With Meta-Analysis and Trial Sequential Analysis. J Thoracic Disease 2019. doi:10.21037/jtd.2019.04.39 |
| [OE-Kvisselgaard-2025-Rapid] | Kvisselgaard AD, Wolthers SA, Wikkelsø A, et al. Rapid Update and Revision Of: Thromboelastography or Rotational Thromboelastometry Guided Algorithms in Bleeding Patients-an Updated Systematic Review With Meta-Analysis and Trial Sequential Analysis. Acta Anaesthesiol Scand 2025. doi:10.1111/aas.70127 |
| [OE-Kvisselgaard-2025-TEGsurg] | Kvisselgaard AD, Wolthers SA, Wikkelsø A, et al. Thromboelastography or Rotational Thromboelastometry Guided Algorithms in Bleeding Patients: An Updated Systematic Review With Meta-Analysis and Trial Sequential Analysis. Acta Anaesthesiol Scand 2025. doi:10.1111/aas.14558 |
| [OE-ASA-2015-Perioperative] | -. Practice Guidelines for Perioperative Blood Management: An Updated Report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management. Anesthesiology* 2015. doi:10.1097/aln.0000000000000463 |
| [OE-Ker-2012-TXAmeta] | Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of Tranexamic Acid on Surgical Bleeding: Systematic Review and Cumulative Meta-Analysis. BMJ 2012. doi:10.1136/bmj.e3054 |
| [OE-Myles-2017-ATACAS] | Myles PS, Smith JA, Forbes A, et al. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. N Engl J Med 2017. doi:10.1056/nejmoa1606424 |
| [OE-Shi-2022-OPTIMAL] | Shi J, Zhou C, Pan W, et al. Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The OPTIMAL Randomized Clinical Trial. JAMA 2022. doi:10.1001/jama.2022.10725 |
| [OE-Zufferey-2021-TXAExposure] | Zufferey PJ, Lanoiselée J, Graouch B, et al. Exposure-Response Relationship of Tranexamic Acid in Cardiac Surgery. Anesthesiology 2021. doi:10.1097/aln.0000000000003633 |
| [OE-Schieren-2025-ThoraxTXA] | Schieren M, Collaud S, Bonberg L, et al. Prophylactic Intravenous Tranexamic Acid in Thoracic Surgery: A Matched-Pair Analysis From the German Thoracic Registry. J Cardiothorac Vasc Anesth 2025. doi:10.1053/j.jvca.2025.06.005 |
| [OE-Taeuber-2021-TXAmeta] | Taeuber I, Weibel S, Herrmann E, et al. Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality: A Systematic Review, Meta-analysis, and Meta-regression. JAMA Surgery 2021. doi:10.1001/jamasurg.2021.0884 |
| [OE-Hong-2022-TXAumbrella] | Hong P, Liu R, Rai S, et al. Does Tranexamic Acid Reduce the Blood Loss in Various Surgeries? An Umbrella Review of State-of-the-Art Meta-Analysis. Front Pharmacol 2022. doi:10.3389/fphar.2022.887386 |
| [OE-Hunt-2015-TXAreview] | Hunt BJ. The Current Place of Tranexamic Acid in the Management of Bleeding. Anaesthesia 2015. doi:10.1111/anae.12910 |
| [OE-Karanicolas-2024-TXA-CABG] | Karanicolas PJ, Lin Y, McCluskey SA, et al. Tranexamic Acid in Patients Undergoing Liver Resection: The HeLiX Randomized Clinical Trial. JAMA 2024. doi:10.1001/jama.2024.11783 |
| [OE-Wallia-2017-LTxGlycemic] | Wallia A, Schmidt K, Oakes DJ, et al. Glycemic Control Reduces Infections in Post-Liver Transplant Patients: Results of a Prospective, Randomized Study. J Clin Endocrinol Metab 2017. doi:10.1210/jc.2016-3279 |
| [OE-Garcia-2013-Heart] | Garcia C, Wallia A, Gupta S, et al. Intensive Glycemic Control After Heart Transplantation Is Safe and Effective for Diabetic and Non-Diabetic Patients. Clinical Transplantation 2013. doi:10.1111/ctr.12118 |
| [OE-Hackman-2017-LTxGlucose] | Hackman KL, Snell GI, Bach LA. Poor Glycemic Control Is Associated With Decreased Survival in Lung Transplant Recipients. Transplantation 2017. doi:10.1097/tp.0000000000001555 |
| [OE-Galindo-2016-Hyperglycemia] | Galindo RJ, Wallia A. Hyperglycemia and Diabetes Mellitus Following Organ Transplantation. Current Diabetes Reports 2016. doi:10.1007/s11892-015-0707-1 |
| [OE-ADA-2026-S16] | ADA Professional Practice Committee. (see OE article ). Diabetes Care 2026. doi:10.2337/dc26-s016 |
| [OE-Sun-2025-Perioperative] | Sun Y, Wen Z, Ren Y, Hua Z. Perioperative Tight Glucose Control Regimens for Preventing Surgical Site Infections Following Cardiac Surgery-a Systematic Review and Metanalysis of Randomized Controlled Trials. J Clin Anesth 2025. doi:10.1016/j.jclinane.2025.112051 |
| [OE-Rogers-2024-Cochrane] | Rogers LJ, Vaja R, et al. (see OE article ). Cochrane Database Syst Rev 2024. doi:10.1002/14651858.cd013332.pub2 |
| [OE-Lawton-2022-ACC-CABG] | Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. JACC 2022. doi:10.1016/j.jacc.2021.09.006 |
V.9 v2.1 Ch06 OE 證據（2026-04-21）— 18 筆新增
| 代碼 | 全名 |
|---|---|
| [OE-Levy-2014-Fibrinogen] | Levy JH, Welsby I, Goodnough LT. Fibrinogen as a therapeutic target for bleeding: a review of critical levels and replacement therapy. Transfusion 2014. doi:10.1111/trf.12431 |
| [OE-Callum-2019-FIBRES] | Callum J, Farkouh ME, Scales DC, et al. Effect of Fibrinogen Concentrate vs Cryoprecipitate on Blood Component Transfusion After Cardiac Surgery: The FIBRES Randomized Clinical Trial. JAMA 2019. doi:10.1001/jama.2019.17312 |
| [OE-Ranucci-2020-FibrinogenTrials] | Ranucci M, Di Dedda U, Baryshnikova E. Fibrinogen Supplementation in Cardiac Surgery Bleeding: A Meta-Analysis of Randomized Controlled Trials. Anesthesia and Analgesia 2020. doi:10.1213/ane.0000000000004522 |
| [OE-Vajter-2023-POCLungTx] | Vajter J, Vachtenheim J, Prikrylova Z, et al. Effect of targeted coagulopathy management and 5% albumin as alternative to plasma on intraoperative bleeding and early postoperative outcomes in lung transplantation. BMC Pulmonary Medicine 2023. doi:10.1186/s12890-023-02372-0 |
| [OE-Christie-2024-NEJMReview] | Christie JD, Van Raemdonck D, Fisher AJ. Lung Transplantation. NEJM 2024. doi:10.1056/nejmra2401039 |
| [OE-ChaconAlberty-2023-PGD] | Chacon-Alberty L, Fernandez R, Jindra P, et al. Primary Graft Dysfunction in Lung Transplantation: A Review of Mechanisms and Future Applications. Transplantation 2023. doi:10.1097/tp.0000000000004503 |
| [OE-Cadd-2025-PCCvsrFVIIa] | Cadd M, Puntis D, Bullard S, et al. Prothrombin Complex Concentrate vs Recombinant Factor VIIa for Refractory Bleeding in Cardiac Surgery: Systematic Review and Meta-Analysis. J Cardiothorac Vasc Anesth 2025. doi:10.1053/j.jvca.2025.09.043 |
| [OE-Hayes-2022-CochranePCC] | Hayes K, Fernando MC, Jordan V. Prothrombin complex concentrate versus fresh frozen plasma or recombinant factor VIIa for the reduction of bleeding in cardiac surgery: a systematic review. Cochrane Database of Systematic Reviews 2022. doi:10.1002/14651858.cd013551.pub2 |
| [OE-Caldwell-2024-PCCrFVIIa] | Caldwell L, Bhakta R, Naik N, et al. Comparison of 4F-PCC and rFVIIa for Refractory Bleeding in Adult Cardiac Surgery. Journal of Pharmacy Practice 2024. doi:10.1177/08971900241228766 |
| [OE-Katz-2022-PCCrFVIIa] | Katz A, Ahuja T, Arnouk S, et al. A Comparison of Prothrombin Complex Concentrate and Recombinant Activated Factor VII for the Management of Bleeding With Cardiac Surgery. Journal of Intensive Care Medicine 2022. doi:10.1177/0885066620984443 |
| [OE-Bhaskar-2013-rFVIIaLTx] | Bhaskar B, Zeigenfuss M, Choudhary J, Fraser JF. Use of recombinant activated factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications. Transfusion 2013. doi:10.1111/j.1537-2995.2012.03801.x |
| [OE-Neira-2025-rFVIIa] | Neira VM, Neira CD, Matheson K, et al. Rescue recombinant activated factor VII in cardiac surgery: propensity-matched analysis. Interdisciplinary Cardiovascular and Thoracic Surgery 2025. doi:10.1093/icvts/ivaf185 |
| [OE-Erdoes-2021-EACTA-Bleeding] | Erdoes G, Koster A, Ortmann E, et al. A European consensus statement on the use of four-factor prothrombin complex concentrate for cardiac and non-cardiac surgical patients. Anaesthesia 2021. doi:10.1111/anae.15181 |
| [OE-Laxar-2023-rFVIIaLTx] | Laxar D, Schaden E, Wiegele M, et al. Use of Off-Label Recombinant Activated Factor VII in Lung Transplantation: Safety and Efficacy. Journal of Clinical Medicine 2023. doi:10.3390/jcm12083020 |
| [OE-Tanaka-2018-VAECMO-MAP] | Tanaka D, Shimada S, Mullin M, et al. What Is the Optimal Blood Pressure on Veno-Arterial Extracorporeal Membrane Oxygenation? Impact of Mean Arterial Pressure on Survival. ASAIO Journal 2018. doi:10.1097/mat.0000000000000824 |
| [OE-Lorusso-2021-ELSOConsensus] | Lorusso R, Whitman G, Milojevic M, et al. 2020 EACTS/ELSO/STS/AATS expert consensus on post-cardiotomy extracorporeal life support in adult patients. J Thorac Cardiovasc Surg 2021. doi:10.1016/j.jtcvs.2020.09.045 |
| [OE-Tucker-2024-DukeAnticoag] | Tucker WD, Gannon WD, Petree B, et al. Impact of anticoagulation intensity on outcomes after intraoperative extracorporeal membrane oxygenation for lung transplantation. J Heart Lung Transplant 2024. doi:10.1016/j.healun.2024.02.008 |
| [OE-Raman-2019-LowHeparin] | Raman J, Alimohamed M, Dobrilovic N, Lateef O, Aziz S. A bias-corrected, mixed-effects meta-analysis on the use of full dose or low-dose unfractionated heparin during veno-venous extracorporeal membrane oxygenation. J Heart Lung Transplant 2019. doi:10.1016/j.healun.2019.01.1313 |
V.10 v2.1 Ch07 OE 證據（2026-04-22）— 55 筆新增
| 代碼 | 全名 |
|---|---|
| [OE-Villavicencio-2026-VAECMO-RCT] | Villavicencio MA, Saddoughi SA, Spencer PJ, et al. Venoarterial extracorporeal membrane oxygenation versus off-pump lung transplantation: interim analysis of a multicenter RCT. J Thorac Cardiovasc Surg 2026. doi:10.1016/j.jtcvs.2025.12.021 |
| [OE-Hoetzenecker-2018-ViennaRoutineECMO] | Hoetzenecker K, Schwarz S, Muckenhuber M, et al. Intraoperative extracorporeal membrane oxygenation and the possibility of postoperative prolongation improve survival in bilateral lung transplantation. J Thorac Cardiovasc Surg 2018. doi:10.1016/j.jtcvs.2017.10.144 |
| [OE-Messika-2024-ECMOToP] | Messika J, Eloy P, Boulate D, et al. Extracorporeal membrane oxygenation to prevent primary graft dysfunction during lung transplantation (ECMOToP): protocol for a multicentre RCT. BMJ Open 2024. doi:10.1136/bmjopen-2023-077770 |
| [OE-Diamond-2013-FiO2-PGD] | Diamond JM, Lee JC, Kawut SM, et al. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2013. doi:10.1164/rccm.201210-1865oc |
| [OE-Diamond-2016-F2iso-PGD] | Diamond JM, Porteous MK, Roberts LJ, et al. The relationship between plasma lipid peroxidation products and primary graft dysfunction after lung transplantation is modified by donor smoking. J Heart Lung Transplant 2016. doi:10.1016/j.healun.2015.12.012 |
| [OE-Shaver-2018-cfHb-PGD] | Shaver CM, Wickersham N, McNeil JB, et al. Cell-free hemoglobin promotes primary graft dysfunction through oxidative lung endothelial injury. JCI Insight 2018. doi:10.1172/jci.insight.98546 |
| [OE-Gu-2024-Hyperoxia-ECMO-Meta] | Gu WJ, Shi R, Cen Y, et al. Association between hyperoxia and mortality in adult patients on ECMO: a systematic review and meta-analysis. Anesth Analg 2024. doi:10.1213/ane.0000000000007348 |
| [OE-Zeng-2025-Hyperoxia-Meta] | Zeng M, Lv X, Zhu J, et al. Association between hyperoxia and mortality in adult ECMO: updated meta-analysis. J Crit Care 2025. doi:10.1016/j.jcrc.2025.155338 |
| [OE-Munshi-2017-ELSO-VV-O2] | Munshi L, Kiss A, Cypel M, et al. Oxygen thresholds and mortality during extracorporeal life support in adult patients. Crit Care Med 2017. doi:10.1097/ccm.0000000000002643 |
| [OE-Burrell-2024-EXCEL-VAECMO-O2] | Burrell A, Bailey MJ, Bellomo R, et al. EXCEL: conservative vs liberal oxygen targets in VA-ECMO randomized trial. Intensive Care Med 2024. doi:10.1007/s00134-024-07564-8 |
| [OE-Ellman-2005-Hyperoxic-Rabbit] | Ellman PI, Alvis JS, Tache-Leon C, et al. Hyperoxic ventilation exacerbates lung reperfusion injury. J Thorac Cardiovasc Surg 2005. doi:10.1016/j.jtcvs.2005.06.037 |
| [OE-Premraj-2024-OxygenationECMO] | Premraj L, Brown A, Fraser JF, et al. Oxygenation targets on ECMO. Crit Care Med 2024. doi:10.1097/ccm.0000000000006134 |
| [OE-Hoetzenecker-2020-ViennaPGD24h] | Hoetzenecker K, Benazzo A, Stork T, et al. Bilateral lung transplantation on intraoperative ECMO: Vienna 2020 update. J Thorac Cardiovasc Surg 2020. doi:10.1016/j.jtcvs.2019.10.155 |
| [OE-Harano-2021-RescueECMO-PGD] | Harano T, Ryan JP, Morrell MR, Luketich JD, Sanchez PG. Extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation. ASAIO J 2021. doi:10.1097/mat.0000000000001350 |
| [OE-Takahashi-2023-PGD3-VV-VA] | Takahashi T, Terada Y, Pasque MK, et al. Outcomes of VV vs VA ECMO for primary graft dysfunction after lung transplantation. Ann Thorac Surg 2023. doi:10.1016/j.athoracsur.2022.12.038 |
| [OE-Luu-2023-ECMOManagement-LTx] | Luu HY, Santos J, Isaza E, Brzezinski M, Kukreja J. Management of extracorporeal membrane oxygenation in lung transplantation. J Thorac Dis 2023. doi:10.21037/jtd-22-1387 |
| [OE-Minqiang-2021-LTx-ECMO] | Minqiang L, Xiaoshan L, Bo X, et al. A comparison of early versus delayed extracorporeal membrane oxygenation withdrawal after lung transplantation. Transplantation 2021. doi:10.1097/tp.0000000000003290 |
| [OE-Guervilly-2022-UltraProtective] | Guervilly C, Fournier T, Chommeloux J, et al. Ultra-protective ventilation versus EOLIA strategy in VV-ECMO for severe ARDS: RCT. Crit Care 2022. doi:10.1186/s13054-022-04272-x |
| [OE-Rozencwajg-2019-UltraProtective] | Rozencwajg S, Guihot A, Franchineau G, et al. Ultra-protective ventilation reduces biotrauma in VV-ECMO. Crit Care Med 2019. doi:10.1097/ccm.0000000000003894 |
| [OE-Schmidt-2019-EOLIA-MechanicalPower] | Schmidt M, Pham T, Arcadipane A, et al. Mechanical ventilation management during ECMO for ARDS: an international multicenter prospective cohort. Am J Respir Crit Care Med 2019. doi:10.1164/rccm.201806-1094oc |
| [OE-Noda-2024-VV-PGD] | Noda K, Jawad-Makki MH, Chan EG, et al. Veno-venous ECMO for primary graft dysfunction after lung transplantation. Clin Transplant 2024. doi:10.1111/ctr.70029 |
| [OE-Christie-2024-PGD-NEJM] | Christie JD, Van Raemdonck D, Fisher AJ. Lung transplantation. N Engl J Med 2024. doi:10.1056/nejmra2401039 |
| [OE-Rodriguez-2025-ECMO-Physiology] | Rodriguez Y, Thomachot A, Deniel G, et al. Physiological approach to ECMO ventilation. Ann Intensive Care 2025. doi:10.1186/s13613-025-01525-0 |
| [OE-Alviar-2018-PositivePressureECMO] | Alviar CL, Miller PE, McAreavey D, et al. Positive pressure ventilation in the cardiac intensive care unit. J Am Coll Cardiol 2018. doi:10.1016/j.jacc.2018.06.074 |
| [OE-Gratz-2020-ViennaLMWH] | Gratz J, Pausch A, Schaden E, et al. Low molecular weight heparin versus unfractionated heparin for anticoagulation during perioperative ECMO in lung transplantation. Artif Organs 2020. doi:10.1111/aor.13642 |
| [OE-Wiegele-2022-EnoxaparinCOVID-ECMO] | Wiegele M, Laxar D, Schaden E, et al. Subcutaneous enoxaparin versus UFH in COVID-19 patients on ECMO. Front Med 2022. doi:10.3389/fmed.2022.879425 |
| [OE-Piwowarczyk-2021-Nadroparin-VV] | Piwowarczyk P, Borys M, Kutnik P, et al. Unfractionated heparin versus nadroparin for VV-ECMO. ASAIO J 2021. doi:10.1097/mat.0000000000001166 |
| [OE-Krueger-2017-Enoxaparin-VV] | Krueger K, Schmutz A, Zieger B, Kalbhenn J. Venovenous ECMO with prophylactic-dose enoxaparin only. Artif Organs 2017. doi:10.1111/aor.12737 |
| [OE-Seelhammer-2024-CochraneECMO-Anticoag] | Seelhammer T, Ninan J, Nei S, et al. Anticoagulation during ECMO in adults (Cochrane protocol). Cochrane Database Syst Rev 2024. doi:10.1002/14651858.cd015685 |
| [OE-Levy-2021-HeparinNEJM] | Levy JH, Connors JM. Heparin-induced thrombocytopenia, a prothrombotic disease. N Engl J Med 2021. doi:10.1056/nejmra2104091 |
| [OE-Sun-2023-AntiXa-Systematic] | Sun J, Ma Y, Su W, et al. Comparison of anticoagulation monitoring strategies during ECMO: systematic review. Heart Lung 2023. doi:10.1016/j.hrtlng.2023.05.003 |
| [OE-FigueroaVillalba-2020-ACTtoAntiXa] | Figueroa Villalba CA, Brogan TV, McMullan DM, et al. Conversion from ACT to anti-Xa monitoring on pediatric ECMO. Crit Care Med 2020. doi:10.1097/ccm.0000000000004615 |
| [OE-AlJazairi-2021-ECMOmonitoring] | Al-Jazairi A, Raslan S, Al-Mehizia R, et al. Performance of anti-Xa vs aPTT vs ACT in adult ECMO. Ann Pharmacother 2021. doi:10.1177/1060028020960409 |
| [OE-Ranucci-2020-AntiXaECMO] | Ranucci M, Cotza M, Isgrò G, et al. Anti-Xa monitoring on ECMO. Semin Thromb Hemost 2020. doi:10.1055/s-0039-1697950 |
| [OE-Kanji-2022-Optimal] | Kanji R, Vandenbriele C, Arachchillage DRJ, Price S, Gorog DA. Optimal anticoagulation monitoring on ECMO. Thromb Haemost 2022. doi:10.1055/a-1508-8230 |
| [OE-Martucci-2024-PROTECMO-AJRCCM] | Martucci G, Giani M, Schmidt M, et al. Anticoagulation during VV-ECMO: PROTECMO aPTT analysis. Am J Respir Crit Care Med 2024. doi:10.1164/rccm.202305-0896oc |
| [OE-Hu-2025-Bivalirudin-Meta] | Hu Y, Yu L, Yang W. Effectiveness of bivalirudin vs heparin in adult ECMO: meta-analysis. Medicine (Baltimore) 2025. doi:10.1097/md.0000000000042696 |
| [OE-Chen-2023-NetworkMeta] | Chen J, Chen G, Zhao W, Peng W. Anticoagulation in adult ECMO: network meta-analysis. Pharmacotherapy 2023. doi:10.1002/phar.2859 |
| [OE-Liu-2022-Bivalirudin] | Liu L, Liu F, Tan J, Zhao L. Bivalirudin versus heparin for ECMO anticoagulation: meta-analysis. Pharmacol Res 2022. doi:10.1016/j.phrs.2022.106089 |
| [OE-Li-2022-Bivalirudin] | Li MJ, Shi JY, Zhang JH. Bivalirudin versus heparin for adult ECMO: meta-analysis. Br J Clin Pharmacol 2022. doi:10.1111/bcp.15251 |
| [OE-Kartika-2024-Bivalirudin-VV] | Kartika T, Mathews R, Migneco G, et al. Bivalirudin vs heparin in VV-ECMO. Eur J Haematol 2024. doi:10.1111/ejh.14146 |
| [OE-Lofy-2026-Bivalirudin-Retro] | Lofy T, Juul J, Duewell B, et al. Retrospective bivalirudin vs heparin ECMO cohort. Ann Pharmacother 2026. doi:10.1177/10600280251371081 |
| [OE-Saura-2025-ECMO-Anticoag] | Saura O, Levy D, Schmidt M. Anticoagulation during ECMO: current opinion. Curr Opin Anaesthesiol 2025. doi:10.1097/aco.0000000000001603 |
| [OE-Martucci-2023-PROTECMO-Lancet] | Martucci G, Schmidt M, Agerstrand C, et al. Transfusion practice in VV-ECMO: PROTECMO. Lancet Respir Med 2023. doi:10.1016/s2213-2600(22)00353-8 |
| [OE-Boscolo-2025-TransfusionMeta] | Boscolo A, Sella N, Pettenuzzo T, et al. Transfusion thresholds on ECMO: network meta-analysis. Artif Organs 2025. doi:10.1111/aor.70001 |
| [OE-Pratt-2024-Hb-VV] | Pratt EH, Pulsipher AM, Moulton NG, et al. Association of hemoglobin thresholds with mortality in VV-ECMO. Chest 2024. doi:10.1016/j.chest.2024.05.043 |
| [OE-Ng-2023-RestrictiveECMO] | Ng PY, Chan HCV, Ip A, et al. Restrictive vs liberal transfusion strategy on ECMO. Transfusion 2023. doi:10.1111/trf.17221 |
| [OE-Thao-2025-LiberalRestrictive] | Thao LTP, Buscher H, Nguyen TL, et al. Liberal vs restrictive transfusion on ECMO: target-trial emulation. Crit Care 2025. doi:10.1186/s13054-025-05606-1 |
| [OE-Raasveld-2023-Plt-PROTECMO] | Raasveld SJ, van den Oord C, Schenk J, et al. Thrombocytopenia and bleeding on VV-ECMO: PROTECMO sub-study. Crit Care 2023. doi:10.1186/s13054-023-04612-5 |
| [OE-Young-2025-ELSO-BTT-Volume] | Young SD, Weber MP, Ryan KJ, et al. Impact of center volume on outcomes in bridge-to-transplant ECMO. Ann Thorac Surg 2025. doi:10.1016/j.athoracsur.2025.04.017 |
| [OE-Halpern-2019-BTT-Volume] | Halpern AL, Kohtz PD, Helmkamp L, et al. Improved outcomes of lung transplantation at high-volume centers in patients requiring ECMO. Ann Thorac Surg 2019. doi:10.1016/j.athoracsur.2019.03.057 |
| [OE-Deitz-2023-BTT-Waitlist] | Deitz RL, Emerel L, Chan EG, et al. Waitlist outcomes of BTT ECMO by center volume. Ann Thorac Surg 2023. doi:10.1016/j.athoracsur.2023.02.062 |
| [OE-Omar-2015-pfHb-ECMO] | Omar HR, Mirsaeidi M, Socias S, et al. Plasma-free hemoglobin predicts mortality in adult ECMO. PLoS One 2015. doi:10.1371/journal.pone.0124034 |
| [OE-Graw-2022-pfHb-AKI] | Graw JA, Hildebrandt P, Krannich A, et al. Plasma-free hemoglobin and AKI in VV-ECMO ARDS. Crit Care 2022. doi:10.1186/s13054-022-03894-5 |
| [OE-Lehle-2015-pfHb-VV] | Lehle K, Philipp A, Zeman F, et al. Technical complications of ECMO and plasma-free hemoglobin. PLoS One 2015. doi:10.1371/journal.pone.0143527 |
V.11 v2.1 Ch09 OE 證據（2026-04-22）— 28 筆新增
| 代碼 | 全名 |
|---|---|
| [OE-Porteous-2017-PAH-PGD] | Porteous MK, Lee JC, Lederer DJ, et al. Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction After Lung Transplantation in Patients with Pulmonary Hypertension. Ann Am Thorac Soc 2017. doi:10.1513/annalsats.201610-810oc |
| [OE-Ehrsam-2022-mPAP-PGD3] | Ehrsam JP, Held U, Opitz I, et al. Recipient Risk Factors and Outcomes After Lung Transplantation: A Single-Center Experience. Transpl Int 2022. doi:10.3389/ti.2022.10451 |
| [OE-Kuntz-2009-UNOS-PGD] | Kuntz CL, Hadjiliadis D, Ahya VN, et al. Risk Factors for Early Primary Graft Dysfunction After Lung Transplantation: A Registry Study. Clin Transplant 2009. doi:10.1111/j.1399-0012.2008.00951.x |
| [OE-Liu-2013-PGD-Meta] | Liu Y, Liu Y, Su L, Jiang SJ. Recipient-Related Clinical Risk Factors for Primary Graft Dysfunction After Lung Transplantation: A Systematic Review and Meta-Analysis. PloS One 2013. doi:10.1371/journal.pone.0092773 |
| [OE-Fang-2011-mPAP-IPF] | Fang A, Studer S, Kawut SM, et al. Elevated Pulmonary Artery Pressure Is a Risk Factor for Primary Graft Dysfunction Following Lung Transplantation for Idiopathic Pulmonary Fibrosis. Chest 2011. doi:10.1378/chest.09-2806 |
| [OE-Cottini-2018-mPAP-PGD] | Cottini SR, Della Torre A, Steiger P, et al. Pulmonary Hypertension as a Risk Factor for Primary Graft Dysfunction After Lung Transplantation. Clin Transplant 2018. doi:10.1111/ctr.13251 |
| [OE-Schnickel-2006-ControlledReperfusion] | Schnickel GT, Ross DJ, Beygui R, et al. Modified Reperfusion in Clinical Lung Transplantation: The Results of 100 Consecutive Cases. J Thorac Cardiovasc Surg 2006. doi:10.1016/j.jtcvs.2005.08.045 |
| [OE-Ardehali-2003-ControlledReperfusion] | Ardehali A, Laks H, Levine M, et al. Modified Reperfusion and Ischemia-Reperfusion Injury in Human Lung Transplantation. J Thorac Cardiovasc Surg 2003. doi:10.1016/s0022-5223(03)00976-0 |
| [OE-Currey-2010-ReperfusionGuideline] | Currey J, Pilcher DV, Davies A, et al. Implementation of a Management Guideline Aimed at Minimizing the Severity of Primary Graft Dysfunction After Lung Transplant. J Thorac Cardiovasc Surg 2010. doi:10.1016/j.jtcvs.2009.08.031 |
| [OE-Halldorsson-1998-AnnThorac] | Halldorsson AO, Kronon M, Allen BS, et al. Controlled Reperfusion Prevents Pulmonary Injury After 24 Hours of Lung Preservation. Ann Thorac Surg 1998. doi:10.1016/s0003-4975(98)00673-0 |
| [OE-Halldorsson-1998-JTCVS] | Halldorsson A, Kronon M, Allen BS, et al. Lowering Reperfusion Pressure Reduces the Injury After Pulmonary Ischemia. J Thorac Cardiovasc Surg 1998. doi:10.1016/s0022-5223(98)70286-7 |
| [OE-Fiser-2002-ControlledReperfusion] | Fiser SM, Kron IL, Long SM, et al. Controlled Perfusion Decreases Reperfusion Injury After High-Flow Reperfusion. J Heart Lung Transplant 2002. doi:10.1016/s1053-2498(01)00774-4 |
| [OE-Lick-2000-ReperfusionTechnique] | Lick SD, Brown PS Jr, Kurusz M, et al. A Simple Technique to Minimize Reperfusion Injury After Lung Transplantation. Ann Thorac Surg 2000. doi:10.1016/s0003-4975(99)01436-8 |
| [OE-PerezTeran-2016-EuRespJ] | Perez-Teran P, Roca O, Rodriguez-Palomares J, et al. Prospective Validation of Right Heart Catheterization Predictors of Long-Term Outcome in Lung Transplantation. Eur Respir J 2016. doi:10.1183/13993003.02136-2015 |
| [OE-PerezTeran-2015-JHLT] | Perez-Teran P, Roca O, Rodriguez-Palomares J, et al. Influence of Right Ventricular Function on the Outcome of Lung Transplantation. J Heart Lung Transplant 2015. doi:10.1016/j.healun.2015.05.026 |
| [OE-Orlitova-2023-RVFunction-IRI] | Orlitova M, Vanstapel A, Van Slambrouck J, et al. The Role of Right Ventricular Function in Ischemia-Reperfusion Injury After Lung Transplantation. Am J Physiol Lung Cell Mol Physiol 2023. doi:10.1152/ajplung.00281.2022 |
| [OE-Schafer-2026-RVStrain-PGD] | Schafer M, et al. Reduced Preoperative Right Ventricular Function Is Associated with Primary Graft Dysfunction After Lung Transplantation. Ann Thorac Surg 2026. doi:10.1016/j.athoracsur.2026.02.030 |
| [OE-Huang-2008-PGD-BOS] | Huang HJ, Yusen RD, Meyers BF, et al. Late Primary Graft Dysfunction After Lung Transplantation and Bronchiolitis Obliterans Syndrome. Am J Transplant 2008. doi:10.1111/j.1600-6143.2008.02389.x |
| [OE-DerHovanessian-2016-PGD-BOS] | DerHovanessian A, Weigt SS, Palchevskiy V, et al. The Role of TGF-β in the Association Between Primary Graft Dysfunction and Bronchiolitis Obliterans Syndrome. Am J Transplant 2016. doi:10.1111/ajt.13475 |
| [OE-Li-2021-Toronto-BLAD] | Li D, Liu Y, Wang B, et al. Baseline Lung Allograft Dysfunction in Primary Graft Dysfunction Survivors After Lung Transplantation. Respir Med 2021. doi:10.1016/j.rmed.2021.106617 |
| [OE-Wong-2023-Pediatric-PGD-CLAD] | Wong W, Josephson MB, Heltshe SL, et al. Primary Graft Dysfunction and Chronic Lung Allograft Dysfunction in Pediatric Lung Transplantation. J Heart Lung Transplant 2023. doi:10.1016/j.healun.2022.12.014 |
| [OE-Whitson-2007-PGD-BOSfree] | Whitson BA, Prekker ME, Herrington CS, et al. Primary Graft Dysfunction and Long-Term Pulmonary Function After Lung Transplantation. J Heart Lung Transplant 2007. doi:10.1016/j.healun.2007.07.018 |
| [OE-Gouchoe-2024-UNOS-Longterm] | Gouchoe DA, Whitson BA, et al. Long-Term Outcomes After Primary Graft Dysfunction in Lung Transplantation. J Surg Res 2024. doi:10.1016/j.jss.2023.12.006 |
| [OE-Pavlisko-2022-LateALI] | Pavlisko EN, Adegunsoye A, Todd JL, et al. Prognostic Implications of Late Acute Lung Injury/Organizing Pneumonia in Lung Transplant Recipients. Am J Transplant 2022. doi:10.1111/ajt.17183 |
| [OE-Young-2019-Chest-PGD] | Young KA, Dilling DF, et al. The Future of Lung Transplantation. Chest 2019. doi:10.1016/j.chest.2018.08.1036 |
| [OE-Shah-2018-PGDReview] | Shah RJ, Diamond JM. Primary Graft Dysfunction After Lung Transplantation. Semin Respir Crit Care Med 2018. doi:10.1055/s-0037-1615797 |
| [OE-Benazzo-2025-EVLP-PGD72h] | Benazzo A, Peel J, Mariscal A, et al. Differential Outcomes of ISHLT PGD 3 After Ex-Vivo Lung Perfusion Compared to PGD 3 After Direct Transplantation. J Heart Lung Transplant 2025. doi:10.1016/j.healun.2025.08.002 |
| [OE-Cantu-2022-PGDtrends] | Cantu E, Diamond JM, Cevasco M, et al. Contemporary Trends in PGD Incidence, Outcomes, and Therapies. J Heart Lung Transplant 2022. doi:10.1016/j.healun.2022.08.013 |
V.12 v2.1 Ch08 OE 證據（2026-04-22）— 68 筆新增
| 代碼 | 全名 |
|---|---|
| [OE-Niroomand-2022-PEEP-PGD] | Niroomand A, Qvarnström S, Stenlo M, et al. The role of mechanical ventilation in primary graft dysfunction in the postoperative lung transplant recipient: a single center study and literature review. Acta Anaesthesiol Scand 2022. doi:10.1111/aas.14025 |
| [OE-Beer-2014-VentSurvey] | Beer A, Reed RM, Bölükbas S, et al. Mechanical ventilation after lung transplantation. An international survey of practices and preferences. Ann Am Thorac Soc 2014. doi:10.1513/annalsats.201312-419oc |
| [OE-Morgan-2023-VentScopingReview] | Morgan S, Aneman A, Nair P. Mechanical ventilation post-bilateral lung transplantation: a scoping review. Acta Anaesthesiol Scand 2023. doi:10.1111/aas.14219 |
| [OE-Xuan-2024-DrivingPressure] | Xuan C, Gu J, Chen J, Xu H. Driving pressure association with mortality in post-lung transplant patients: a prospective observational study. J Int Med Res 2024. doi:10.1177/03000605241259442 |
| [OE-Urner-2023-DrivingPressureGformula] | Urner M, Jüni P, Rojas-Saunero LP, et al. Limiting dynamic driving pressure in patients requiring mechanical ventilation. Crit Care Med 2023. doi:10.1097/ccm.0000000000005844 |
| [OE-Lertjitbanjong-2019-AKImeta] | Lertjitbanjong P, Thongprayoon C, Cheungpasitporn W, et al. Acute Kidney Injury after Lung Transplantation: A Systematic Review and Meta-Analysis. J Clin Med 2019. doi:10.3390/jcm8101713 · PMID 31627379 |
| [OE-Hansen-2020-OR-Extubation] | Hansen LN, Westhoff CC, Schaper J, et al. Take a Deep Breath: Operating Room Extubation After Bilateral Lung Transplantation. J Cardiothorac Vasc Anesth 2025. doi:10.1053/j.jvca.2024.11.023 |
| [OE-Felten-2016-OR-Extubation-COPD] | Felten ML, Sinaceur M, Treilhaud M, et al. Immediate extubation after bilateral lung transplantation in emphysema. J Thorac Cardiovasc Surg 2016. |
| [OE-Assenzo-2018-OR-Extubation-CF] | Assenzo V, Assenzo C, Filloux B, et al. The feasibility of extubation in the operating room after bilateral lung transplantation. Eur J Cardiothorac Surg 2018. doi:10.1093/ejcts/ezy196 |
| [OE-Smith-2018-LTOG-Delirium] | Smith PJ, Stonerock GL, Ingle KK, et al. Postoperative delirium after lung transplantation: incidence and risk factors. J Heart Lung Transplant 2018. |
| [OE-Anderson-2022-UCLA-Delirium] | Anderson BJ, Bermúdez CA, Diamond JM, et al. Postoperative delirium in lung transplant recipients: outcomes from a single-center cohort. Clin Transplant 2022. |
| [OE-Sher-2017-Delirium-LTx] | Sher Y, Mooney J, Dhillon G, et al. Delirium after lung transplantation: Association with recipient characteristics. Pediatr Transplant 2017. doi:10.1111/petr.12892 |
| [OE-Raghavan-2015-POAF-LTx] | Raghavan D, Gao A, Ahn C, et al. Contemporary analysis of incidence of post-operative atrial fibrillation, its predictors, and association with clinical outcomes in lung transplantation. J Heart Lung Transplant 2015. doi:10.1016/j.healun.2014.09.032 |
| [OE-Waldron-2017-POAF-Meta] | Waldron NH, Klinger RY, Hartwig MG, et al. Atrial fibrillation following lung transplantation: a systematic review and meta-analysis. Clin Transplant 2017. |
| [OE-Mason-2007-AF-LTx] | Mason DP, Marsh DH, Alster JM, et al. Atrial fibrillation after lung transplantation: timing, risk factors, and treatment. Ann Thorac Surg 2007. doi:10.1016/j.athoracsur.2007.07.014 |
| [OE-Roukoz-2017-AF-LTx-Review] | Roukoz H, Benditt DG. Atrial arrhythmias after lung transplantation. Trends Cardiovasc Med 2017. doi:10.1016/j.tcm.2017.07.009 |
| [OE-Magnusson-2022-AmioCLAD] | Magnusson JM, Bobbio E, Danielsson C, et al. A retrospective study of posttransplant amiodarone exposition on CLAD development and survival after lung transplantation. Transplant Proc 2022. doi:10.1016/j.transproceed.2021.11.031 |
| [OE-Escamilla-2026-Amio-LTx] | Escamilla J, January S, Fester K, et al. Amiodarone for the management of acute atrial arrhythmias after lung transplant. Cardiovasc Drugs Ther 2026. doi:10.1007/s10557-025-07725-x |
| [OE-Marazzato-2023-Atrial-LTx] | Marazzato J, Eikermann M, Di Biase L. Management of atrial arrhythmias after lung transplant. JACC Clin Electrophysiol 2023. doi:10.1016/j.jacep.2023.01.021 |
| [OE-Frendl-2014-AATS-AF] | Frendl G, Sodickson AC, Chung MK, et al. 2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures. J Thorac Cardiovasc Surg 2014. doi:10.1016/j.jtcvs.2014.06.036 |
| [OE-Nicolau-1992-AmioCSA] | Nicolau DP, Uber WE, Crumbley AJ, Strange C. Amiodarone-cyclosporine interaction in a heart transplant patient. J Heart Lung Transplant 1992. |
| [OE-Chitwood-1993-AmioCSA] | Chitwood KK, Abdul-Haqq AJ, Heim-Duthoy KL. Cyclosporine-amiodarone interaction. Ann Pharmacother 1993. doi:10.1177/106002809302700506 |
| [OE-Jennings-2015-AmioHeart] | Jennings DL, Martinez B, Montalvo S, Lanfear DE. Impact of pre-implant amiodarone exposure on outcomes in cardiac transplant recipients. Heart Fail Rev 2015. doi:10.1007/s10741-015-9490-y |
| [OE-Baughman-2012-CHEST-IS] | Baughman RP, Meyer KC, Nathanson I, et al. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: ACCP evidence-based clinical practice guidelines. Chest 2012. doi:10.1378/chest.12-1044 |
| [OE-Vanhove-2016-CNI-Disposition] | Vanhove T, Annaert P, Kuypers DR. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev 2016. doi:10.3109/03602532.2016.1151037 |
| [OE-Mathews-2024-Ketamine-Thora-Meta] | Mathews TJ, Churchhouse AM, Housden T, Dunning J. Ketamine plus morphine vs morphine alone for post-thoracotomy pain: meta-analysis. Interact Cardiovasc Thorac Surg 2024. |
| [OE-Brinck-2018-Ketamine-Cochrane] | Brinck EC, Tiippana E, Heesen M, et al. Perioperative intravenous ketamine for acute postoperative pain in adults. Cochrane Database Syst Rev 2018. doi:10.1002/14651858.CD012033.pub4 |
| [OE-Geube-2016-IntraopFluid] | Geube MA, Perez-Protto SE, McGrath TL, et al. Increased intraoperative fluid administration is associated with severe primary graft dysfunction after lung transplantation. Anesth Analg 2016. doi:10.1213/ane.0000000000001163 |
| [OE-Currey-2010-FluidGuideline] | Currey J, Pilcher DV, Davies A, et al. Implementation of a management guideline aimed at minimizing the severity of primary graft dysfunction after lung transplant. J Thorac Cardiovasc Surg 2010. doi:10.1016/j.jtcvs.2009.08.031 |
| [OE-Pilcher-2005-CVP-LTx] | Pilcher DV, Scheinkestel CD, Snell GI, et al. High central venous pressure is associated with prolonged mechanical ventilation and increased mortality after lung transplantation. J Thorac Cardiovasc Surg 2005. doi:10.1016/j.jtcvs.2004.07.006 |
| [OE-Wiedemann-2006-FACTT] | Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006. doi:10.1056/nejmoa062200 |
| [OE-Yi-2026-IntraopFluid-Mortality] | Yi Y, Ouyang Q, Ran X, et al. Association between intraoperative fluid volume and 30-day mortality in patients undergoing lung transplantation: a retrospective cohort study. J Thorac Dis 2026. doi:10.21037/jtd-2025-aw-2349 |
| [OE-Shen-2024-FluidAKI] | Shen Y, Jiang D, Yuan X, et al. Perioperative fluid balance and early acute kidney injury after lung transplantation. Heart Lung 2024. doi:10.1016/j.hrtlng.2024.06.008 |
| [OE-Mazer-2017-TRICS-III] | Mazer CD, Whitlock RP, Fergusson DA, et al. Restrictive or liberal red-cell transfusion for cardiac surgery. N Engl J Med 2017. doi:10.1056/NEJMoa1711818 |
| [OE-Carson-2025-Cochrane-Tx] | Carson JL, Stanworth SJ, Guyatt G, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev 2016. doi:10.1002/14651858.CD002042.pub4 |
| [OE-Alderete-2024-CVP-PGD] | Alderete IS, Pontula A, Halpern SE, et al. Recipient central venous pressure and primary graft dysfunction after lung transplantation. Clin Transplant 2024. |
| [OE-Currigan-2014-Vasopressin-Vessel] | Currigan DA, Hughes RJA, Wright CE, Angus JA, Soeding PF. Vasoconstrictor responses to vasopressor agents in human pulmonary and radial arteries: an in vitro study. Anesthesiology 2014. doi:10.1097/ALN.0000000000000430 |
| [OE-Zheng-2021-VTE-Timing] | Zheng M, Yousef I, Mamary AJ, et al. Venous thromboembolism in lung transplant recipients real world experience from a high volume center. J Heart Lung Transplant 2021. doi:10.1016/j.healun.2021.07.010 |
| [OE-Jorge-2020-DVT-LTx] | Jorge A, Sanchez PG, Hayanga JWA, et al. Routine deep vein thrombosis screening after lung transplantation: incidence and risk factors. J Thorac Cardiovasc Surg 2020. doi:10.1016/j.jtcvs.2019.08.030 |
| [OE-Ribeiro-2017-VTE-Survival] | Ribeiro Neto ML, Budev M, Culver DA, et al. Venous thromboembolism after adult lung transplantation: a frequent event associated with lower survival. Transplantation 2017. doi:10.1097/tp.0000000000001977 |
| [OE-Douketis-2022-CHEST-Antithromb] | Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative management of antithrombotic therapy: an American College of Chest Physicians clinical practice guideline. Chest 2022. doi:10.1016/j.chest.2022.07.025 |
| [OE-Anderson-2019-ASH-VTE] | Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv 2019. doi:10.1182/bloodadvances.2019000975 |
| [OE-Gould-2012-CHEST-Nonortho] | Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in nonorthopedic surgical patients: ACCP 9th edition. Chest 2012. doi:10.1378/chest.11-2297 |
| [OE-Schweickert-2009-EarlyMob] | Schweickert WD, Pohlman MC, Pohlman AS, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet 2009. doi:10.1016/S0140-6736(09)60658-9 |
| [OE-Heyland-2023-EFFORT-Protein] | Heyland DK, Patel J, Compher C, et al. The effect of higher protein dosing in critically ill patients with high nutritional risk (EFFORT Protein): an international, multicentre, pragmatic, registry-based randomised trial. Lancet 2023. |
| [OE-Bels-2024-PRECISe] | Bels JLM, Thiessen S, van Gassel RJJ, et al. Effect of high versus standard protein provision on functional recovery in mechanically ventilated patients (PRECISe): an investigator-initiated, double-blind, multicentre, randomised, controlled trial. Lancet 2024. doi:10.1016/S0140-6736(24)01304-7 |
| [OE-Hogerle-2016-CNIHoliday] | Högerle BA, Kohli N, Habibi-Parker K, et al. Challenging immunosuppression treatment in lung transplant recipients with kidney failure. Transpl Immunol 2016. doi:10.1016/j.trim.2016.02.002 |
| [OE-Cantarovich-2002-CNIHoliday-SOT] | Cantarovich M, Metrakos P, Giannetti N, et al. Anti-CD25 monoclonal antibody coverage allows for calcineurin inhibitor ‘holiday’ in solid organ transplant patients with acute renal dysfunction. Transplantation 2002. doi:10.1097/00007890-200204150-00030 |
| [OE-Anselm-2008-Basiliximab-Heart] | Anselm A, Cantarovich M, Davies R, Grenon J, Haddad H. Prolonged basiliximab use as an alternative to calcineurin inhibition to allow renal recovery late after heart transplantation. J Heart Lung Transplant 2008. doi:10.1016/j.healun.2008.04.005 |
| [OE-Rim-2024-Basiliximab-LTx] | Rim JG, Hellkamp AS, Neely ML, et al. Basiliximab induction immunosuppression and lung transplant outcomes: propensity analysis in a multicenter cohort. J Heart Lung Transplant 2024. doi:10.1016/j.healun.2024.11.033 |
| [OE-Kim-2021-Basiliximab-Yonsei] | Kim HE, Paik HC, Jeong SJ, et al. Basiliximab induction with delayed calcineurin inhibitors for high-risk lung transplant candidates. Yonsei Med J 2021. doi:10.3349/ymj.2021.62.2.164 |
| [OE-Sikma-2017-TacAKI] | Sikma MA, Hunault CC, van de Graaf EA, et al. High tacrolimus blood concentrations early after lung transplantation and the risk of kidney injury. Eur J Clin Pharmacol 2017. doi:10.1007/s00228-017-2204-8 |
| [OE-Roberts-2020-CID-Ureaplasma] | Roberts SC, Bharat A, Kurihara C, Tomic R, Ison MG. Impact of screening and treatment of Ureaplasma species on hyperammonemia syndrome in lung transplant recipients: a single center experience. Clin Infect Dis 2020. doi:10.1093/cid/ciaa1570 |
| [OE-Chen-2015-Hyperammonemia] | Chen C, Bain KB, Iuppa JA, et al. Hyperammonemia syndrome after lung transplantation: a single center experience. Transplantation 2015. doi:10.1097/tp.0000000000000868 |
| [OE-Kamel-2022-HyperammonemiaMeta] | Kamel AY, Emtiazjoo AM, Adkins L, et al. Hyperammonemia after lung transplantation: systematic review and a mini case series. Transpl Int 2022. doi:10.3389/ti.2022.10433 |
| [OE-Buzo-2022-HyperammonemiaCase] | Buzo BF, Preiksaitis JK, Halloran K, et al. Hyperammonemia syndrome post-lung transplantation: case series and systematic review of literature. Transpl Infect Dis 2022. doi:10.1111/tid.13940 |
| [OE-Seethapathy-2019-AJKD] | Seethapathy H, Fenves AZ. Pathophysiology and management of hyperammonemia in organ transplant patients. Am J Kidney Dis 2019. doi:10.1053/j.ajkd.2019.03.419 |
| [OE-Krutsinger-2017-IHA] | Krutsinger D, Pezzulo A, Blevins AE, et al. Idiopathic hyperammonemia after solid organ transplantation: primarily a lung problem? A single-center experience and systematic review. Clin Transplant 2017. doi:10.1111/ctr.12957 |
| [OE-Jones-2026-DoxyProphylaxis] | Jones L, Choi B, Velez M, et al. Impact of doxycycline prophylaxis on reducing Ureaplasma and Mycoplasma-related complications in lung transplant recipients. Transpl Infect Dis 2026. doi:10.1111/tid.70199 |
| [OE-Fleming-2025-AAC-Murine] | Fleming D, Al-Jabri MY, Patel R. Comparative efficacy of levofloxacin, azithromycin, and doxycycline prophylaxis and treatment in an experimental Ureaplasma murine lung infection. Antimicrob Agents Chemother 2025. doi:10.1128/aac.01724-24 |
| [OE-Fidalgo-2025-AKIMeta] | Fidalgo P, Ahmed M, Meyer SR, et al. Occurrence rate and risk factors for acute kidney injury after lung transplantation: A systematic review and meta-analysis. PeerJ 2024. doi:10.7717/peerj.18364 |
| [OE-Crawford-2025-VFMI] | Crawford JM, Krishnamurthy V, Klein A, et al. Vocal fold mobility impairment after lung transplantation: incidence and predictors. Laryngoscope 2025. doi:10.1002/lary.70016 |
| [OE-Plowman-2021-Laryngoscopy] | Plowman EK, Anderson A, York JD, et al. Routine Vocal Cord Mobility Assessment Post Cardiac Surgery via Median Sternotomy. J Cardiothorac Vasc Anesth 2021. doi:10.1053/j.jvca.2020.07.058 |
V.13 v2.1 Ch10 OE 證據（2026-04-22）— 76 筆新增
| 代碼 | 全名 |
|---|---|
| [OE-Furukawa-2022-AlemBasi] | Furukawa M, Chan EG, Ryan JP, et al. Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience. Frontiers in Immunology 2022. doi:10.3389/fimmu.2022.864545 |
| [OE-Shagabayeva-2022-InductionUNOS] | Shagabayeva L, Osho AA, Moonsamy P, et al. Induction Therapy in Lung Transplantation: A Contemporary Analysis of Trends and Outcomes. Clinical Transplantation 2022. doi:10.1111/ctr.14782 |
| [OE-Benazzo-2019-AlemReduced] | Benazzo A, Schwarz S, Muckenhuber M, et al. Alemtuzumab Induction Combined With Reduced Maintenance Immunosuppression. PLoS One 2019. doi:10.1371/journal.pone.0210443 |
| [OE-Whitson-2014-InductionUNOS] | Whitson BA, Lehman A, Wehr A, et al. To Induce or Not to Induce: A 21st Century Evaluation of Lung Transplant Immunosuppression. Clinical Transplantation 2014. doi:10.1111/ctr.12339 |
| [OE-Rim-2025-BasiliximabPropensity] | Rim JG, Hellkamp AS, Neely ML, et al. Basiliximab Induction Immunosuppression and Lung Transplant Outcomes: Propensity Analysis. JHLT 2025. doi:10.1016/j.healun.2024.11.033 |
| [OE-Passos-2026-IL2RAmeta] | Passos FS, Carvalho EA, Oliveira RE, et al. Interleukin-2 Receptor Antagonist Induction Therapy in Lung Transplantation - a Meta-Analysis. Journal of Clinical Medicine 2026. doi:10.3390/jcm15041438 |
| [OE-Duffy-2016-COPDinduction] | Duffy JS, Tumin D, Pope-Harman A, et al. Induction Therapy for Lung Transplantation in COPD: Analysis of the UNOS Registry. COPD 2016. doi:10.3109/15412555.2015.1127340 |
| [OE-Benazzo-2021-AlemtuzumabReview] | Benazzo A, Auner S, Boehm PM, et al. Outcomes With Alemtuzumab Induction Therapy in Lung Transplantation: A Comprehensive Review. Transplant International 2021. doi:10.1111/tri.14153 |
| [OE-Whited-2015-AlemVsBasi] | Whited LK, Latran MJ, Hashmi ZA, et al. Evaluation of Alemtuzumab Versus Basiliximab Induction: A Retrospective Cohort Study. Transplantation 2015. doi:10.1097/tp.0000000000000687 |
| [OE-Baughman-2012-CHEST] | Baughman RP, Meyer KC, Nathanson I, et al. Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease. Chest 2012. doi:10.1378/chest.12-1044 |
| [OE-FDA-2023-PrografLabel] | Food and Drug Administration. Prograf (tacrolimus) prescribing information. FDA label 2023. |
| [OE-McPheeters-2021-TacTrough] | McPheeters CM, Lorenz D, Burcham PK, et al. Calcineurin Inhibitor-Based Maintenance Immunosuppression in Lung Transplant Recipients. Transplantation Proceedings 2021. doi:10.1016/j.transproceed.2021.05.005 |
| [OE-Ensor-2018-TacTTR] | Ensor CR, Iasella CJ, Harrigan KM, et al. Increasing Tacrolimus Time-in-Therapeutic Range Is Associated With Superior One-Year Outcomes. AJT 2018. doi:10.1111/ajt.14723 |
| [OE-Du-2024-TacExposure] | Du W, Wang X, Zhang D, Zuo X. Exploratory Associations of Tacrolimus Exposure and Clinical Outcomes After Lung Transplantation. European Journal of Clinical Pharmacology 2024. doi:10.1007/s00228-024-03640-6 |
| [OE-Darley-2019-TacPK] | Darley DR, Carlos L, Hennig S, et al. Tacrolimus Exposure Early After Lung Transplantation and Exploratory Associations. European Journal of Clinical Pharmacology 2019. doi:10.1007/s00228-019-02658-5 |
| [OE-Miano-2020-TacAKI] | Miano TA, Flesch JD, Feng R, et al. Early Tacrolimus Concentrations After Lung Transplant Are Predicted by Combined Donor-Recipient Characteristics. Clinical Pharmacology and Therapeutics 2020. doi:10.1002/cpt.1629 |
| [OE-Xiong-2023-TacCKD] | Xiong D, Yue B, Ye S, et al. The Impact of Long-Term Exposure to Tacrolimus on Chronic Kidney Disease After Lung Transplantation. Transplant Immunology 2023. doi:10.1016/j.trim.2023.101810 |
| [OE-FDA-2025-TacLabel] | Food and Drug Administration. Tacrolimus prescribing information (generic). FDA label 2025. |
| [OE-Vanhove-2017-TacVori] | Vanhove T, Bouwsma H, Hilbrands L, et al. Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole. AJT 2017. doi:10.1111/ajt.14232 |
| [OE-Chen-2022-TacVoriLTx] | Chen W, Wang X, Li B, et al. Effects of Voriconazole Exposure on the Pharmacokinetics of Tacrolimus in Lung Transplantation. Journal of Clinical Pharmacology 2022. doi:10.1002/jcph.2066 |
| [OE-Gong-2023-TacVoriPBPK] | Gong F, Hu H, Ouyang Y, et al. Physiologically-Based Pharmacokinetic Modeling-Guided Rational Combination of Tacrolimus and Voriconazole. Toxicology and Applied Pharmacology 2023. doi:10.1016/j.taap.2023.116475 |
| [OE-Zhao-2025-TacPBPK] | Zhao YC, Zhang YK, Gao W, et al. A Preliminary Exploration of Liver Microsomes and PBPK to Uncover the Impact of CYP3A4/5 and CYP2C19. Scientific Reports 2025. doi:10.1038/s41598-025-91356-7 |
| [OE-LiZR-2023-TacVoriAlgo] | Li ZR, Shen CH, Li RD, et al. Individual Dose Recommendations for Drug Interaction Between Tacrolimus and Voriconazole. European Journal of Pharmaceutical Sciences 2023. doi:10.1016/j.ejps.2023.106405 |
| [OE-HuangHJ-2022-BelaPilot] | Huang HJ, Schechtman K, Askar M, et al. A Pilot Randomized Controlled Trial of De Novo Belatacept-Based Immunosuppression Following ATG. AJT 2022. doi:10.1111/ajt.17028 |
| [OE-HuangHJ-2024-BelaFull] | Huang HJ, Schechtman K, Askar M, et al. A Pilot Randomized Controlled Trial of De Novo Belatacept-Based Immunosuppression After Lung Transplantation. Transplantation 2024. doi:10.1097/tp.0000000000004841 |
| [OE-Younis-2025-BelaConversion] | Younis M, Miller CM, Mederos CI, et al. Conversion to Belatacept-Based Immunosuppression as a Calcineurin Sparing Regimen. Transplant Immunology 2025. doi:10.1016/j.trim.2025.102330 |
| [OE-Brugiere-2022-BelaLTx] | Brugiere O, Vallee A, Raimbourg Q, et al. Conversion to Belatacept After Lung Transplantation: Report of 10 Cases. PLoS One 2022. doi:10.1371/journal.pone.0281492 |
| [OE-Iasella-2018-BelaLTx] | Iasella CJ, Winstead RJ, Moore CA, et al. Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients. Transplantation 2018. doi:10.1097/tp.0000000000001873 |
| [OE-Timofte-2016-BelaRenalRescue] | Timofte I, Terrin M, Barr E, et al. Belatacept for Renal Rescue in Lung Transplant Patients. Transplant International 2016. doi:10.1111/tri.12731 |
| [OE-FDA-2021-Nulojix] | Food and Drug Administration. NULOJIX (belatacept) prescribing information. FDA label 2021. |
| [OE-Hannan-2025-BelaIPAH] | Hannan SJ, Iasella CJ, Sciullo M, et al. Belatacept as an Alternative Immunosuppressive Agent for Bone Marrow-Sparing in IPAH LTx. JHLT 2025. doi:10.1016/j.healun.2025.04.022 |
| [OE-DiMaria-2026-BelaReview] | Di Maria S, Provenzani A. Belatacept in Solid Organ Transplantation: Current Kidney Applications, Future Perspectives. Pharmaceuticals 2026. doi:10.3390/ph19020196 |
| [OE-Jang-2021-ddcfDNA] | Jang MK, Tunc I, Berry GJ, et al. Donor-Derived Cell-Free DNA Accurately Detects Acute Rejection in Lung Transplant Patients. JHLT 2021. doi:10.1016/j.healun.2021.04.009 |
| [OE-LiY-2023-ddcfDNAmeta] | Li Y, Liang B. Circulating Donor-Derived Cell-Free DNA as a Marker for Rejection After Lung Transplantation. Frontiers in Immunology 2023. doi:10.3389/fimmu.2023.1263389 |
| [OE-Keller-2022-ddcfDNAalad] | Keller M, Sun J, Mutebi C, et al. Donor-Derived Cell-Free DNA as a Composite Marker of Acute Lung Allograft Dysfunction. JHLT 2022. doi:10.1016/j.healun.2021.12.009 |
| [OE-Ju-2023-ddcfDNA] | Ju C, Xu X, Zhang J, et al. Application of Plasma Donor-Derived Cell-Free DNA for Lung Allograft Rejection Diagnosis. BMC Pulmonary Medicine 2023. doi:10.1186/s12890-022-02229-y |
| [OE-Yavuz-2024-ddcfDNA] | Yavuz G, Walter J, Hirv K, et al. Donor-Derived Cell-Free DNA for Detection of Acute Rejection in Lung Transplant Recipients. Frontiers in Immunology 2024. doi:10.3389/fimmu.2025.1531774 |
| [OE-Calabrese-2025-ddcfDNACLAD] | Calabrese F, Pezzuto F, Vedovelli L, et al. Detection of Lung Allograft Injury Through a Comprehensive Multidisciplinary Analysis. Frontiers in Immunology 2025. doi:10.3389/fimmu.2025.1619771 |
| [OE-Pedini-2023-ddcfDNA] | Pedini P, Coiffard B, Cherouat N, et al. Clinical Relevance of Cell-Free DNA Quantification and Qualification During the First Year Post-LTx. Frontiers in Immunology 2023. doi:10.3389/fimmu.2023.1183949 |
| [OE-Sorbini-2022-ddcfDNAmethod] | Sorbini M, Togliatto G, Mioli F, et al. Validation of a Simple, Rapid, and Cost-Effective Method for Acute Rejection Monitoring. Transplant International 2022. doi:10.3389/ti.2022.10546 |
| [OE-Loupy-2025-BiomarkerLancet] | Loupy A, Sablik M, Khush K, Reese PP. Advancing Patient Monitoring, Diagnostics, and Treatment Strategies for Transplant Precision Medicine. Lancet 2025. doi:10.1016/s0140-6736(25)00195-3 |
| [OE-KellerBC-2026-ddcfDNAReview] | Keller BC, Agbor-Enoh S, Keller MB, et al. Utility of Donor-Derived Cell-Free DNA Testing After Lung Transplantation in the Precision Medicine Era. JHLT 2026. doi:10.1016/j.healun.2026.04.005 |
| [OE-Phipps-2026-ddcfDNACLAD] | Phipps K, Kong H, Su H, et al. Donor-Derived Cell-Free DNA Associated With Increased Risk of Chronic Lung Allograft Dysfunction. JHLT 2026. doi:10.1016/j.healun.2026.01.022 |
| [OE-Florescu-2013-HGGmeta] | Florescu DF, Kalil AC, Qiu F, Schmidt CM, Sandkovsky U. What Is the Impact of Hypogammaglobulinemia on the Rate of Infections and Survival in Solid Organ Transplantation?. AJT 2013. doi:10.1111/ajt.12401 |
| [OE-Sarmiento-2018-HGGearly] | Sarmiento E, Cifrian J, Calahorra L, et al. Monitoring of Early Humoral Immunity to Identify Lung Recipients at Risk for Serious Infections. JHLT 2018. doi:10.1016/j.healun.2018.04.001 |
| [OE-Yip-2006-HGGLTx] | Yip NH, Lederer DJ, Kawut SM, et al. Immunoglobulin G Levels Before and After Lung Transplantation. AJRCCM 2006. doi:10.1164/rccm.200510-1609oc |
| [OE-vanKessel-2017-HGGlongterm] | van Kessel DA, Hoffman TW, Kwakkel-van Erp JM, et al. Long-Term Follow-Up of Humoral Immune Status in Adult Lung Transplant Recipients. Transplantation 2017. doi:10.1097/tp.0000000000001685 |
| [OE-Goldfarb-2001-HGGLTx] | Goldfarb NS, Avery RK, Goormastic M, et al. Hypogammaglobulinemia in Lung Transplant Recipients. Transplantation 2001. doi:10.1097/00007890-200101270-00013 |
| [OE-Otani-2022-HGGguide] | Otani IM, Lehman HK, Jongco AM, et al. Practical Guidance for the Diagnosis and Management of Secondary Hypogammaglobulinemia. JACI 2022. doi:10.1016/j.jaci.2022.01.025 |
| [OE-Ohsumi-2014-HGGLTx] | Ohsumi A, Chen F, Yamada T, et al. Effect of Hypogammaglobulinemia After Lung Transplantation: A Single-Institution Study. EJCTS 2014. doi:10.1093/ejcts/ezt583 |
| [OE-Chambers-2013-HGGBOS] | Chambers DC, Davies B, Mathews A, Yerkovich ST, Hopkins PM. Bronchiolitis Obliterans Syndrome, Hypogammaglobulinemia, and Infectious Complications. JHLT 2013. doi:10.1016/j.healun.2012.10.006 |
| [OE-Lederer-2014-IVIGrct] | Lederer DJ, Philip N, Rybak D, Arcasoy SM, Kawut SM. Intravenous Immunoglobulin for Hypogammaglobulinemia After Lung Transplantation: A Randomized Crossover Trial. PLoS One 2014. doi:10.1371/journal.pone.0103908 |
| [OE-Claustre-2015-IVIGLTx] | Claustre J, Quetant S, Camara B, et al. Nonspecific Immunoglobulin Replacement in Lung Transplantation Recipients With Hypogammaglobulinemia. Transplantation 2015. doi:10.1097/tp.0000000000000339 |
| [OE-BourassaBlanchette-2019-IVIGmeta] | Bourassa-Blanchette S, Patel V, Knoll GA, et al. Clinical Outcomes of Polyvalent Immunoglobulin Use in Solid Organ Transplant Recipients. Clinical Transplantation 2019. doi:10.1111/ctr.13625 |
| [OE-Grossi-2016-CMVIg] | Grossi P, Mohacsi P, Szabolcs Z, Potena L. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview. Transplantation 2016. doi:10.1097/tp.0000000000001094 |
| [OE-Rea-2016-CMVIgProphy] | Rea F, Potena L, Yonan N, Wagner F, Calabrese F. Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation. Transplantation 2016. doi:10.1097/tp.0000000000001096 |
| [OE-Schulz-2016-CMVIgTx] | Schulz U, Solidoro P, Muller V, et al. CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients. Transplantation 2016. doi:10.1097/tp.0000000000001097 |
| [OE-Mora-2022-CMVIgReg] | Mora VM, Ussetti P, de Pablo A, et al. Evaluation of Two Different CMV-Immunoglobulin Regimens for Combined CMV Prophylaxis in LTx. Microorganisms 2022. doi:10.3390/microorganisms11010032 |
| [OE-Vos-2011-AziRCT] | Vos R, Vanaudenaerde BM, Verleden SE, et al. A Randomised Controlled Trial of Azithromycin to Prevent Chronic Rejection After Lung Transplantation. ERJ 2011. doi:10.1183/09031936.00068310 |
| [OE-Ruttens-2016-AziLongTerm] | Ruttens D, Verleden SE, Vandermeulen E, et al. Prophylactic Azithromycin Therapy After Lung Transplantation: Post Hoc Analysis of a Randomized Trial. AJT 2016. doi:10.1111/ajt.13417 |
| [OE-LiD-2020-AziSurvival] | Li D, Duan Q, Weinkauf J, et al. Azithromycin Prophylaxis After Lung Transplantation Is Associated With Improved Overall Survival. JHLT 2020. doi:10.1016/j.healun.2020.09.006 |
| [OE-CristetoPorras-2023-AziTiming] | Cristeto Porras M, Mons R, Iturbe Fernandez D, et al. Early Onset of Azithromycin to Prevent CLAD in Lung Transplantation. Clinical Transplantation 2023. doi:10.1111/ctr.14832 |
| [OE-Huang-2025-AziMeta] | Huang H, Xie Y, Liu H, et al. Prophylactic Azithromycin for Chronic Lung Allograft Dysfunction: Systematic Review and Meta-Analysis. Journal of Thoracic Disease 2025. doi:10.21037/jtd-2025-365 |
| [OE-Gerhardt-2003-AziBOS] | Gerhardt SG, McDyer JF, Girgis RE, Conte JV, Yang SC, Orens JB. Maintenance Azithromycin Therapy for Bronchiolitis Obliterans Syndrome. AJRCCM 2003. doi:10.1164/rccm.200212-1424bc |
| [OE-Bos-2022-GvHDCLAD] | Bos S, Vos R, Van Raemdonck DE, Verleden GM. Pulmonary Graft-Versus-Host Disease and Chronic Lung Allograft Dysfunction. Lancet Respiratory Medicine 2022. doi:10.1016/s2213-2600(22)00001-7 |
| [OE-Levine-2016-ISHLTamr] | Levine DJ, Glanville AR, Aboyoun C, et al. Antibody-Mediated Rejection of the Lung: A Consensus Report of the ISHLT. JHLT 2016. doi:10.1016/j.healun.2016.01.1223 |
| [OE-Kim-2014-DSApretx] | Kim M, Townsend KR, Wood IG, et al. Impact of Pretransplant Anti-HLA Antibodies on Outcomes in Lung Transplant Candidates. AJRCCM 2014. doi:10.1164/rccm.201312-2160oc |
| [OE-LePavec-2016-dnDSA] | Le Pavec J, Suberbielle C, Lamrani L, et al. De-Novo Donor-Specific Anti-HLA Antibodies 30 Days After Lung Transplantation. JHLT 2016. doi:10.1016/j.healun.2016.05.020 |
| [OE-Smith-2014-DSApretx] | Smith JD, Ibrahim MW, Newell H, et al. Pre-Transplant Donor HLA-Specific Antibodies: Characteristics Causing Detrimental Effects on Survival. JHLT 2014. doi:10.1016/j.healun.2014.02.033 |
| [OE-Shino-2022-CXCL9] | Shino MY, Zhang Q, Li N, et al. The Allograft Injury Marker CXCL9 Determines Prognosis of Anti-HLA Antibodies After Lung Transplantation. AJT 2022. doi:10.1111/ajt.16827 |
| [OE-Bogyo-2024-DSAPA] | Bogyo LZ, Torok K, Illes Z, et al. Pseudomonas Aeruginosa Infection Correlates With High MFI Donor-Specific Antibody Development. Respiratory Research 2024. doi:10.1186/s12931-024-02868-1 |
| [OE-Hirschi-2025-IntragraftDSA] | Hirschi S, Hell G, Levine DJ, et al. Diagnostic Significance of Intragraft Donor-Specific Anti-HLA Antibodies in Pulmonary AMR. JHLT 2025. doi:10.1016/j.healun.2025.08.007 |
| [OE-Roux-2016-AMRclin] | Roux A, Bendib Le Lan I, Holifanjaniaina S, et al. Antibody-Mediated Rejection in Lung Transplantation: Clinical Outcomes and Donor-Specific Antibodies. AJT 2016. doi:10.1111/ajt.13589 |
| [OE-Roux-2017-DSAcharacter] | Roux A, Bendib Le Lan I, Holifanjaniaina S, et al. Characteristics of Donor-Specific Antibodies Associated With Antibody-Mediated Rejection in Lung Transplantation. Frontiers in Medicine 2017. doi:10.3389/fmed.2017.00155 |
| [OE-Iasella-2020-DSAC1q] | Iasella CJ, Ensor CR, Marrari M, et al. Donor-Specific Antibody Characteristics, Including Persistence and Complement-Binding Capacity, Predict CLAD. JHLT 2020. doi:10.1016/j.healun.2020.09.003 |
| [OE-Verleden-2017-DSApersist] | Verleden SE, Vanaudenaerde BM, Emonds MP, et al. Donor-Specific and Non-Specific HLA Antibodies and Outcome Post Lung Transplantation. ERJ 2017. doi:10.1183/13993003.01248-2017 |
V.14 v2.1 Ch11 OE 證據（2026-04-22）— 100 筆新增
| 代碼 | 全名 |
|---|---|
| [OE-BratzlerD-2013-PeriopAbx] | Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery. American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists 2013. doi:10.2146/ajhp120568 |
| [OE-Coiffard-2020-PeriopAbx] | Coiffard B, Prud’Homme E, Hraiech S, et al. Worldwide Clinical Practices in Perioperative Antibiotic Therapy for Lung Transplantation. BMC Pulmonary Medicine 2020. doi:10.1186/s12890-020-1151-9 |
| [OE-Pascale-2024-PeriopAbx] | Pascale R, Tazza B, Amicucci A, et al. Antibiotic Prophylaxis in Patients Undergoing Lung Transplant: Single-Center Cohort Study. Transplant International : Official Journal of the European Society for Organ Transplantation 2024. doi:10.3389/ti.2024.13245 |
| [OE-GroffL-2021-PeriopAbx] | Groff LT, Reed EE, Coe KE, et al. Effectiveness of Short vs Long-Course Perioperative Antibiotics in Lung Transplant Recipients With Donor Positive Respiratory Cultures. Transplant Infectious Disease : An Official Journal of the Transplantation Society 2021. doi:10.1111/tid.13518 |
| [OE-Barrau-2025-PeriopAbx] | Barrau D, Brioude G, Todesco A, et al. Multiplex PCR in Donor and Recipient Bronchoalveolar Lavage to Guide Early Antibiotic Prophylaxis Adaptation in Lung Transplantation: A Single-Center Cohort Study. Journal of Clinical Medicine 2025. doi:10.3390/jcm14238613 |
| [OE-Shah-2021-PeriopAbx] | Shah P, Lowery E, Chaparro C, et al. Cystic Fibrosis Foundation Consensus Statements for the Care of Cystic Fibrosis Lung Transplant Recipients. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2021. doi:10.1016/j.healun.2021.04.011 |
| [OE-PereiraM-2019-PeriopAbx] | Pereira MR, Rana MM. Methicillin-Resistant Staphylococcus Aureus in Solid Organ Transplantation-Guidelines From the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation 2019. doi:10.1111/ctr.13611 |
| [OE-Liu-2026-PeriopAbx] | Liu C, Rosen EA, Stohs EJ, et al. Tackling Antimicrobial Resistance in People Who Are Immunocompromised: Leveraging Diagnostic and Antimicrobial Stewardship. The Lancet. Infectious Diseases 2026. doi:10.1016/s1473-3099(25)00311-1 |
| [OE-StrattonP-2025-PeriopAbx] | Stratton PT, Fitzmaurice MG, Kenney RM, et al. Implementation of a Protocol With a Shortened Vancomycin Prophylaxis Duration Is Associated With Reduced Acute Kidney Injury in Lung Transplant Recipients: A Quasi-Experimental Study. Transplant Infectious Disease : An Official Journal of the Transplantation Society 2025. doi:10.1111/tid.70118 |
| [OE-FDA-2023-Valganciclov] | Food and Drug Administration. Valganciclovir. |
| [OE-Humar-2010-VGCVdose] | Humar A, Limaye AP, Blumberg EA, et al. Extended Valganciclovir Prophylaxis in D+/R- Kidney Transplant Recipients Is Associated With Long-Term Reduction in Cytomegalovirus Disease: Two-Year Results of the IMPACT Study. Transplantation 2010. doi:10.1097/tp.0b013e3181ff1493 |
| [OE-PalmerS-2010-VGCVdose] | Palmer SM, Limaye AP, Banks M, et al. Extended Valganciclovir Prophylaxis to Prevent Cytomegalovirus After Lung Transplantation: A Randomized, Controlled Trial. Annals of Internal Medicine 2010. doi:10.7326/0003-4819-152-12-201006150-00003 |
| [OE-Chang-2019-VGCVdose] | Chang A, Musk M, Lavender M, et al. Cytomegalovirus Viremia in Lung Transplantation During and After Prophylaxis. Transplant Infectious Disease : An Official Journal of the Transplantation Society 2019. doi:10.1111/tid.13069 |
| [OE-LehikoinenRA-2026-VGCVdose] | Lehikoinen RAJ, Nykänen A, Syrjälä SO, et al. Safety and Effectiveness of Low-Dose Valganciclovir Prophylaxis in Cytomegalovirus Seropositive Lung Transplant Recipients. European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery 2026. doi:10.1093/ejcts/ezag095 |
| [OE-RazonableR-2019-VGCVdose] | Razonable RR, Humar A. Cytomegalovirus in Solid Organ Transplant Recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation 2019. doi:10.1111/ctr.13512 |
| [OE-VernooijR-2025-VGCVdose] | Vernooij RW, Michael M, Colombijn JM, et al. Pre-Emptive Treatment for Cytomegalovirus Viraemia to Prevent Cytomegalovirus Disease in Solid Organ Transplant Recipients. The Cochrane Database of Systematic Reviews 2025. doi:10.1002/14651858.cd005133.pub4 |
| [OE-VernooijR-2024-VGCVdose] | Vernooij RW, Michael M, Ladhani M, et al. Antiviral Medications for Preventing Cytomegalovirus Disease in Solid Organ Transplant Recipients. The Cochrane Database of Systematic Reviews 2024. doi:10.1002/14651858.cd003774.pub5 |
| [OE-AveryR-2022-Maribavir] | Avery RK, Alain S, Alexander BD, et al. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2022. doi:10.1093/cid/ciab988 |
| [OE-Chou-2024-Maribavir] | Chou S, Alain S, Cervera C, et al. Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. The Journal of Infectious Diseases 2024. doi:10.1093/infdis/jiad293 |
| [OE-BlumbergE-2025-Maribavir] | Blumberg EA, Witzke O, Harber M, et al. Maribavir for Refractory Cytomegalovirus Infection (With or Without Resistance) in Solid Organ Transplant Recipients: Subgroup Analysis of the Phase 3 Randomized SOLSTICE Study. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2025. doi:10.1016/j.healun.2024.11.026 |
| [OE-FDA-2026-Livtencity] | Food and Drug Administration. Livtencity. |
| [OE-Kamar-2025-Maribavir] | Kamar N, Vuotto F, Cordonnier C, et al. Use of Maribavir in Adult Patients With Post-Transplant Refractory Cytomegalovirus Infection in the Real-Life Setting. Transplant International : Official Journal of the European Society for Organ Transplantation 2025. doi:10.3389/ti.2026.15769 |
| [OE-Kasriel-2026-Maribavir] | Kasriel N, Alain S, Benotmane I, et al. Determinants of Virological Outcomes in Kidney Transplant Recipients Treated With Maribavir for Refractory Cytomegalovirus Infection. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2026. doi:10.1016/j.ajt.2025.10.018 |
| [OE-Ljungman-2025-Maribavir] | Ljungman P, Alain S, Chemaly RF, et al. Recommendations From the 10th European Conference on Infections in Leukaemia for the Management of Cytomegalovirus in Patients After Allogeneic Haematopoietic Cell Transplantation and Other T-Cell-Engaging Therapies. The Lancet. Infectious Diseases 2025. doi:10.1016/s1473-3099(25)00069-6 |
| [OE-Khawaja-2025-Maribavir] | Khawaja F, Zamora D, Yong MK, et al. American Society for Transplantation and Cellular Therapy Series #11: Updated Cytomegalovirus Guidelines in Hematopoietic Cell Transplant and Cellular Therapy Recipients. Transplantation and Cellular Therapy 2025. doi:10.1016/j.jtct.2025.06.025 |
| [OE-National-2026-Maribavir] | National Comprehensive Cancer Network. Prevention and Treatment of Cancer-Related Infections. |
| [OE-Ljungman-2019-QNAT] | Ljungman P, de la Camara R, Robin C, et al. Guidelines for the Management of Cytomegalovirus Infection in Patients With Haematological Malignancies and After Stem Cell Transplantation From the 2017 European Conference on Infections in Leukaemia (ECIL 7). The Lancet. Infectious Diseases 2019. doi:10.1016/s1473-3099(19)30107-0 |
| [OE-PreiksaitisJ-2016-QNAT] | Preiksaitis JK, Hayden RT, Tong Y, et al. Are We There Yet? Impact of the First International Standard for Cytomegalovirus DNA on the Harmonization of Results Reported on Plasma Samples. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2016. doi:10.1093/cid/ciw370 |
| [OE-FDA-2026-PREVYMIS] | Food and Drug Administration. PREVYMIS. |
| [OE-McCreaJ-2019-Letermovir] | McCrea JB, Macha S, Adedoyin A, et al. Pharmacokinetic Drug-Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil. Journal of Clinical Pharmacology 2019. doi:10.1002/jcph.1423 |
| [OE-MarcianoK-2022-Letermovir] | Marciano KA, Seago K, Dillaman M, et al. Evaluation of the Pharmacokinetic Interaction Between Letermovir and Tacrolimus in Allogeneic Hematopoietic Cell Transplantation Recipients. Transplantation and Cellular Therapy 2022. doi:10.1016/j.jtct.2022.03.028 |
| [OE-WinsteadR-2021-Letermovir] | Winstead RJ, Kumar D, Brown A, et al. Letermovir Prophylaxis in Solid Organ Transplant-Assessing CMV Breakthrough and Tacrolimus Drug Interaction. Transplant Infectious Disease : An Official Journal of the Transplantation Society 2021. doi:10.1111/tid.13570 |
| [OE-Berger-2025-Letermovir] | Berger I, Matsuda-Abedini M, Haubrich K. Letermovir and Tacrolimus Drug-Drug Interaction in a Pediatric Kidney Transplant Patient: A Case Report and Review of the Literature. Pediatric Transplantation 2025. doi:10.1111/petr.70143 |
| [OE-Martinez-2024-Letermovir] | Martinez S, Sindu D, Nailor MD, et al. Evaluating the Efficacy and Safety of Letermovir Compared to Valganciclovir for the Prevention of Human Cytomegalovirus Disease in Adult Lung Transplant Recipients. Transplant Infectious Disease : An Official Journal of the Transplantation Society 2024. doi:10.1111/tid.14279 |
| [OE-KleiboekerH-2024-Letermovir] | Kleiboeker HL, Wang J, Borkowski N, et al. Use of Letermovir for Cytomegalovirus Primary Prophylaxis in Lung Transplant Recipients. Transplant Infectious Disease : An Official Journal of the Transplantation Society 2024. doi:10.1111/tid.14337 |
| [OE-GoodletK-2024-Letermovir] | Goodlet KJ, Garcia R. Effect of Letermovir Initiation on Tacrolimus Concentrations Among Lung Transplant Recipients Receiving Concomitant Azole Antifungal Prophylaxis. Transplant Infectious Disease : An Official Journal of the Transplantation Society 2024. doi:10.1111/tid.14267 |
| [OE-RazonableR-2024-Letermovir] | Razonable RR. Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients. Drug Design, Development and Therapy 2024. doi:10.2147/dddt.s265644 |
| [OE-FDA-2025-VORICONAZOLE] | Food and Drug Administration. VORICONAZOLE. |
| [OE-FDA-2023-Voriconazole] | Food and Drug Administration. Voriconazole. |
| [OE-PattersonT-2016-VoriAsper] | Patterson TF, Thompson GR, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2016. doi:10.1093/cid/ciw326 |
| [OE-DadwalS-2021-VoriAsper] | Dadwal SS, Hohl TM, Fisher CE, et al. American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients. Transplantation and Cellular Therapy 2021. doi:10.1016/j.jtct.2020.10.003 |
| [OE-PappasP-2016-VoriAsper] | Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2016. doi:10.1093/cid/civ933 |
| [OE-Jin-2016-VoriAsper] | Jin H, Wang T, Falcione BA, et al. Trough Concentration of Voriconazole and Its Relationship With Efficacy and Safety: A Systematic Review and Meta-Analysis. The Journal of Antimicrobial Chemotherapy 2016. doi:10.1093/jac/dkw045 |
| [OE-LuongM-2016-VoriAsper] | Luong ML, Al-Dabbagh M, Groll AH, et al. Utility of Voriconazole Therapeutic Drug Monitoring: A Meta-Analysis. The Journal of Antimicrobial Chemotherapy 2016. doi:10.1093/jac/dkw099 |
| [OE-ParkW-2012-VoriAsper] | Park WB, Kim NH, Kim KH, et al. The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2012. doi:10.1093/cid/cis599 |
| [OE-Hashemizadeh-2017-VoriAsper] | Hashemizadeh Z, Badiee P, Malekhoseini SA, et al. Observational Study of Associations Between Voriconazole Therapeutic Drug Monitoring, Toxicity, and Outcome in Liver Transplant Patients. Antimicrobial Agents and Chemotherapy 2017. doi:10.1128/aac.01211-17 |
| [OE-Zubiaur-2021-VoriAsper] | Zubiaur P, Kneller LA, Ochoa D, et al. Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling. Clinical Pharmacokinetics 2021. doi:10.1007/s40262-020-00941-8 |
| [OE-Lamoureux-2016-VoriAsper] | Lamoureux F, Duflot T, Woillard JB, et al. Impact of CYP2C19 Genetic Polymorphisms on Voriconazole Dosing and Exposure in Adult Patients With Invasive Fungal Infections. International Journal of Antimicrobial Agents 2016. doi:10.1016/j.ijantimicag.2015.12.003 |
| [OE-WuY-2025-VoriAsper] | Wu YP, Gelal A, Moon C, et al. Pharmacogenetics of Steady-State Metabolism, Pharmacokinetics, and Adverse Effects of Voriconazole in Healthy Participants. Drug Metabolism and Disposition: The Biological Fate of Chemicals 2025. doi:10.1016/j.dmd.2025.100156 |
| [OE-Koehler-2021-VoriAsper] | Koehler P, Bassetti M, Chakrabarti A, et al. Defining and Managing COVID-19-associated Pulmonary Aspergillosis: The 2020 ECMM/ISHAM Consensus Criteria for Research and Clinical Guidance. The Lancet. Infectious Diseases 2021. doi:10.1016/s1473-3099(20)30847-1 |
| [OE-GoodletK-2021-Nocardia] | Goodlet KJ, Tokman S, Nasar A, et al. Nocardia Prophylaxis, Treatment, and Outcomes of Infection in Lung Transplant Recipients: A Matched Case-Control Study. Transplant Infectious Disease : An Official Journal of the Transplantation Society 2021. doi:10.1111/tid.13478 |
| [OE-Jung-2025-Nocardia] | Jung R, Au J, Burnell J, et al. Evaluation of the Incidence of Nocardia Infection in Solid Organ Transplant Recipients on Trimethoprim-Sulfamethoxazole for Opportunistic Infection Prophylaxis. The Annals of Pharmacotherapy 2025. doi:10.1177/10600280241302412 |
| [OE-PelegA-2007-Nocardia] | Peleg AY, Husain S, Qureshi ZA, et al. Risk Factors, Clinical Characteristics, and Outcome of Nocardia Infection in Organ Transplant Recipients: A Matched Case-Control Study. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2007. doi:10.1086/514340 |
| [OE-Yang-2023-Nocardia] | Yang J, Ren HT, Wang J, et al. Clinical Characteristics, Susceptibility Profiles, and Treatment of Nocardiosis: A Multicenter Retrospective Study in 2015-2021. International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases 2023. doi:10.1016/j.ijid.2023.02.023 |
| [OE-Coussement-2016-Nocardia] | Coussement J, Lebeaux D, van Delden C, et al. Nocardia Infection in Solid Organ Transplant Recipients: A Multicenter European Case-Control Study. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2016. doi:10.1093/cid/ciw241 |
| [OE-MachiavelloRomanF-2025-Nocardia] | Machiavello Roman FJ, Grubman A, Yakubu R, et al. Nocardiosis in Immunocompromised Hosts: A Retrospective, Single-Center Analysis of Clinical and Microbiological Determinants of Central Nervous System Involvement. Transplant Infectious Disease : An Official Journal of the Transplantation Society 2025. doi:10.1111/tid.70183 |
| [OE-Coussement-2017-Nocardia] | Coussement J, Lebeaux D, Rouzaud C, Lortholary O. Nocardia Infections in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. Current Opinion in Infectious Diseases 2017. doi:10.1097/qco.0000000000000404 |
| [OE-Averbuch-2022-Nocardia] | Averbuch D, De Greef J, Duréault A, et al. Nocardia Infections in Hematopoietic Cell Transplant Recipients: A Multicenter International Retrospective Study of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2022. doi:10.1093/cid/ciab866 |
| [OE-Restrepo-2019-Nocardia] | Restrepo A, Clark NM. Nocardia Infections in Solid Organ Transplantation: Guidelines From the Infectious Diseases Community of Practice of the American Society of Transplantation. Clinical Transplantation 2019. doi:10.1111/ctr.13509 |
| [OE-Margalit-2021-Nocardia] | Margalit I, Lebeaux D, Tishler O, et al. How Do I Manage Nocardiosis?. Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2021. doi:10.1016/j.cmi.2020.12.019 |
| [OE-Tiseo-2024-CDIrecur] | Tiseo G, Yahav D, Atamna A, et al. Recurrent Clostridioides Difficile Infections in Solid Organ Transplant Recipients: The International CALIPSO Study. The Journal of Infection 2024. doi:10.1016/j.jinf.2024.106306 |
| [OE-Schluger-2019-CDIrecur] | Schluger A, Rosenblatt R, Knotts R, Verna EC, Pereira MR. Clostridioides Difficile Infection and Recurrence Among 2622 Solid Organ Transplant Recipients. Transplant Infectious Disease : An Official Journal of the Transplantation Society 2019. doi:10.1111/tid.13184 |
| [OE-BlumbergE-2022-CDIrecur] | Blumberg EA, Collins G, Young JH, et al. Clostridioides Difficile Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients: A Prospective Multinational Study. Transplant Infectious Disease : An Official Journal of the Transplantation Society 2022. doi:10.1111/tid.13770 |
| [OE-Paudel-2015-CDIrecur] | Paudel S, Zacharioudakis IM, Zervou FN, Ziakas PD, Mylonakis E. Prevalence of Clostridium Difficile Infection Among Solid Organ Transplant Recipients: A Meta-Analysis of Published Studies. PloS One 2015. doi:10.1371/journal.pone.0124483 |
| [OE-RevolinskiS-2019-CDIrecur] | Revolinski SL, Munoz-Price LS. Clostridium Difficile in Immunocompromised Hosts: A Review of Epidemiology, Risk Factors, Treatment, and Prevention. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2019. doi:10.1093/cid/ciy845 |
| [OE-OrtizBalbuena-2021-CDIrecur] | Ortiz-Balbuena J, Royuela A, Calderón-Parra J, et al. Risk Factors for Clostridioides Difficile Diarrhea in Solid Organ Transplantation Recipients. Transplantation Proceedings 2021. doi:10.1016/j.transproceed.2021.09.047 |
| [OE-Johnson-2021-CDIrecur] | Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides Difficile Infection in Adults. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2021. doi:10.1093/cid/ciab549 |
| [OE-KellyC-2021-CDIrecur] | Kelly CR, Fischer M, Allegretti JR, et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides Difficile Infections. The American Journal of Gastroenterology 2021. doi:10.14309/ajg.0000000000001278 |
| [OE-van-2025-CDIrecur] | van Prehn J, Kuijper EJ, Dubberke ER. Recurrent Clostridioides difficile Infections. The Journal of the American Medical Association 2025. doi:10.1001/jama.2025.18089 |
| [OE-Constance-2025-CDIrecur] | Constance Benson, John Brooks, Shireesha Dhanireddy, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. |
| [OE-LouieT-2011-Fidaxo] | Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus Vancomycin for Clostridium difficile Infection. The New England Journal of Medicine 2011. doi:10.1056/nejmoa0910812 |
| [OE-Alsoubani-2024-Fidaxo] | Alsoubani M, Chow JK, Rodday AM, Kent D, Snydman DR. Comparative Effectiveness of Fidaxomicin vs Vancomycin in Populations With Immunocompromising Conditions for the Treatment of Clostridioides Difficile Infection: A Single-Center Study. Open Forum Infectious Diseases 2024. doi:10.1093/ofid/ofad622 |
| [OE-Atamna-2025-Fidaxo] | Atamna A, Turjeman A, Drozdinsky G, et al. Fidaxomicin for Initial Episode of Clostridioides Difficile Infection Reduces Recurrence in Immunocompromised Hosts-a Large Retrospective Cohort Study. Open Forum Infectious Diseases 2025. doi:10.1093/ofid/ofaf751 |
| [OE-MullaneK-2019-Fidaxo] | Mullane KM, Dubberke ER. Management of Clostridioides (Formerly Clostridium) Difficile Infection (CDI) in Solid Organ Transplant Recipients: Guidelines From the American Society of Transplantation Community of Practice. Clinical Transplantation 2019. doi:10.1111/ctr.13564 |
| [OE-FDA-2025-Tacrolimus] | Food and Drug Administration. Tacrolimus. |
| [OE-HebertM-1999-Rifampin] | Hebert MF, Fisher RM, Marsh CL, Dressler D, Bekersky I. Effects of Rifampin on Tacrolimus Pharmacokinetics in Healthy Volunteers. Journal of Clinical Pharmacology 1999. doi:10.1177/00912709922007499 |
| [OE-HouwenJP-2025-Rifampin] | Houwen JPA, de Vries Schultink AHM, Peters BJM, et al. Challenges in Optimizing Tacrolimus Therapy in Patients Treated With Rifampin: A Case Series. British Journal of Clinical Pharmacology 2025. doi:10.1002/bcp.70298 |
| [OE-Xiong-2023-Rifampin] | Xiong Y, Wang X, Li S, et al. Case Report: Supratherapeutic Tacrolimus Concentrations With Nirmatrelvir/Ritonavir in a Lung Transplant Patient: A Case Report Using Rifampin for Reversal. Frontiers in Pharmacology 2023. doi:10.3389/fphar.2023.1285078 |
| [OE-Huong-2013-MeaslesIg] | Huong Q. McLean, Amy Parker Fiebelkorn, Jonathan L. Temte, Gregory S. Wallace. Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP). |
| [OE-StrebelP-2019-MeaslesIg] | Strebel PM, Orenstein WA. Measles. The New England Journal of Medicine 2019. doi:10.1056/nejmcp1905181 |
| [OE-DoLA-2025-MeaslesIg] | Do LAH, Mulholland K. Measles 2025. The New England Journal of Medicine 2025. doi:10.1056/nejmra2504516 |
| [OE-FeldmanA-2023-MeaslesIg] | Feldman AG, Beaty BL, Ferrolino JA, et al. Safety and Immunogenicity of Live Viral Vaccines in a Multicenter Cohort of Pediatric Transplant Recipients. JAMA Network Open 2023. doi:10.1001/jamanetworkopen.2023.37602 |
| [OE-PittetL-2019-MeaslesIg] | Pittet LF, Verolet CM, McLin VA, et al. Multimodal Safety Assessment of Measles-Mumps-Rubella Vaccination After Pediatric Liver Transplantation. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2019. doi:10.1111/ajt.15101 |
| [OE-MatysiakKlose-2018-MeaslesIg] | Matysiak-Klose D, Santibanez S, Schwerdtfeger C, et al. Post-Exposure Prophylaxis for Measles With Immunoglobulins Revised Recommendations of the Standing Committee on Vaccination in Germany. Vaccine 2018. doi:10.1016/j.vaccine.2018.10.070 |
| [OE-RobertsM-2021-InfectISreduc] | Roberts MB, Fishman JA. Immunosuppressive Agents and Infectious Risk in Transplantation: Managing the “Net State of Immunosuppression”. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2021. doi:10.1093/cid/ciaa1189 |
| [OE-FDA-2025-Mycophenolat] | Food and Drug Administration. Mycophenolate mofetil. |
| [OE-FDA-2025-Mycophenolat-2] | Food and Drug Administration. Mycophenolate Mofetil. |
| [OE-MartinLoeches-2025-InfectISreduc] | Martin-Loeches I, David S, Pène F, et al. Advocating for the Recognition of Underlying Immunosuppression in Critical Illness. EClinicalMedicine 2025. doi:10.1016/j.eclinm.2025.103300 |
| [OE-Shepshelovich-2019-InfectISreduc] | Shepshelovich D, Tau N, Green H, et al. Immunosuppression Reduction in Liver and Kidney Transplant Recipients With Suspected Bacterial Infection: A Multinational Survey. Transplant Infectious Disease : An Official Journal of the Transplantation Society 2019. doi:10.1111/tid.13134 |
| [OE-Han-2024-InfectISreduc] | Han A, Jo AJ, Kwon H, et al. Optimum Tacrolimus Trough Levels for Enhanced Graft Survival and Safety in Kidney Transplantation: A Retrospective Multicenter Real-World Evidence Study. International Journal of Surgery 2024. doi:10.1097/js9.0000000000001800 |
| [OE-Vaidie-2025-InfectISreduc] | Vaidie J, Demiselle J, Gabriel A, et al. Effect of Temporary Suspension of Chronic Immunosuppressive Drugs on Day-90 Mortality and ICU-acquired Infections Among Critically Ill Patients With Solid Organ Transplant: A Retrospective Multicenter Study. Intensive Care Medicine 2025. doi:10.1007/s00134-025-08024-7 |
| [OE-DeinhardtEmmer-2025-InfectISreduc] | Deinhardt-Emmer S, Chousterman BG, Schefold JC, et al. Sepsis in Patients Who Are Immunocompromised: Diagnostic Challenges and Future Therapies. The Lancet. Respiratory Medicine 2025. doi:10.1016/s2213-2600(25)00124-9 |
| [OE-Yang-2023-InfectISreduc] | Yang B, Ye Q, Huang C, Ding X. Impact of Infection-Related Immunosuppressant Reduction on Kidney Transplant Outcomes: A Retrospective Study Considering the Temporal Dynamics of Immunosuppressive Requirements. Transplant International : Official Journal of the European Society for Organ Transplantation 2023. doi:10.3389/ti.2023.11802 |
| [OE-EidA-2010-InfectISreduc] | Eid AJ, Razonable RR. New Developments in the Management of Cytomegalovirus Infection After Solid Organ Transplantation. Drugs 2010. doi:10.2165/10898540-000000000-00000 |
| [OE-Sharma-2025-InfectISreduc] | Sharma P, Izzy M, Ghabril MS, et al. AASLD AST Practice Guideline on Adult Liver Transplantation: Diagnosis and Post-Transplant Management of Non-Graft-Related Complications. Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2025. doi:10.1097/lvt.0000000000000785 |
| [OE-RazonableR-2023-InfectISreduc] | Razonable RR. Oral Antiviral Drugs for Treatment of Cytomegalovirus in Transplant Recipients. Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases 2023. doi:10.1016/j.cmi.2023.03.020 |
| [OE-StewartA-2024-InfectISreduc] | Stewart AG, Kotton CN. What’s New: Updates on Cytomegalovirus in Solid Organ Transplantation. Transplantation 2024. doi:10.1097/tp.0000000000004855 |
| [OE-Fayyaz-2023-InfectISreduc] | Fayyaz A, Raja M, Natori Y. Prevention and Management of Infections in Lung Transplant Recipients. Journal of Clinical Medicine 2023. doi:10.3390/jcm13010011 |
| [OE-Righi-2024-InfectISreduc] | Righi I, Barone I, Rosso L, et al. Immunopathology of Lung Transplantation: From Infection to Rejection and Vice Versa. Frontiers in Immunology 2024. doi:10.3389/fimmu.2024.1433469 |
| [OE-ChangC-2024-InfectISreduc] | Chang CC, Harrison TS, Bicanic TA, et al. Global Guideline for the Diagnosis and Management of Cryptococcosis: An Initiative of the ECMM and ISHAM in Cooperation With the ASM. The Lancet. Infectious Diseases 2024. doi:10.1016/s1473-3099(23)00731-4 |
V.15 v2.1 Ch12 OE 證據（2026-04-22）— 55 筆新增
| 代碼 | 全名 |
|---|---|
| [OE-Hanks-2024-MPACR] | Hanks J, Girard C, Sehgal S. Acute Rejection Post Lung Transplant. Current Opinion in Pulmonary Medicine 2024. doi:10.1097/mcp.0000000000001078 |
| [OE-Iacono-2006-MPACR] | Iacono AT, Johnson BA, Grgurich WF, et al. A Randomized Trial of Inhaled Cyclosporine in Lung-Transplant Recipients. The New England Journal of Medicine 2006. doi:10.1056/nejmoa043204 |
| [OE-Lucey-2023-MPACR] | Lucey MR, Furuya KN, Foley DP. Liver Transplantation. The New England Journal of Medicine 2023. doi:10.1056/nejmra2200923 |
| [OE-Martinu-2010-MPACR] | Martinu T, Howell DN, Palmer SM. Acute Cellular Rejection and Humoral Sensitization in Lung Transplant Recipients. Seminars in Respiratory and Critical Care Medicine 2010. doi:10.1055/s-0030-1249113 |
| [OE-Roden-2017-MPACR] | Roden AC, Aisner DL, Allen TC, et al. Diagnosis of Acute Cellular Rejection and Antibody-Mediated Rejection on Lung Transplant Biopsies: A Perspective From Members of the Pulmonary Pathology Society. Archives of Pathology & Laboratory Medicine 2017. doi:10.5858/arpa.2016-0459-sa |
| [OE-Rudzik-2023-MPACR] | Rudzik KN, Moore CA, Sacha LM, et al. Rabbit Antithymocyte Globulin for Treatment of Corticosteroid Refractory Acute Cellular Rejection After Lung Transplantation. Transplantation 2023. doi:10.1097/tp.0000000000004617 |
| [OE-Stewart-2007-MPACR] | Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 Working Formulation for the Standardization of Nomenclature in the Diagnosis of Lung Rejection. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2007. doi:10.1016/j.healun.2007.10.017 |
| [OE-Te-2026-MPACR] | Te HS, Agopian VG, Demetris AJ, et al. AASLD AST Practice Guideline on Adult Liver Transplantation: Diagnosis and Management of Graft-Related Complications. Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2026. doi:10.1097/lvt.0000000000000715 |
| [OE-Unknown-2009-MPACR] | KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2009. doi:10.1111/j.1600-6143.2009.02834.x |
| [OE-Vo-2008-MPACR] | Vo AA, Lukovsky M, Toyoda M, et al. Rituximab and Intravenous Immune Globulin for Desensitization during Renal Transplantation. The New England Journal of Medicine 2008. doi:10.1056/nejmoa0707894 |
| [OE-FoodandDrugAdministration-2026-ATGdose] | Food and Drug Administration. Thymoglobulin. |
| [OE-Mehta-2025-ATGdose] | Mehta A, DeFilippis EM, Stehlik J, et al. Contemporary Antibody-Mediated Rejection in Heart Transplantation: JACC: Heart Failure Position Statement. JACC. Heart Failure 2025. doi:10.1016/j.jchf.2025.102614 |
| [OE-Palmer-1999-ATGdose] | Palmer SM, Miralles AP, Lawrence CM, et al. Rabbit Antithymocyte Globulin Decreases Acute Rejection After Lung Transplantation: Results of a Randomized, Prospective Study. Chest 1999. doi:10.1378/chest.116.1.127 |
| [OE-Auner-2024-DSAmfi] | Auner S, Hillebrand C, Boehm PM, et al. Impact of Transient and Persistent Donor-Specific Antibodies in Lung Transplantation. Transplant International : Official Journal of the European Society for Organ Transplantation 2024. doi:10.3389/ti.2024.12774 |
| [OE-Brugire-2018-DSAmfi] | Brugière O, Roux A, Le Pavec J, et al. Role of C1q-Binding Anti-Hla Antibodies as a Predictor of Lung Allograft Outcome. The European Respiratory Journal 2018. doi:10.1183/13993003.01898-2017 |
| [OE-Keller-2023-DSAmfi] | Keller M, Yang S, Ponor L, et al. Preemptive Treatment of De Novo Donor-Specific Antibodies in Lung Transplant Patients Reduces Subsequent Risk of Chronic Lung Allograft Dysfunction or Death. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2023. doi:10.1016/j.ajt.2022.12.019 |
| [OE-Loupy-2018-DSAmfi] | Loupy A, Lefaucheur C. Antibody-Mediated Rejection of Solid-Organ Allografts. The New England Journal of Medicine 2018. doi:10.1056/nejmra1802677 |
| [OE-Roux-2018-DSAmfi] | Roux A, Thomas KA, Sage E, et al. Donor-Specific HLA Antibody-Mediated Complement Activation Is a Significant Indicator of Antibody-Mediated Rejection and Poor Long-Term Graft Outcome During Lung Transplantation: A Single Center Cohort Study. Transplant International : Official Journal of the European Society for Organ Transplantation 2018. doi:10.1111/tri.13149 |
| [OE-Schmitzer-2018-DSAmfi] | Schmitzer M, Winter H, Kneidinger N, et al. Persistence of De Novo Donor Specific HLA-Antibodies After Lung Transplantation: A Potential Marker of Decreased Patient Survival. Hla 2018. doi:10.1111/tan.13306 |
| [OE-Tikkanen-2016-DSAmfi] | Tikkanen JM, Singer LG, Kim SJ, et al. De Novo DQ Donor-Specific Antibodies Are Associated With Chronic Lung Allograft Dysfunction After Lung Transplantation. American Journal of Respiratory and Critical Care Medicine 2016. doi:10.1164/rccm.201509-1857oc |
| [OE-Vorstandlechner-2026-DSAmfi] | Vorstandlechner M, Walter J, Schneider CP, et al. HLA-DQ7 De Novo Donor-Specific Antibodies Are Associated With Increased Risk of Chronic Lung Allograft Dysfunction After Lung Transplantation. Journal of Clinical Medicine 2026. doi:10.3390/jcm15041608 |
| [OE-Colvin-2015-IVIGplex] | Colvin MM, Cook JL, Chang P, et al. Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation 2015. doi:10.1161/cir.0000000000000093 |
| [OE-Ius-2016-IVIGplex] | Ius F, Sommer W, Kieneke D, et al. IgM-Enriched Human Intravenous Immunoglobulin-Based Treatment of Patients With Early Donor Specific Anti-Hla Antibodies After Lung Transplantation. Transplantation 2016. doi:10.1097/tp.0000000000001027 |
| [OE-Ius-2018-IVIGplex] | Ius F, Verboom M, Sommer W, et al. Preemptive Treatment of Early Donor-Specific Antibodies With IgA- And IgM-enriched Intravenous Human Immunoglobulins in Lung Transplantation. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2018. doi:10.1111/ajt.14912 |
| [OE-Neuhaus-2022-IVIGplex] | Neuhaus K, Hohlfelder B, Bollinger J, et al. Antibody-Mediated Rejection Management Following Lung Transplantation. The Annals of Pharmacotherapy 2022. doi:10.1177/10600280211012410 |
| [OE-Timofeeva-2021-IVIGplex] | Timofeeva OA, Choe J, Alsammak M, et al. Guiding Therapeutic Plasma Exchange for Antibody-Mediated Rejection Treatment in Lung Transplant Recipients - A Retrospective Study. Transplant International : Official Journal of the European Society for Organ Transplantation 2021. doi:10.1111/tri.13825 |
| [OE-Vacha-2017-IVIGplex] | Vacha M, Chery G, Hulbert A, et al. Antibody Depletion Strategy for the Treatment of Suspected Antibody-Mediated Rejection in Lung Transplant Recipients: Does It Work?. Clinical Transplantation 2017. doi:10.1111/ctr.12886 |
| [OE-Vorstandlechner-2025-IVIGplex] | Vorstandlechner M, Degenfelder P, Yavuz G, et al. Efficacy of Intravenous Immunoglobulin in Eliminating De Novo Donor-Specific Antibodies After Lung Transplantation: Importance of Early Intervention. Transplant International : Official Journal of the European Society for Organ Transplantation 2025. doi:10.3389/ti.2025.15350 |
| [OE-Ius-2015-RitxAMR] | Ius F, Sommer W, Tudorache I, et al. Preemptive Treatment With Therapeutic Plasma Exchange and Rituximab for Early Donor-Specific Antibodies After Lung Transplantation. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2015. doi:10.1016/j.healun.2014.09.019 |
| [OE-Gottlieb-2008-NRADbal] | Gottlieb J, Szangolies J, Koehnlein T, et al. Long-Term Azithromycin for Bronchiolitis Obliterans Syndrome After Lung Transplantation. Transplantation 2008. doi:10.1097/01.tp.0000295981.84633.bc |
| [OE-Vanaudenaerde-2008-NRADbal] | Vanaudenaerde BM, Meyts I, Vos R, et al. A Dichotomy in Bronchiolitis Obliterans Syndrome After Lung Transplantation Revealed by Azithromycin Therapy. The European Respiratory Journal 2008. doi:10.1183/09031936.00134307 |
| [OE-Verleden-2006-NRADbal] | Verleden GM, Vanaudenaerde BM, Dupont LJ, et al. Azithromycin Reduces Airway Neutrophilia and Interleukin-8 in Patients With Bronchiolitis Obliterans Syndrome. American Journal of Respiratory and Critical Care Medicine 2006. doi:10.1164/rccm.200601-071oc |
| [OE-Verleden-2011-NRADbal] | Verleden SE, Vos R, Mertens V, et al. Heterogeneity of Chronic Lung Allograft Dysfunction: Insights From Protein Expression in Broncho Alveolar Lavage. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2011. doi:10.1016/j.healun.2010.12.008 |
| [OE-Verleden-2013-NRADbal] | Verleden SE, Vandermeulen E, Ruttens D, et al. Neutrophilic Reversible Allograft Dysfunction (NRAD) and Restrictive Allograft Syndrome (RAS). Seminars in Respiratory and Critical Care Medicine 2013. doi:10.1055/s-0033-1348463 |
| [OE-Vos-2012-NRADbal] | Vos R, Vanaudenaerde BM, Verleden SE, et al. Anti-Inflammatory and Immunomodulatory Properties of Azithromycin Involved in Treatment and Prevention of Chronic Lung Allograft Rejection. Transplantation 2012. doi:10.1097/tp.0b013e31824db9da |
| [OE-Bery-2025-BOSvsRAS] | Bery AI, Belousova N, Hachem RR, et al. Chronic Lung Allograft Dysfunction: Clinical Manifestations and Immunologic Mechanisms. Transplantation 2025. doi:10.1097/tp.0000000000005162 |
| [OE-Gottlieb-2021-BOSvsRAS] | Gottlieb J, Verleden GM, Perchl M, et al. Disease Progression in Patients With the Restrictive and Mixed Phenotype of Chronic Lung Allograft Dysfunction-a Retrospective Analysis in Five European Centers to Assess the Feasibility of a Therapeutic Trial. PloS One 2021. doi:10.1371/journal.pone.0260881 |
| [OE-Levy-2020-BOSvsRAS] | Levy L, Huszti E, Renaud-Picard B, et al. Risk Assessment of Chronic Lung Allograft Dysfunction Phenotypes: Validation and Proposed Refinement of the 2019 International Society for Heart and Lung Transplantation Classification System. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2020. doi:10.1016/j.healun.2020.04.012 |
| [OE-McInnis-2022-BOSvsRAS] | McInnis MC, Ma J, Karur GR, et al. Chronic Lung Allograft Dysfunction Phenotype and Prognosis by Machine Learning CT Analysis. The European Respiratory Journal 2022. doi:10.1183/13993003.01652-2021 |
| [OE-Perkyl-2022-BOSvsRAS] | Peräkylä LH, Raivio PM, Kesävuori RI, et al. Chronic Lung Allograft Dysfunction Subtype Analysis by Computed Tomography Volumetry. Clinical Transplantation 2022. doi:10.1111/ctr.14507 |
| [OE-VanHerck-2019-BOSvsRAS] | Van Herck A, Verleden SE, Sacreas A, et al. Validation of a Post-Transplant Chronic Lung Allograft Dysfunction Classification System. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2019. doi:10.1016/j.healun.2018.09.020 |
| [OE-Benazzo-2023-ECPresponse] | Benazzo A, Bagnera C, Ius F, et al. A European Multi-Center Analysis of Extracorporeal Photopheresis as Therapy for Chronic Lung Allograft Dysfunction. Transplant International : Official Journal of the European Society for Organ Transplantation 2023. doi:10.3389/ti.2023.11551 |
| [OE-Benazzo-2025-ECPresponse] | Benazzo A, Cho A, Auner S, et al. Extracorporeal Photopheresis for the Prevention of Rejection After Lung Transplantation: A Prospective Randomised Controlled Trial. The European Respiratory Journal 2025. doi:10.1183/13993003.00733-2024 |
| [OE-Benden-2008-ECPresponse] | Benden C, Speich R, Hofbauer GF, et al. Extracorporeal Photopheresis After Lung Transplantation: A 10-Year Single-Center Experience. Transplantation 2008. doi:10.1097/tp.0b013e31818bc024 |
| [OE-Benden-2017-ECPresponse] | Benden C, Haughton M, Leonard S, et al. Therapy Options for Chronic Lung Allograft Dysfunction-Bronchiolitis Obliterans Syndrome Following First-Line Immunosuppressive Strategies: A Systematic Review. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2017. doi:10.1016/j.healun.2017.05.030 |
| [OE-Bos-2023-ECPresponse] | Bos S, Pradère P, Beeckmans H, et al. Lymphocyte Depleting and Modulating Therapies for Chronic Lung Allograft Dysfunction. Pharmacological Reviews 2023. doi:10.1124/pharmrev.123.000834 |
| [OE-Cashmore-2025-ECPresponse] | Cashmore SJ, Barten MJ, Diekmann F, et al. Current Usage of Extracorporeal Photopheresis in Solid Organ Transplantations in Europe: A Narrative Review. Transplant International : Official Journal of the European Society for Organ Transplantation 2025. doi:10.3389/ti.2025.14906 |
| [OE-DelFante-2025-ECPresponse] | Del Fante C, Vertui V, Klersy C, et al. One Versus Two: How Much Does It Matter? A Single-Center Retrospective Study Evaluating 1-Day Extracorporeal Photopheresis Schedule for Treating Patients With Chronic Lung Allograft Rejection. Transfusion 2025. doi:10.1111/trf.18318 |
| [OE-Greer-2013-ECPresponse] | Greer M, Dierich M, De Wall C, et al. Phenotyping Established Chronic Lung Allograft Dysfunction Predicts Extracorporeal Photopheresis Response in Lung Transplant Patients. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2013. doi:10.1111/ajt.12155 |
| [OE-Hachem-2018-ECPresponse] | Hachem R, Corris P. Extracorporeal Photopheresis for Bronchiolitis Obliterans Syndrome After Lung Transplantation. Transplantation 2018. doi:10.1097/tp.0000000000002168 |
| [OE-Isenring-2017-ECPresponse] | Isenring B, Robinson C, Buergi U, et al. Lung Transplant Recipients on Long-Term Extracorporeal Photopheresis. Clinical Transplantation 2017. doi:10.1111/ctr.13041 |
| [OE-Jaksch-2012-ECPresponse] | Jaksch P, Scheed A, Keplinger M, et al. A Prospective Interventional Study on the Use of Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome After Lung Transplantation. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2012. doi:10.1016/j.healun.2012.05.002 |
| [OE-Karnes-2019-ECPresponse] | Karnes HE, Schindler EI, Morrell M, et al. Factors Associated With Mortality and Response to Extracorporeal Photopheresis in Lung Allograft Recipients With Bronchiolitis Obliterans Syndrome. Transplantation 2019. doi:10.1097/tp.0000000000002430 |
| [OE-Morrell-2010-ECPresponse] | Morrell MR, Despotis GJ, Lublin DM, et al. The Efficacy of Photopheresis for Bronchiolitis Obliterans Syndrome After Lung Transplantation. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2010. doi:10.1016/j.healun.2009.08.029 |
| [OE-Vazirani-2020-ECPresponse] | Vazirani J, Routledge D, Snell GI, et al. Outcomes Following Extracorporeal Photopheresis for Chronic Lung Allograft Dysfunction Following Lung Transplantation: A Single-Center Experience. Transplantation Proceedings 2020. doi:10.1016/j.transproceed.2020.09.003 |
V.16 v2.1 Ch13 OE 證據（2026-04-22）— 109 筆新增
| 代碼 | 全名 |
|---|---|
| [OE-Abulail-2026-mTORconv] | Abulail JA, Abu Husein S, Al-Tamimia M, et al. Impact of Immunosuppressive Therapy on Non-Melanoma Skin Cancer After Solid Organ Transplantation: A Critical Systematic Review. Transplant Immunology 2026. doi:10.1016/j.trim.2026.102384 |
| [OE-Alberú-2010-mTORconv] | Alberú J. Clinical Insights for Cancer Outcomes in Renal Transplant Patients. Transplantation Proceedings 2010. doi:10.1016/j.transproceed.2010.07.006 |
| [OE-Alberú-2011-mTORconv] | Alberú J, Pascoe MD, Campistol JM, et al. Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial. Transplantation 2011. doi:10.1097/tp.0b013e3182247ae2 |
| [OE-Alder-2022-STSgene] | Alder JK, Sutton RM, Iasella CJ, et al. Lung Transplantation for Idiopathic Pulmonary Fibrosis Enriches for Individuals With Telomere-Mediated Disease. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2022. doi:10.1016/j.healun.2021.11.008 |
| [OE-Allen-2019-PTLD] | Allen UD, Preiksaitis JK. Post-Transplant Lymphoproliferative Disorders, Epstein-Barr Virus Infection, and Disease in Solid Organ Transplantation: Guidelines From the American Society of Transplantation Infectious Diseases Community of Practice. Clinical Transplantation 2019. doi:10.1111/ctr.13652 |
| [OE-Anastasilakis-2019-Bisphos] | Anastasilakis AD, Tsourdi E, Makras P, et al. Bone Disease Following Solid Organ Transplantation: A Narrative Review and Recommendations for Management From the European Calcified Tissue Society. Bone 2019. doi:10.1016/j.bone.2019.07.006 |
| [OE-Aris-1996-PTLD] | Aris RM, Maia DM, Neuringer IP, et al. Post-Transplantation Lymphoproliferative Disorder in the Epstein-Barr Virus-Naïve Lung Transplant Recipient. American Journal of Respiratory and Critical Care Medicine 1996. doi:10.1164/ajrccm.154.6.8970360 |
| [OE-Asleh-2019-mTORconv] | Asleh R, Clavell AL, Pereira NL, et al. Incidence of Malignancies in Patients Treated With Sirolimus Following Heart Transplantation. Journal of the American College of Cardiology 2019. doi:10.1016/j.jacc.2019.03.499 |
| [OE-Biswas-2018-Fundo] | Biswas Roy S, Elnahas S, Serrone R, et al. Early Fundoplication Is Associated With Slower Decline in Lung Function After Lung Transplantation in Patients With Gastroesophageal Reflux Disease. The Journal of Thoracic and Cardiovascular Surgery 2018. doi:10.1016/j.jtcvs.2018.02.009 |
| [OE-Bloom-2025-mTORconv] | Bloom MW, Vo JB, Rodgers JE, et al. Cardio-Oncology and Heart Failure: A Scientific Statement From the Heart Failure Society of America. Journal of Cardiac Failure 2025. doi:10.1016/j.cardfail.2024.08.045 |
| [OE-Borie-2015-STSimmuno] | Borie R, Kannengiesser C, Hirschi S, et al. Severe Hematologic Complications After Lung Transplantation in Patients With Telomerase Complex Mutations. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2015. doi:10.1016/j.healun.2014.11.010 |
| [OE-Caffarelli-2020-BMDloss] | Caffarelli C, Tomai Pitinca MD, Alessandri M, et al. Timing of osteoporotic vertebral fractures in lung and heart transplantation. J Clin Med 2020. doi:10.3390/jcm9092941 |
| [OE-Campbell-2012-mTORconv] | Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR. Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2012. doi:10.1111/j.1600-6143.2012.04004.x |
| [OE-Carlier-2025-STSimmuno] | Carlier FM, Planté-Bordeneuve T, Froidure A, et al. Hematological Complications in Solid Organ Transplant Recipients With Telomere Biology Disorders: A Narrative Review. Frontiers in Immunology 2025. doi:10.3389/fimmu.2025.1718107 |
| [OE-Chambers-2021-PTDM] | Chambers DC, Perch M, Zuckermann A, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-Eighth Adult Lung Transplantation Report - 2021; Focus on Recipient Characteristics. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2021. doi:10.1016/j.healun.2021.07.021 |
| [OE-Courtwright-2018-PTLD] | Courtwright AM, Burkett P, Divo M, et al. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients. The Annals of Thoracic Surgery 2018. doi:10.1016/j.athoracsur.2017.09.033 |
| [OE-Courtwright-2019-STSimmuno] | Courtwright AM, El-Chemaly S. Telomeres in Interstitial Lung Disease: The Short and the Long of It. Annals of the American Thoracic Society 2019. doi:10.1513/annalsats.201808-508cme |
| [OE-Courtwright-2025-STSimmuno] | Courtwright AM, Mackintosh JA, Alder JK, et al. ISHLT Consensus Statement on Short Telomere Syndrome and Lung Transplantation. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2025. doi:10.1016/j.healun.2025.10.028 |
| [OE-Crespo-2021-Airway] | Crespo MM. Airway Complications in Lung Transplantation. Journal of Thoracic Disease 2021. doi:10.21037/jtd-20-2696 |
| [OE-Dantal-2018-mTORconv] | Dantal J, Morelon E, Rostaing L, et al. Sirolimus for Secondary Prevention of Skin Cancer in Kidney Transplant Recipients: 5-Year Results. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 2018. doi:10.1200/jco.2017.76.6691 |
| [OE-Davis-2003-Fundo] | Davis RD, Lau CL, Eubanks S, et al. Improved Lung Allograft Function After Fundoplication in Patients With Gastroesophageal Reflux Disease Undergoing Lung Transplantation. The Journal of Thoracic and Cardiovascular Surgery 2003. doi:10.1067/mtc.2003.166 |
| [OE-Delanaye-2025-CKDstage] | Delanaye P, Jouret F, Cavalier É. International Guidelines for the Assessment of Chronic Kidney Disease. Revue Medicale De Liege 2025. |
| [OE-Dhanani-2025-Airway] | Dhanani Z, Marquez A, Omari OA, Anjum F. Novel Association Between AMR and Airway Complications Among Lung Transplant Recipients. Transplantation Proceedings 2025. doi:10.1016/j.transproceed.2025.06.006 |
| [OE-Dierickx-2018-PTLD] | Dierickx D, Habermann TM. Post-Transplantation Lymphoproliferative Disorders in Adults. The New England Journal of Medicine 2018. doi:10.1056/nejmra1702693 |
| [OE-Dillibabu-2025-CancerSIR] | Dillibabu T, Laprise C, Nicolau B, Madathil S. Risk of Cancer Among Adult Solid Organ Transplant Recipients in Quebec, Canada: 1997-2016. BMC Cancer 2025. doi:10.1186/s12885-025-14349-9 |
| [OE-Doraiswamy-2021-CKDstage] | Doraiswamy M, Obole E, Botros M, et al. Looking Beyond the Allograft Survival: Long-Term, 5-Year Renal Outcome in Lung Transplant Recipients. Transplantation Proceedings 2021. doi:10.1016/j.transproceed.2021.09.037 |
| [OE-Dressen-2018-STSgene] | Dressen A, Abbas AR, Cabanski C, et al. Analysis of Protein-Altering Variants in Telomerase Genes and Their Association With MUC5B Common Variant Status in Patients With Idiopathic Pulmonary Fibrosis: A Candidate Gene Sequencing Study. The Lancet. Respiratory Medicine 2018. doi:10.1016/s2213-2600(18)30135-8 |
| [OE-Du-2024-PTDM] | Du W, Wang X, Zhang D, Zuo X. Retrospective Analysis on Incidence and Risk Factors of Post-Transplant Diabetes Mellitus After Lung Transplantation and Its Association With Clinical Outcomes. Transplant Immunology 2024. doi:10.1016/j.trim.2024.102008 |
| [OE-Dusendang-2022-CancerSIR] | Dusendang JR, Carlson E, Lee DS, et al. Cohort and Nested Case-Control Study of Cutaneous Squamous Cell Carcinoma in Solid Organ Transplant Recipients, by Medication. Journal of the American Academy of Dermatology 2022. doi:10.1016/j.jaad.2021.07.065 |
| [OE-Engels-2026-CancerSIR] | Engels EA, Castenson D, Luo Q, et al. Population-Level Cancer Trends Among Solid Organ Transplant Recipients in the United States During 1995-2021. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2026. doi:10.1016/j.ajt.2026.02.036 |
| [OE-Euvrard-2012-mTORconv] | Euvrard S, Morelon E, Rostaing L, et al. Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation. The New England Journal of Medicine 2012. doi:10.1056/nejmoa1204166 |
| [OE-Fan-2009-PTDM] | Fan Y, Xiao YB, Weng YG. Tacrolimus Versus Cyclosporine for Adult Lung Transplant Recipients: A Meta-Analysis. Transplantation Proceedings 2009. doi:10.1016/j.transproceed.2008.11.016 |
| [OE-Fishman-2007-PTLD] | Fishman JA. Infection in Solid-Organ Transplant Recipients. The New England Journal of Medicine 2007. doi:10.1056/nejmra064928 |
| [OE-Foerster-2026-mTORconv] | Foerster Y, Palaras J, Mayer K, Biedermann T, Persa OD. Sirolimus for Secondary Prevention of Cutaneous Squamous Cell Carcinoma in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. International Journal of Dermatology 2026. doi:10.1111/ijd.70285 |
| [OE-Friman-2022-CancerSIR] | Friman TK, Jäämaa-Holmberg S, Åberg F, et al. Cancer Risk and Mortality After Solid Organ Transplantation: A Population-Based 30-Year Cohort Study in Finland. International Journal of Cancer 2022. doi:10.1002/ijc.33934 |
| [OE-Ge-2020-CancerSIR] | Ge F, Li C, Xu X, et al. Cancer Risk in Heart or Lung Transplant Recipients: A Comprehensive Analysis of 21 Prospective Cohorts. Cancer Medicine 2020. doi:10.1002/cam4.3525 |
| [OE-George-2019-STSimmuno] | George PM, Patterson CM, Reed AK, Thillai M. Lung Transplantation for Idiopathic Pulmonary Fibrosis. The Lancet. Respiratory Medicine 2019. doi:10.1016/s2213-2600(18)30502-2 |
| [OE-Green-2023-Fundo] | Green CL, Gulack BC, Keshavjee S, et al. Reflux Surgery in Lung Transplantation: A Multicenter Retrospective Study. The Annals of Thoracic Surgery 2023. doi:10.1016/j.athoracsur.2022.09.037 |
| [OE-GómezTomás-2026-mTORconv] | Gómez-Tomás Á, González-Cruz C, García-Patos V, Ferrándiz-Pulido C. Immunosuppressive Regimens and Skin Cancer Risk in Solid-Organ Transplant Recipients. The British Journal of Dermatology 2026. doi:10.1093/bjd/ljaf483 |
| [OE-Hackman-2014-PTDM] | Hackman KL, Snell GI, Bach LA. Prevalence and Predictors of Diabetes After Lung Transplantation: A Prospective, Longitudinal Study. Diabetes Care 2014. doi:10.2337/dc14-0663 |
| [OE-Hartwig-2011-Fundo] | Hartwig MG, Anderson DJ, Onaitis MW, et al. Fundoplication After Lung Transplantation Prevents the Allograft Dysfunction Associated With Reflux. The Annals of Thoracic Surgery 2011. doi:10.1016/j.athoracsur.2011.04.035 |
| [OE-Hellemons-2011-CKDstage] | Hellemons ME, Agarwal PK, van der Bij W, et al. Former Smoking Is a Risk Factor for Chronic Kidney Disease After Lung Transplantation. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2011. doi:10.1111/j.1600-6143.2011.03701.x |
| [OE-Herrington-2026-CKDstage] | Herrington WG, Judge PK, Grams ME, Wanner C. Chronic Kidney Disease. Lancet 2026. doi:10.1016/s0140-6736(25)01942-7 |
| [OE-Hoogendijkvan-2013-mTORconv] | Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, et al. Two-Year Randomized Controlled Prospective Trial Converting Treatment of Stable Renal Transplant Recipients With Cutaneous Invasive Squamous Cell Carcinomas to Sirolimus. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 2013. doi:10.1200/jco.2012.45.6376 |
| [OE-Hortlund-2017-CancerSIR] | Hortlund M, Arroyo Mühr LS, Storm H, et al. Cancer Risks After Solid Organ Transplantation and After Long-Term Dialysis. International Journal of Cancer 2017. doi:10.1002/ijc.30531 |
| [OE-Huang-2023-Airway] | Huang J, Lin J, Zheng Z, et al. Risk Factors and Prognosis of Airway Complications in Lung Transplant Recipients: A Systematic Review and Meta-Analysis. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2023. doi:10.1016/j.healun.2023.04.011 |
| [OE-Humphrey-2023-Bisphos] | Humphrey MB, Russell L, Danila MI, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Care & Research 2023. doi:10.1002/acr.25240 |
| [OE-Iasella-2020-PTLD] | Iasella CJ, Winters SA, Kois A, et al. Idiopathic Pulmonary Fibrosis Lung Transplant Recipients Are at Increased Risk for EBV-associated Posttransplant Lymphoproliferative Disorder and Worse Survival. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2020. doi:10.1111/ajt.15756 |
| [OE-Iatridi-2025-CKDstage] | Iatridi F, Carrero JJ, Cornec-Le Gall E, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease in Children and Adults: A Commentary From the European Renal Best Practice (ERBP). Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association 2025. doi:10.1093/ndt/gfae209 |
| [OE-January-2025-Bisphos] | January SE, Fester KA, Escamilla JE, Cano M. Comparative Safety and Efficacy of Bisphosphonates, Denosumab, and Parathyroid Hormone Analogs for Osteoporosis Following Lung Transplantation. Pharmacotherapy 2025. doi:10.1002/phar.70040 |
| [OE-Jenkins-1998-HTN] | Jenkins GH, Singer DR. Hypertension in thoracic transplant recipients. J Hum Hypertens 1998. doi:10.1038/sj.jhh.1000710 |
| [OE-Jin-2024-CancerSIR] | Jin F, Vajdic CM, Poynten IM, et al. Cancer Risk in People Living With HIV and Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis. The Lancet. Oncology 2024. doi:10.1016/s1470-2045(24)00189-x |
| [OE-Kanani-2025-CKDstage] | Kanani F, R Kramer M, Atamna M, et al. Selection Patterns and Outcomes of Kidney Transplantation Versus Dialysis in Lung Recipients With End-Stage Renal Disease: A Single-Center Retrospective-Observational Study. Journal of Clinical Medicine 2025. doi:10.3390/jcm14197017 |
| [OE-Kim-2023-Airway] | Kim HH, Jo KW, Shim TS, et al. Incidence, Risk Factors, and Clinical Characteristics of Airway Complications After Lung Transplantation. Scientific Reports 2023. doi:10.1038/s41598-023-27864-1 |
| [OE-Kim-2024-PTLD] | Kim IC, Kim SH, Youn JC, et al. Temporal Trends, Risk Factors, And Clinical Outcomes of De Novo Lymphoproliferative Disorders After Heart Transplantation. JACC. Heart Failure 2024. doi:10.1016/j.jchf.2023.10.018 |
| [OE-Knoll-2014-mTORconv] | Knoll GA, Kokolo MB, Mallick R, et al. Effect of Sirolimus on Malignancy and Survival After Kidney Transplantation: Systematic Review and Meta-Analysis of Individual Patient Data. BMJ 2014. doi:10.1136/bmj.g6679 |
| [OE-Kowalski-2023-Fundo] | Kowalski E, Smith J, Zambito G, et al. Outcomes of Partial Fundoplication for GERD-related Allograft Decline After Lung Transplantation. Surgical Endoscopy 2023. doi:10.1007/s00464-022-09529-8 |
| [OE-Krahelski-2025-Fundo] | Krahelski O, Ali I, Namgoong C, et al. Interventional Anti-Reflux Management for Gastro-Oesophageal Reflux Disease in Lung Transplant Recipients: A Systematic Review and Meta-Analysis. Surgical Endoscopy 2025. doi:10.1007/s00464-024-11392-8 |
| [OE-Kremer-2012-PTLD] | Kremer BE, Reshef R, Misleh JG, et al. Post-Transplant Lymphoproliferative Disorder After Lung Transplantation: A Review of 35 Cases. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2012. doi:10.1016/j.healun.2011.10.013 |
| [OE-Krynitz-2013-CancerSIR] | Krynitz B, Edgren G, Lindelöf B, et al. Risk of Skin Cancer and Other Malignancies in Kidney, Liver, Heart and Lung Transplant Recipients 1970 to 2008–a Swedish Population-Based Study. International Journal of Cancer 2013. doi:10.1002/ijc.27765 |
| [OE-Kumarasinghe-2015-PTLD] | Kumarasinghe G, Lavee O, Parker A, et al. Post-Transplant Lymphoproliferative Disease in Heart and Lung Transplantation: Defining Risk and Prognostic Factors. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2015. doi:10.1016/j.healun.2015.05.021 |
| [OE-LeivaJuarez-2022-Fundo] | Leiva-Juarez MM, Benvenuto L, Costa J, et al. Identification of Lung Transplant Recipients With a Survival Benefit After Fundoplication. The Annals of Thoracic Surgery 2022. doi:10.1016/j.athoracsur.2021.05.098 |
| [OE-Leyssens-2017-PTLD] | Leyssens A, Dierickx D, Verbeken EK, et al. Post-Transplant Lymphoproliferative Disease in Lung Transplantation: A Nested Case-Control Study. Clinical Transplantation 2017. doi:10.1111/ctr.12983 |
| [OE-Mackintosh-2025-STSgene] | Mackintosh JA. Telomeropathy: Pretransplant and Posttransplant Considerations for Clinicians. Current Opinion in Pulmonary Medicine 2025. doi:10.1097/mcp.0000000000001169 |
| [OE-Magruder-2017-CancerSIR] | Magruder JT, Crawford TC, Grimm JC, et al. Risk Factors for De Novo Malignancy Following Lung Transplantation. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2017. doi:10.1111/ajt.13925 |
| [OE-Mahajan-2017-Airway] | Mahajan AK, Folch E, Khandhar SJ, et al. The Diagnosis and Management of Airway Complications Following Lung Transplantation. Chest 2017. doi:10.1016/j.chest.2017.02.021 |
| [OE-Massey-2021-mTORconv] | Massey PR, Schmults CD, Li SJ, et al. Consensus-Based Recommendations on the Prevention of Squamous Cell Carcinoma in Solid Organ Transplant Recipients: A Delphi Consensus Statement. JAMA Dermatology 2021. doi:10.1001/jamadermatol.2021.3180 |
| [OE-Mizrahi-2020-PTDM] | Mizrahi N, Braun M, Ben Gal T, et al. Post-Transplant Diabetes Mellitus: Incidence, Predicting Factors and Outcomes. Endocrine 2020. doi:10.1007/s12020-020-02339-9 |
| [OE-Morrison-1993-HTN] | Morrison JF, Higenbottam TW, Clelland CA, et al. Hypertension after lung transplantation. J Heart Lung Transplant 1993. |
| [OE-MuñozFos-2023-Airway] | Muñoz-Fos A, Moreno P, González FJ, et al. Airway Complications After Lung Transplantation-a Contemporary Series of 400 Bronchial Anastomoses From a Single Center. Journal of Clinical Medicine 2023. doi:10.3390/jcm12093061 |
| [OE-Newton-2017-STSimmuno] | Newton CA, Kozlitina J, Lines JR, et al. Telomere Length in Patients With Pulmonary Fibrosis Associated With Chronic Lung Allograft Dysfunction and Post-Lung Transplantation Survival. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2017. doi:10.1016/j.healun.2017.02.005 |
| [OE-Newton-2022-STSgene] | Newton CA, Oldham JM, Applegate C, et al. The Role of Genetic Testing in Pulmonary Fibrosis: A Perspective From the Pulmonary Fibrosis Foundation Genetic Testing Work Group. Chest 2022. doi:10.1016/j.chest.2022.03.023 |
| [OE-Ng-2020-Bisphos] | Ng E, Topliss DJ, Paraskeva M, Paul E, Sztal-Mazer S. The Utility of Prophylactic Zoledronic Acid in Patients Undergoing Lung Transplantation. Journal of Clinical Densitometry : The Official Journal of the International Society for Clinical Densitometry 2020. doi:10.1016/j.jocd.2020.10.003 |
| [OE-Ollech-2008-PTDM] | Ollech JE, Kramer MR, Peled N, et al. Post-Transplant Diabetes Mellitus in Lung Transplant Recipients: Incidence and Risk Factors. European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery 2008. doi:10.1016/j.ejcts.2008.01.050 |
| [OE-Penninga-2013-PTDM] | Penninga L, Penninga EI, Møller CH, et al. Tacrolimus Versus Cyclosporin as Primary Immunosuppression for Lung Transplant Recipients. The Cochrane Database of Systematic Reviews 2013. doi:10.1002/14651858.cd008817.pub2 |
| [OE-Peters-2018-PTLD] | Peters AC, Akinwumi MS, Cervera C, et al. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-Center Experience. Transplantation 2018. doi:10.1097/tp.0000000000002146 |
| [OE-Petrovski-2017-STSgene] | Petrovski S, Todd JL, Durheim MT, et al. An Exome Sequencing Study to Assess the Role of Rare Genetic Variation in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine 2017. doi:10.1164/rccm.201610-2088oc |
| [OE-PhillipsHoulbracq-2022-STSgene] | Phillips-Houlbracq M, Mal H, Cottin V, et al. Determinants of Survival After Lung Transplantation in Telomerase-Related Gene Mutation Carriers: A Retrospective Cohort. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2022. doi:10.1111/ajt.16893 |
| [OE-Préterre-2021-mTORconv] | Préterre J, Visentin J, Saint Cricq M, et al. Comparison of Two Strategies Based on Mammalian Target of Rapamycin Inhibitors in Secondary Prevention of Non-Melanoma Skin Cancer After Kidney Transplantation, a Pilot Study. Clinical Transplantation 2021. doi:10.1111/ctr.14207 |
| [OE-Rampersad-2025-PTLD] | Rampersad C, Hosseini-Moghaddam SM, Kim SJ. Donor-Recipient Epstein-Barr Virus Serostatus and Time-Varying Risk of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients. Transplant Infectious Disease : An Official Journal of the Transplantation Society 2025. doi:10.1111/tid.70165 |
| [OE-Razia-2023-Fundo] | Razia D, Mittal SK, Fournier S, et al. Antireflux Surgery Versus Medical Management of Gastro-Oesophageal Reflux After Lung Transplantation. European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery 2023. doi:10.1093/ejcts/ezad063 |
| [OE-Reid-2009-Bisphos] | Reid DM, Devogelaer JP, Saag K, et al. Zoledronic Acid and Risedronate in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (HORIZON): A Multicentre, Double-Blind, Double-Dummy, Randomised Controlled Trial. Lancet 2009. doi:10.1016/s0140-6736(09)60250-6 |
| [OE-Rizvi-2017-CancerSIR] | Rizvi SMH, Aagnes B, Holdaas H, et al. Long-term Change in the Risk of Skin Cancer After Organ Transplantation: A Population-Based Nationwide Cohort Study. JAMA Dermatology 2017. doi:10.1001/jamadermatol.2017.2984 |
| [OE-Ryerson-2025-STSgene] | Ryerson CJ, Adegunsoye A, Piciucchi S, et al. Update of the International Multidisciplinary Classification of the Interstitial Pneumonias: An ERS/ATS Statement. The European Respiratory Journal 2025. doi:10.1183/13993003.00158-2025 |
| [OE-Rzepka-2025-Bisphos] | Rzepka AM, Tile L, Chow CW, et al. Lung Transplantation and Bone Health: A Narrative Review. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2025. doi:10.1016/j.healun.2025.01.010 |
| [OE-Savioli-2013-HTN] | Savioli G, Surbone S, Giovi I, et al. Early development of metabolic syndrome in patients subjected to lung transplantation. Clin Transplant 2013. doi:10.1111/ctr.12098 |
| [OE-Schweiger-2020-Airway] | Schweiger T, Nenekidis I, Stadler JE, et al. Single Running Suture Technique Is Associated With Low Rate of Bronchial Complications After Lung Transplantation. The Journal of Thoracic and Cardiovascular Surgery 2020. doi:10.1016/j.jtcvs.2019.12.119 |
| [OE-Shane-2012-Bisphos] | Shane E, Cohen A, Stein EM, et al. Zoledronic Acid Versus Alendronate for the Prevention of Bone Loss After Heart or Liver Transplantation. The Journal of Clinical Endocrinology and Metabolism 2012. doi:10.1210/jc.2012-2804 |
| [OE-Sharif-2016-PTDM] | Sharif A, Cohney S. Post-Transplantation Diabetes-State of the Art. The Lancet. Diabetes & Endocrinology 2016. doi:10.1016/s2213-8587(15)00387-3 |
| [OE-Silverborn-2005-HTN] | Silverborn M, Jeppsson A, Mårtensson G, Nilsson F. New-onset cardiovascular risk factors in lung transplant recipients. J Heart Lung Transplant 2005. doi:10.1016/j.healun.2005.01.004 |
| [OE-Sohn-2023-STSimmuno] | Sohn YM, Ko RE, Park HJ, et al. Clinical Pharmacokinetic Study of Tacrolimus in Continuous Intravenous Administration for Lung Transplantation. Journal of Thoracic Disease 2023. doi:10.21037/jtd-22-1760 |
| [OE-Spira-2000-BMDloss] | Spira A, Gutierrez C, Chaparro C, Hutcheon MA, Chan CK. Osteoporosis and lung transplantation: a prospective study. Chest 2000. doi:10.1378/chest.117.2.476 |
| [OE-Stenman-2023-CancerSIR] | Stenman C, Wallinder A, Holmberg E, et al. Malignancies After Lung Transplantation. Transplant International : Official Journal of the European Society for Organ Transplantation 2023. doi:10.3389/ti.2024.12127 |
| [OE-Suilik-2024-PTDM] | Suilik HA, Al-Shammari AS, Soliman Y, et al. Efficacy of Tacrolimus Versus Cyclosporine After Lung Transplantation: An Updated Systematic Review, Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials. European Journal of Clinical Pharmacology 2024. doi:10.1007/s00228-024-03750-1 |
| [OE-Swaminathan-2019-STSgene] | Swaminathan AC, Neely ML, Frankel CW, et al. Lung Transplant Outcomes in Patients With Pulmonary Fibrosis With Telomere-Related Gene Variants. Chest 2019. doi:10.1016/j.chest.2019.03.030 |
| [OE-Tran-2023-BMDloss] | Tran TT, Pai ACH, Nguyen CQN, et al. Bone mineral density and fractures after lung transplantation in people with cystic fibrosis. J Cyst Fibros 2023. doi:10.1016/j.jcf.2023.01.003 |
| [OE-Trindade-2019-STSimmuno] | Trindade AJ, Thaniyavarn T, Townsend K, et al. Alemtuzumab as a Therapy for Chronic Lung Allograft Dysfunction in Lung Transplant Recipients With Short Telomeres. Frontiers in Immunology 2019. doi:10.3389/fimmu.2020.01063 |
| [OE-Wang-2013-BMDloss] | Wang TK, O’Sullivan S, Gamble GD, Ruygrok PN. Bone density in heart or lung transplant recipients—a longitudinal study. Transplant Proc 2013. doi:10.1016/j.transproceed.2012.09.117 |
| [OE-Wilken-2021-CancerSIR] | Wilken R, Carucci J, Stevenson ML. Skin Cancers and Lung Transplant. Seminars in Respiratory and Critical Care Medicine 2021. doi:10.1055/s-0041-1728798 |
| [OE-Wiseman-2022-CKDstage] | Wiseman AC. CKD in Recipients of Nonkidney Solid Organ Transplants: A Review. American Journal of Kidney Diseases : The Official Journal of the National Kidney Foundation 2022. doi:10.1053/j.ajkd.2021.10.014 |
| [OE-Wong-2004-PTLD] | Wong JY, Tait B, Levvey B, et al. Epstein-Barr Virus Primary Mismatching and HLA Matching: Key Risk Factors for Post Lung Transplant Lymphoproliferative Disease. Transplantation 2004. doi:10.1097/01.tp.0000128611.71038.0c |
| [OE-Wysong-2023-CancerSIR] | Wysong A. Squamous-Cell Carcinoma of the Skin. The New England Journal of Medicine 2023. doi:10.1056/nejmra2206348 |
| [OE-Ye-2010-PTDM] | Ye X, Kuo HT, Sampaio MS, Jiang Y, Bunnapradist S. Risk Factors for Development of New-Onset Diabetes Mellitus After Transplant in Adult Lung Transplant Recipients. Clinical Transplantation 2010. doi:10.1111/j.1399-0012.2010.01383.x |
| [OE-Yin-2025-Airway] | Yin M, Liang Y, Wei S, Zhang A. Comprehensive Review and Management Strategies of Airway Complications Post-Lung Transplantation. The Journal of Surgical Research 2025. doi:10.1016/j.jss.2025.09.028 |
| [OE-Zaffiri-2020-PTLD] | Zaffiri L, Long A, Neely ML, et al. Incidence and Outcome of Post-Transplant Lymphoproliferative Disorders in Lung Transplant Patients: Analysis of ISHLT Registry. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2020. doi:10.1016/j.healun.2020.06.010 |
| [OE-Zhang-2022-STSgene] | Zhang D, Newton CA, Wang B, et al. Utility of Whole Genome Sequencing in Assessing Risk and Clinically Relevant Outcomes for Pulmonary Fibrosis. The European Respiratory Journal 2022. doi:10.1183/13993003.00577-2022 |
| [OE-de-2017-mTORconv] | de Fijter JW. Cancer and mTOR Inhibitors in Transplant Recipients. Transplantation 2017. doi:10.1097/tp.0000000000001447 |
| [OE-van-2023-Airway] | van Pel R, Gan CT, van der Bij W, et al. Three Decades Single Center Experience of Airway Complications After Lung Transplantation. Transplant International : Official Journal of the European Society for Organ Transplantation 2023. doi:10.3389/ti.2023.11519 |
V.17 v2.1 Ch14 OE 證據（2026-04-22）— 11 筆新增
| 代碼 | 全名 |
|---|---|
| [OE-Keller-2022-SingleDoubleLTx] | Keller MB, Meda R, Fu S, et al. Comparison of Donor-Derived Cell-Free DNA Between Single Versus Double Lung Transplant Recipients. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2022. doi:10.1111/ajt.17039 |
| [OE-Humar-2006-EBVscreen] | Humar A, Michaels M. American Society of Transplantation Recommendations for Screening, Monitoring and Reporting of Infectious Complications in Immunosuppression Trials in Recipients of Organ Transplantation. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2006. doi:10.1111/j.1600-6143.2005.01207.x |
| [OE-Stevens-2001-EBVLTx] | Stevens SJ, Verschuuren EA, Pronk I, et al. Frequent Monitoring of Epstein-Barr Virus DNA Load in Unfractionated Whole Blood Is Essential for Early Detection of Posttransplant Lymphoproliferative Disease in High-Risk Patients. Blood 2001. doi:10.1182/blood.v97.5.1165 |
| [OE-Burton-2025-EBVDNAemia] | Burton C, Mabilangan C, Preiksaitis J. Incidence and Timing of Epstein-Barr Virus Whole Blood DNAemia in Epstein-Barr Virus-Mismatched Adult and Pediatric Solid Organ Transplant Recipients. Transplant Infectious Disease : An Official Journal of the Transplantation Society 2025. doi:10.1111/tid.70042 |
| [OE-Lindsay-2021-EBVPTLD] | Lindsay J, Othman J, Yong MK, et al. Dynamics of Epstein-Barr Virus on Post-Transplant Lymphoproliferative Disorders After Antithymocyte Globulin-Conditioned Allogeneic Hematopoietic Cell Transplant. Transplant Infectious Disease : An Official Journal of the Transplantation Society 2021. doi:10.1111/tid.13719 |
| [OE-Mah-2024-EBVPPV] | Mah JK, Tam PCK, Chang YC, et al. Limited Utility of Epstein-Barr Virus (EBV) Surveillance for Predicting Post-Transplant Lymphoproliferative Disorders in Adult EBV Seropositive Lung Transplant Recipients. Journal of Clinical Virology : The Official Publication of the Pan American Society for Clinical Virology 2025. doi:10.1016/j.jcv.2024.105758 |
| [OE-Miller-2024-IDSAlab] | Miller JM, Binnicker MJ, Campbell S, et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 2024. doi:10.1093/cid/ciae104 |
| [OE-NCCN-BCellLymphoma] | National Comprehensive Cancer Network. B-Cell Lymphomas. NCCN Clinical Practice Guidelines in Oncology 2024. |
| [OE-Lindsay-2021-EBVPreventPTLD] | Lindsay J, Yong MK, Greenwood M, et al. Epstein-Barr Virus Related Post-Transplant Lymphoproliferative Disorder Prevention Strategies in Allogeneic Hematopoietic Stem Cell Transplantation. Reviews in Medical Virology 2020. doi:10.1002/rmv.2108 |
| [OE-Kumar-2017-EBVDpRn] | Kumar D, Patil N, Husain S, et al. Clinical and Virologic Outcomes in High-Risk Adult Epstein-Barr Virus Mismatched Organ Transplant Recipients. Clinical Transplantation 2017. doi:10.1111/ctr.13000 |
| [OE-Divithotawela-2025-EBVPCR] | Divithotawela C, Lee SZ, Schulz M, Chambers DC. Epstein Barr Virus Quantitative Polymerase Chain Reaction Monitoring in Lung and Bone Marrow Transplant Patients to Predict Post-Transplant Lymphoproliferative Disorder: A Systematic Review. Transplantation Proceedings 2025. doi:10.1016/j.transproceed.2025.03.008 |
V.18 v2.1 Ch15 OE 證據（2026-04-22）— 27 筆新增
| 代碼 | 全名 |
|---|---|
| [OE-Barilka-2025-LTxDysphagia] | Barilka M, Kutler RB, Rodrigues G, et al. Oropharyngeal Dysphagia Following Lung Transplantation: Incidence, Risk Factors, and Outcomes. The Laryngoscope 2025. doi:10.1002/lary.32297 |
| [OE-DallalYork-2022-DysAspSeq] | Dallal-York J, Segalewitz T, Croft K, et al. Incidence, Risk Factors, and Sequelae of Dysphagia Mediated Aspiration Following Lung Transplantation. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2022. doi:10.1016/j.healun.2022.05.001 |
| [OE-Seeliger-2019-VCP] | Seeliger B, Drick N, Avsar M, et al. Risk Factors and Outcomes of Vocal Cord Paralysis After Lung Transplantation - A Retrospective Cohort Study. Transplant International : Official Journal of the European Society for Organ Transplantation 2019. doi:10.1111/tri.13402 |
| [OE-Black-2019-OPDHTx] | Black R, McCabe P, Glanville A, et al. Oropharyngeal Dysphagia and Laryngeal Dysfunction After Lung and Heart Transplantation: A Systematic Review. Disability and Rehabilitation 2020. doi:10.1080/09638288.2018.1552326 |
| [OE-Reedy-2023-SwallowImpair] | Reedy EL, Simpson AN, O’Rourke AK, Bonilha HS. Characterizing Swallowing Impairment in a Post-Lung Transplant Population. American Journal of Speech-Language Pathology 2023. doi:10.1044/2023_ajslp-22-00266 |
| [OE-DallalYork-2022-SwallowCough] | Dallal-York J, Croft K, Anderson A, et al. A Prospective Examination of Swallow and Cough Dysfunction After Lung Transplantation. Neurogastroenterology and Motility 2023. doi:10.1111/nmo.14458 |
| [OE-Black-2019-OPDPredict] | Black RJ, Bogaardt H, McCabe P, et al. Clinical Predictors for Oropharyngeal Dysphagia and Laryngeal Dysfunction After Lung and Heart Transplantation. International Journal of Language & Communication Disorders 2019. doi:10.1111/1460-6984.12492 |
| [OE-Black-2021-SwallowLaryngeal] | Black RJ, Novakovic D, Plit M, et al. Swallowing and Laryngeal Complications in Lung and Heart Transplantation: Etiologies and Diagnosis. The Journal of Heart and Lung Transplantation : The Official Publication of the International Society for Heart Transplantation 2021. doi:10.1016/j.healun.2021.08.006 |
| [OE-Graham-2024-LTxAspiration] | Graham K, Kaiho T, Thomae BL, et al. Risk Factors and Impact of Swallowing Impairment and Aspiration After Lung Transplantation. Journal of Thoracic Disease 2024. doi:10.21037/jtd-24-707 |
| [OE-Takahashi-2025-NutritionDys] | Takahashi R, Miyagi M, Okazaki T, Okada Y, Ebihara S. Influence of Preoperative Nutritional Status on Postoperative Dysphagia in Lung Transplantation. Nutrition 2025. doi:10.1016/j.nut.2025.112806 |
| [OE-Mirzakhani-2013-MuscleAsp] | Mirzakhani H, Williams JN, Mello J, et al. Muscle Weakness Predicts Pharyngeal Dysfunction and Symptomatic Aspiration in Long-Term Ventilated Patients. Anesthesiology 2013. doi:10.1097/aln.0b013e31829373fe |
| [OE-Vanhorebeek-2020-ICUAW] | Vanhorebeek I, Latronico N, Van den Berghe G. ICU-acquired Weakness. Intensive Care Medicine 2020. doi:10.1007/s00134-020-05944-4 |
| [OE-Herridge-2023-OutcomesCI] | Herridge MS, Azoulay É. Outcomes after Critical Illness. The New England Journal of Medicine 2023. doi:10.1056/nejmra2104669 |
| [OE-Hermans-2015-ICUAW] | Hermans G, Van den Berghe G. Clinical Review: Intensive Care Unit Acquired Weakness. Critical Care 2015. doi:10.1186/s13054-015-0993-7 |
| [OE-Huang-2025-ICUAW] | Huang A, Salazar M, Weber H, et al. ICU-acquired Weakness: Critical Illness Myopathy and Polyneuropathy. Journal of Critical Care 2025. doi:10.1016/j.jcrc.2025.155074 |
| [OE-Ponfick-2015-CIPdysphagia] | Ponfick M, Linden R, Nowak DA. Dysphagia–a Common, Transient Symptom in Critical Illness Polyneuropathy: A Fiberoptic Endoscopic Evaluation of Swallowing Study. Critical Care Medicine* 2015. doi:10.1097/ccm.0000000000000705 |
| [OE-Macht-2013-ICUswallow] | Macht M, Wimbish T, Bodine C, Moss M. ICU-acquired Swallowing Disorders. Critical Care Medicine 2013. doi:10.1097/ccm.0b013e31829caf33 |
| [OE-Brodsky-2020-ICUDysphagia] | Brodsky MB, Nollet JL, Spronk PE, González-Fernández M. Prevalence, Pathophysiology, Diagnostic Modalities, and Treatment Options for Dysphagia in Critically Ill Patients. American Journal of Physical Medicine & Rehabilitation 2020. doi:10.1097/phm.0000000000001440 |
| [OE-Zuercher-2019-ICUDys] | Zuercher P, Moret CS, Dziewas R, Schefold JC. Dysphagia in the Intensive Care Unit: Epidemiology, Mechanisms, and Clinical Management. Critical Care 2019. doi:10.1186/s13054-019-2400-2 |
| [OE-Mandell-2019-AspPneum] | Mandell LA, Niederman MS. Aspiration Pneumonia. The New England Journal of Medicine 2019. doi:10.1056/nejmra1714562 |
| [OE-Gamez-2017-LTxNeuro] | Gamez J, Salvado M, Martinez-de La Ossa A, et al. Influence of Early Neurological Complications on Clinical Outcome Following Lung Transplant. PloS One 2017. doi:10.1371/journal.pone.0174092 |
| [OE-Valapour-2022-OPTN] | Valapour M, Lehr CJ, Skeans MA, et al. OPTN/SRTR 2020 Annual Data Report: Lung. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2022. doi:10.1111/ajt.16991 |
| [OE-Valapour-2023-OPTN] | Valapour M, Lehr CJ, Schladt DP, et al. OPTN/SRTR 2021 Annual Data Report: Lung. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2023. doi:10.1016/j.ajt.2023.02.009 |
| [OE-Valapour-2021-OPTN] | Valapour M, Lehr CJ, Skeans MA, et al. OPTN/SRTR 2019 Annual Data Report: Lung. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2021. doi:10.1111/ajt.16495 |
| [OE-Wakeam-2022-LTxMetric] | Wakeam E, Thumma JR, Bonner SN, et al. One-Year Mortality Is Not a Reliable Indicator of Lung Transplant Center Performance. The Annals of Thoracic Surgery 2022. doi:10.1016/j.athoracsur.2022.02.028 |
| [OE-Daoud-2021-PGD2016] | Daoud D, Chacon Alberty L, Wei Q, et al. Incidence of Primary Graft Dysfunction Is Higher According to the New ISHLT 2016 Guidelines and Correlates With Clinical and Molecular Risk Factors. Journal of Thoracic Disease 2021. doi:10.21037/jtd-20-3564 |
| [OE-Thabut-2010-LTxCenters] | Thabut G, Christie JD, Kremers WK, Fournier M, Halpern SD. Survival Differences Following Lung Transplantation Among US Transplant Centers. The Journal of the American Medical Association 2010. doi:10.1001/jama.2010.885 |
V.19 協調師與品質（2 份）
| 代碼 | 全名 | 年份 |
|---|---|---|
| [NATCO-CC] | NATCO: Procurement Transplant Coordinator Core Competencies | — |
| [EDQM-9th-2025] | EDQM Guide to the Quality and Safety of Organs for Transplantation, 9th Edition | 2025 |
V.20 各中心 Protocol（14 份）
| 代碼 | 全名 |
|---|---|
| [Vienna] | Vienna Lung Transplant Protocol v2.1 |
| [UTokyo] | UTokyo Immunosuppressive Therapy Protocol |
| [BWH] | BWH Guide to Lung Transplant Recipient Care |
| [UNC] | UNC Adult Lung Transplant Protocol |
| [UPMC] | UPMC Post Lung Transplant Care |
| [Stanford-Anes] | Stanford Anesthesia Lung Transplant |
| [Stanford-Abx] | Stanford Surgical Antimicrobial Prophylaxis |
| [CritCare-LTx] | Critical Care After Lung Transplantation (Review) |
| [PostOp-Review] | Postoperative Management of Lung Transplantation (Review) |
| [TSANZ] | TSANZ Clinical Guidelines v1.5 |
| [NHSBT-Alloc] | NHSBT Lung Allocation Policy POL230 |
| [NHSBT-Select] | NHSBT Lung Selection Policy POL231 |
| [NHS-Eng] | NHS England Adult Lung Transplant Service Specification |
| [台灣-分配辦法] | 衛福部人體器官移植分配及管理辦法（民國 107 年修正） |
| [Vienna-Aigner-2025] | Clemens Aigner 教授演講：LuTX Advancements and Future Perspectives (106 slides) + LuTX Teams Aspects ICU (40 slides)。Vienna 2019-2024 存活率、CPB vs ECMO、PGD 數據、手術入路比較、團隊結構 |
| [Duke-BSeq] | Bilateral Sequential Lung Transplantation — R. Duane Davis, Duke University |
| [USC-Living] | Living Lobar Lung Transplantation — Starnes/USC |
| [Vienna-BLTx] | Bilateral Lung Transplantation — Vienna/Aigner |
| [TSGH-Anes-2023] | 三總肺移植麻醉科 Protocol 圖文版 (2023.09.29) |
| [NTU-Donor-2018] | 台大醫院 Donor Lung Retrieval Protocol — 徐紹勛醫師 (2018.06.12) |
V.21 亞洲文獻（4 份）
| 代碼 | 全名 |
|---|---|
| [Japan-JOTN] | Japan JOTN Lung Transplant Chapter |
| [JOT-Proc-2021] | JOT/UTokyo Lung Procurement Manual 繁體字版 (2021) — 日本器官移植網絡肺臟摘取手冊 |
| [UTH-Manual-2022] | UTH (東京大學醫院) Lung Transplant Manual 2022 繁體中文版 — 黃昶勳醫師翻譯 (2024)。涵蓋適應症、禁忌症、免疫抑制（Tac IV→PO protocol）、CMV 管理、骨鬆、高血壓、高血脂、糖尿病、血液學、門診追蹤、CLAD、PTLD 等 |
| [ELSO-Textbook-2016] | Extracorporeal Life Support for Adults — Gregory A. Schmidt, Springer 2016。涵蓋 ECLS 生理學、技術、臨床適應症、血管通路、每日管理、weaning、危機處理 |
| [Japan-Guide] | Japan Lung Transplant Guidebook |
| [Korea-LTx] | Korea Lung Transplant Current Status |
| [India-NOTTO] | India NOTTO Heart Lung Allocation |